



HU000028241T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 028 241**(13) **T2**

EURÓPAI SZABADALOM

SZÖVEGÉNEK FORDÍTÁSA

- (21) Magyar ügyszám: **E 10 075508**
(22) A bejelentés napja: **2003. 12. 05.**
- (96) Az európai bejelentés bejelentési száma:
EP 20030075508
- (97) Az európai bejelentés közzétételi adatai:
EP 2316966 A1 **2011. 05. 04.**
- (97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2316966 B1 **2015. 09. 16.**
- (51) Int. Cl.: **C12Q 1/68** (2006.01)
C12N 151/13 (2006.01)
G01N 33/53 (2006.01)
G01N 335/66 (2006.01)

(30) Elsőbbségi adatok: 0228337 2002. 12. 05. GB	(73) Jogosult(ak): Cizzle Biotechnology Limited, Heslington, York YO10 5DG (GB)
(72) Feltaláló(k): Coverley, Dawn, York, YO10 5YW (GB)	(74) Képviselő: Danubia Szabadalmi és Jogi Iroda Kft., Budapest

- (54) **CIZ1 replikációs protein**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 316 966 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
16.09.2015 Bulletin 2015/38

(51) Int Cl.:
C12Q 1/68 (2006.01) **G01N 33/53** (2006.01)
G01N 33/566 (2006.01) **C12N 15/113** (2010.01)

(21) Application number: **10075508.1**

(22) Date of filing: **05.12.2003**

(54) **CIZ1 replication protein**
Replikationsprotein CIZ1
Protéine de réplication CIZ1

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **05.12.2002 GB 0228337**

(43) Date of publication of application:
04.05.2011 Bulletin 2011/18

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
03782605.4 / 1 570 268

(73) Proprietor: **Cizzle Biotechnology Limited**
Heslington, York YO10 5DG (GB)

(72) Inventor: **Coverley, Dawn**
York, YO10 5YW (GB)

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
WO-A-01/70979

- **STOEBER K ET AL: "CDC6 PROTEIN CAUSES PREMATURE ENTRY INTO S PHASE IN A MAMMALIAN CELL-FREE SYSTEM" EMBO JOURNAL, vol. 17, 1 January 1998 (1998-01-01), pages 7219-7229, XP000974025 OXFORD UNIVERSITY PRESS, SURREY, GB ISSN: 0261-4189 DOI: 10.1093/EMBOJ/17.24.7219**

- **DATABASE UniProt EBI, HINXTON, CAMBRIDGESHIRE, U.K.; 16 October 2001 (2001-10-16), MITSUI K., ET AL.: "Cip1-interacting zinc finger protein (Nuclear protein NP94)." XP002285016 Database accession no. Q9ULV3 & MITSUI KAORU ET AL: "Cloning and characterization of a novel p21 Cip1/Waf1-interacting zinc finger protein, Ciz1" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 264, no. 2, 22 October 1999 (1999-10-22), pages 457-464, XP002285057 ISSN: 0006-291X**
- **DATABASE Geneseq EBI, HINXTON, CAMBRIDGESHIRE, U.K.; 22 October 2001 (2001-10-22), TANG YT. ET AL: "Human polypeptide SEQ ID NO 2772." XP002285017 Database accession no. AAM39627 & WO 01/53312 A (CHEN RUI HONG ; GOODRICH RYLE (US); HYSEQ INC (US); WANG DUNRUI (US);) 26 July 2001 (2001-07-26)**
- **DATABASE Geneseq EBI, HINXTON, CAMBRIDGESHIRE, U.K.; 5 February 2002 (2002-02-05), HILLMAN, JL. ET AL: "Human transcription factor TRFX-47." XP002285018 Database accession no. ABB50196 & WO 01/72777 A (INCYTE GENOMICS INC ; PATTERSON CHANDRA (US); AZIMZAI YALDA (US); MATH) 4 October 2001 (2001-10-04)**
- **DATABASE Geneseq EBI, HINXTON, CAMBRIDGESHIRE, U.K.; 8 February 2001 (2001-02-08), SHIMKETS RA, LEACH M: "Human ORFX ORF3109 polynucleotide sequence SEQ ID NO:6217." XP002285019 Database accession no. AAC77554 & WO 00/58473 A (CURAGEN CORP ; LEACH MARTIN (US); SHIMKETS RICHARD A (US)) 5 October 2000 (2000-10-05)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 316 966 B1

- DATABASE UniProt EBI, HINXTON, CAMBRIDGESHIRE, U.K.; 1 March 2002 (2002-03-01), STRAUSBERG R.: "Hypothetical protein (CIZ1)." XP002285020 Database accession no. Q8VEH2
- DATABASE EMBL EBI, HINXTON, CAMBRIDGESHIRE, U.K.; 10 December 2001 (2001-12-10), STRAUSBERG R.L. ET AL: "Mus musculus CDKN1A interacting zinc finger protein 1, mRNA (cDNA clone MGC:27988 IMAGE: 3597692), complete cds." XP002285021 Database accession no. BC018483
- COVERLEY DAWN ET AL: "Ciz1 promotes mammalian DNA replication" JOURNAL OF CELL SCIENCE, vol. 118, no. 1, 1 January 2005 (2005-01-01), pages 101-112, XP002585230 CAMBRIDGE UNIVERSITY PRESS, LONDON, GB ISSN: 0021-9533 DOI: 10.1242/JCS.01599
- AINSCOUGH JUSTIN F-X ET AL: "C-terminal domains deliver the DNA replication factor Ciz1 to the nuclear matrix" JOURNAL OF CELL SCIENCE, vol. 120, no. 1, 1 January 2007 (2007-01-01), pages 115-124, XP002585229 CAMBRIDGE UNIVERSITY PRESS, LONDON, GB ISSN: 0021-9533 DOI: :10.1242/JCS.03327
- DEN HOLLANDER, P., ET AL.: "Ciz1, a novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action" J. PEPT. RES., vol. 61, no. 4, 1 April 2003 (2003-04-01), XP002626654
- KOVACS TUNDE ET AL: "All three splice variants of the human sarco/endoplasmic reticulum Ca²⁺-ATPase 3 gene are translated to proteins: A study of their co-expression in platelets and lymphoid cells", BIOCHEMICAL JOURNAL, vol. 358, no. 3, 15 September 2001 (2001-09-15), pages 559-568, ISSN: 0264-6021
- FOX STEPHEN B ET AL: "Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms", CANCER RESEARCH, vol. 54, no. 16, 1994, pages 4539-4546, ISSN: 0008-5472

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description

[0001] This specification relates to a screening method for the identification of agents which modulate the activity of a DNA replication protein as a target for intervention in cancer therapy and includes agents which modulate said activity.

[0002] The invention also relates to the use of the DNA replication protein, and its RNA transcripts in the prognosis and diagnosis of proliferative disease e.g., cancer.

Introduction

[0003] Initiation of DNA replication is a major control point in the mammalian cell cycle, and the point of action of many gene products that are mis-regulated in cancer (Hanahan and Weinberg, 2000). The initiation process involves assembly of pre-replication complex proteins, which include the origin recognition complex (ORC), Cdc6, Cdt1 and Mcm proteins, at replication origins during G1 phase of the cell cycle. This is followed by the action of a second group of proteins, which facilitate loading of DNA polymerases and their accessory factors including PCNA, and the transition to S phase. The initiation process is regulated by cyclin-dependent protein kinase 2 (Cdk2), Cdc7-dbf4 and the Cdt1 inhibitor geminin (for review see Bell and Dutta, 2002). In the nucleus of S phase cells, replication forks cluster together to form hundreds of replication 'foci' or factories (Cook, 1999). Replication factories appear to be linked to a structural framework within the nucleus, however the nature of the molecules that form the link and their role in replication fork activity remains unclear.

[0004] Identification of proteins involved in eukaryotic DNA replication and analysis of the basic pathways that regulate their activity during the cell cycle has been driven largely by yeast genetics. These proteins and pathways are generally conserved from yeast to man. However, in multi-cellular organisms that differentiate down diverse developmental pathways, additional layers of complexity are being uncovered. For example, in vertebrates several proteins involved in neuronal differentiation also regulate the G1-S phase transition (Ohnuma et al., 2001). These include the cdk inhibitor p21^{CIP1/WAF1/SDI1} which has been implicated in oligodendrocyte differentiation following growth arrest (Zezula et al., 2001), and in the terminal differentiation of other cell types (Parker et al., 1995).

[0005] Initiation of DNA replication can be reconstituted in vitro with isolated nuclei and cytosolic extracts from mammalian cells (Krude, 2000; Krude et al., 1997; Laman et al., 2001; Stoeber et al., 1998). Furthermore, using recombinant Cdk2 complexed with either cyclins E or A, replication complex assembly and activation of DNA synthesis can be reconstituted independently (Coverley et al., 2002). We have studied the activation step, catalysed in vitro by cyclin A-cdk2, and shown that a relatively unstudied protein, p21-Cip1 interacting zinc-finger protein (Ciz1) functions during this stage of the initiation process. Human Ciz1 was previously identified using a modified yeast two-hybrid screen with cyclin E-p21, and biochemical analysis supported an interaction with p21 (Mitsui et al., 1999). A potential role in transcription was proposed but not demonstrated, and no other function was assigned to Ciz1. More recently the Ciz1 gene was isolated from a human medulloblastoma derived cDNA library using an in vivo tumorigenesis model (Warder and Keherly, 2003). Our analysis shows for the first time that Ciz1 plays a positive role in initiation of DNA replication.

[0006] A number of changes to chromatin bound proteins occur when DNA synthesis is activated *in vitro* by recombinant cyclin A-cdk2. The present invention relates to the finding that a cdc6-related antigen, p85, correlates with the initiation of DNA replication and is regulated by cyclin A-cdk2. The protein was cloned from a mouse embryo library and identified as mouse Ciz1.

[0007] In vitro analysis has shown that Ciz1 protein positively regulates initiation of DNA replication and that its activity is modulated by cdk phosphorylation at threonine 191/2, linking it to the cdk-dependent pathways that control initiation. The Embryonic form mouse Ciz1 is alternately spliced, compared to predicted and somatic forms. Human Ciz1 is also alternately spliced, with variability in the same exons as mouse Ciz1. It has been found that recombinant embryonic form Ciz1 promotes initiation of mammalian DNA replication and that pediatric cancers express 'embryonic-like' forms of Ciz1. Without wishing to be held to one theory, the inventors propose that Ciz1 mis-splicing produces embryonic-like forms of Ciz1 at inappropriate times in development. This promotes inappropriately regulated DNA replication and contributes to formation or progression of cancer cell lineages.

[0008] A number of techniques have been developed in recent years which purport to specifically ablate genes and/or gene products. For example, the use of anti-sense nucleic acid molecules to bind to and thereby block or inactivate target mRNA molecules is an effective means to inhibit the production of gene products.

[0009] A much more recent technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from the exonic or coding sequence of the gene which is to be ablated.

[0010] Nucleic acids and proteins have both a linear sequence structure, as defined by their base or amino acid sequence, and also a three dimensional structure which in part is determined by the linear sequence and also the environment in which these molecules are located. Conventional therapeutic molecules are small molecules, for example,

peptides, polypeptides, or antibodies, which bind target molecules to produce an agonistic or antagonistic effect. It has become apparent that nucleic acid molecules also have potential with respect to providing agents with the requisite binding properties which may have therapeutic utility. These nucleic acid molecules are typically referred to as aptamers. Aptamers are small, usually stabilised, nucleic acid molecules which comprise a binding domain for a target molecule.

[0011] Aptamers may comprise at least one modified nucleotide base. The term "modified nucleotide base" encompasses nucleotides with a covalently modified base and/or sugar. For example, modified nucleotides include nucleotides having sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified nucleotides may also include 2' substituted sugars such as 2'-O-methyl-, 2-O-alkyl-, 2-O-allyl-, 2'-S-alkyl-, 2'-S-allyl-, 2'-fluoro-, 2'-halo or 2-azido-ribose, carbocyclic sugar analogues α -anomeric sugars; epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, and sedoheptulose.

[0012] Modified nucleotides are known in the art and include by example and not by way of limitation; alkylated purines and/or pyrimidines; acylated purines and/or pyrimidines; or other heterocycles. These classes of pyrimidines and purines are known in the art and include, pseudoisocytosine; N4, N4-ethanocytosine; 8-hydroxy-N6-methyladenine; 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil; 5-fluorouracil; 5-bromouracil; 5-carboxymethylaminomethyl-2-thiouracil; 5-carboxymethylaminomethyl uracil; dihydrouracil; inosine; N6-isopentyl-adenine; l-methyladenine; 1-methylpseudouracil; 1-methylguanine; 2,2-dimethylguanine; 2-methyladenine; 2-methylguanine; 3-methylcytosine; 5-methylcytosine; N6-methyladenine; 7-methylguanine; 5-methylaminomethyl uracil; 5-methoxy amino methyl-2-thiouracil; β -D-mannosylqueosine; 5-methoxycarbonylmethyluracil; 5-methoxyuracil; 2 methylthio-N6-isopentenyladenine; uracil-5-oxyacetic acid methyl ester; pseudouracil; 2-thiocytosine; 5-methyl-2 thiouracil, 2-thiouracil; 4-thiouracil; 5-methyluracil; N-uracil-5-oxyacetic acid methylester; uracil 5-oxyacetic acid; queosine; 2-thiocytosine; 5-propyluracil; 5-propylcytosine; 5-ethyluracil; 5-ethylcytosine; 5-butyluracil; 5-pentyluracil; 5-pentylcytosine; and 2,6,-diaminopurine; methylpseudouracil; 1-methylguanine; 1-methylcytosine;

[0013] Aptamers may be synthesized using conventional phosphodiester linked nucleotides using standard solid or solution phase synthesis techniques which are known in the art. Linkages between nucleotides may use alternative linking molecules. For example, linking groups of the formula P(O)S, (thioate); P(S)S, (dithioate); P(O)NR'²; P(O)R'; P(O)OR₆; CO; or CONR'² wherein R is H (or a salt) or alkyl (1-12C) and R₆ is alkyl (1-9C) is joined to adjacent nucleotides through -O- or -S-.

[0014] Other techniques which purport to specifically ablate genes and/or gene products focus on modulating the function or interfering with the activity of protein molecules. Proteins can be targeted by chemical inhibitors drawn, for example, from existing small molecule libraries.

[0015] Antibodies, preferably monoclonal, can be raised for example in mice or rats against different protein isoforms. Antibodies, also known as immunoglobulins, are protein molecules which have specificity for foreign molecules (antigens). Immunoglobulins (Ig) are a class of structurally related proteins consisting of two pairs of polypeptide chains, one pair of light (L) (low molecular weight) chain (κ or λ), and one pair of heavy (H) chains (γ , α , μ , δ and ϵ), all four linked together by disulphide bonds. Both H and L chains have regions that contribute to the binding of antigen and that are highly variable from one Ig molecule to another. In addition, H and L chains contain regions that are non-variable or constant.

[0016] The L chains consist of two domains. The carboxy-terminal domain is essentially identical among L chains of a given type and is referred to as the "constant" (C) region. The amino terminal domain varies from one L chain to another and contributes to the binding site of the antibody. Because of its variability, it is referred to as the "variable" (V) region.

[0017] The H chains of Ig molecules are of several classes, α , μ , σ , α , and γ (of which there are several sub-classes). An assembled Ig molecule consisting of one or more units of two identical H and L chains, derives its name from the H chain that it possesses. Thus, there are five Ig isotypes: IgA, IgM, IgD, IgE and IgG (with four sub-classes based on the differences in the H chains, i.e., IgG1, IgG2, IgG3 and IgG4). Further detail regarding antibody structure and their various functions can be found in, *Using Antibodies: A laboratory manual*, Cold Spring Harbour Laboratory Press.

[0018] Chimeric antibodies are recombinant antibodies in which all of the V-regions of a mouse or rat antibody are combined with human antibody C-regions. Humanised antibodies are recombinant hybrid antibodies which fuse the complementarity determining regions from a rodent antibody V-region with the framework regions from the human antibody V-regions. The C-regions from the human antibody are also used. The complementarity determining regions (CDRs) are the regions within the N-terminal domain of both the heavy and light chain of the antibody to where the majority of the variation of the V-region is restricted. These regions form loops at the surface of the antibody molecule. These loops provide the binding surface between the antibody and antigen.

[0019] Antibodies from non-human animals provoke an immune response to the foreign antibody and its removal from the circulation. Both chimeric and humanised antibodies have reduced antigenicity when injected to a human subject because there is a reduced amount of rodent (i.e. foreign) antibody within the recombinant hybrid antibody, while the human antibody regions do not illicit an immune response. This results in a weaker immune response and a decrease in the clearance of the antibody. This is clearly desirable when using therapeutic antibodies in the treatment of human diseases. Humanised antibodies are designed to have less "foreign" antibody regions and are therefore thought to be

less immunogenic than chimeric antibodies.

[0020] Other techniques for targetting at the protein level include the use of randomly generated peptides that specifically bind to proteins, and any other molecules which bind to proteins or protein variants and modify the function thereof.

[0021] Understanding the DNA replication process is of prime concern in the field of cancer therapy. It is known that cancer cells can become resistant to chemotherapeutic agents and can evade detection by the immune system. There is an on going need to identify targets for cancer therapy so that new agents can be identified. The DNA replication process represents a prime target for drug intervention in cancer therapy. There is a need to identify gene products which modulate DNA replication and which contribute to formation or progression of cancer cell lineages, and to develop agents that affect their function.

Statements of the invention

[0022] According to a first aspect of the present invention there is provided an *in vitro* diagnostic method for the identification of a proliferative disorder, the method comprising detecting the presence or expression of a Ciz1 splice variant, wherein the method provides for a quantitative measure of a Ciz1 protein variant in a sample from a subject, and the protein variant is a human alternatively spliced protein sequence in which the sequence:

- (a) QQLQQLQQQLQQQLQQQLLQLQQLLQQSPP or MFSQQQQQLQQQLQQQLQQQLQQQLQQQLLQLQQLLQQSPPQA is absent;
- (b) GLDQFAMPPATYDTAGLTMPATL is absent;
- (c) DSSSQ is absent;
- (d) PQVQPAHSQPPRQVQLQLQKQVQTQTY, or PQVQPAHSQGPRQVOLQQEAEPLKQVQPQVQPAHSQPPRQVQLQLQKQVQTQTY, or

QVQSQTQPRIPSTDITQVQPKLQKQAQTQTSPEHLVLQKKQVQPQLQQEAEPPKQVQPQVQPAHSQGPRQVQLQQEAEPLKQVQPQVQPAHSQPPRQVQLQLQKQVQTQTY

- is absent; or
- (e) VEEELCKQ is absent.

[0023] According to another aspect of the present invention there is provided an *in vitro* diagnostic method for the identification of a proliferative disorder, the method comprising detecting the presence or expression of a Ciz1 splice variant, wherein the method provides for a quantitative measure of a Ciz1 RNA variant in a sample from a subject, and wherein the Ciz1 RNA variant is a human alternatively spliced RNA sequence in which the sequence:

- (a)

TGGGGGCTGCGGGGCGGGGCCCCATCCGTGGGGGCGACTTGAGCGTTGAGGGCGCGCGGGGAGGCGAGCCACCATGTTTCAGCCAGCAGCAGCAGCAGCTCCAGCAACAGCAGCAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTGCAGCAGCAGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACAGGCC,

or

CAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTGCAGCAGCAGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACA

- is absent;
- (b)

(b) GGACTGGACCAGTTTGCAATGCCACCAGCCACGTATGACACTGCCGGTCTCACCA
T GCCCAGCAACACTG

is absent;
(c) AGGATTCTTCTCTC is absent;
(d)

(d) CCACAGGTGCAGCCCCAGGCACATTCACAGCCCCAAGGCAGGTGCAGCTGCAG
CTGCAGAAGCAGGTCCAGACACAGACATATCC,

or

CCACAGGTACAGCCACAGGCACATTCACAGGGCCCAAGGCAGGTGCAGCTGCAGCA
GGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCCCAGGCACATTCAC
AGCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCCAGACACAGACATAT,

or

CAGGTGCAGTCACAGACTCAGCCGCGGATACCATCCACAGACACCCAGGTGCAGCC
AAAGCTGCAGAAGCAGGCGCAAACACAGACCTCTCCAGAGCACTTAGTGCTGCAAC
AGAAGCAGGTGCAGCCACAGCTGCAGCAGGAGGCAGAGCCACAGAAGCAGGTGCA
GCCACAGGTACAGCCACAGGCACATTCACAGGGCCCAAGGCAGGTGCAGCTGCAGC
AGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCCCAGGCACATTCA
CAGCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCCAGACACAGACATA
T

is absent; or
(e) GTTGAGGAGGAACTCTGCAAGCAG is absent.

[0024] In one embodiment the proliferative disorder is cancer.

[0025] In another embodiment the cancer is a pediatric cancer selected from the group consisting of retinoblastoma, neuroblastoma, Burkett lymphoma, medulloblastoma, and Ewings sarcoma family tumors.

[0026] In another embodiment the cancer is carcinoma, adenocarcinoma, lymphoma or leukemia.

[0027] In another embodiment the cancer is liver, lung, or skin cancer.

[0028] In another embodiment the diagnostic method comprises one or more of the following steps:

- (a) contacting the sample with an agent that specifically binds a polypeptide with Ciz1 activity and measuring the binding of the agent to the polypeptide in the sample;
- (b) using reverse-transcribed PCR or real-time PCR to monitor Ciz1 isoform expression and to measure expression levels;
- (c) measuring the presence of nucleic acid or amino acid mutations based on altered conformational properties of the molecule.

[0029] In one embodiment the agent that specifically binds a polypeptide with Ciz1 activity is an anti-Ciz1 antibody.

[0030] The antibody may be a monoclonal antibody.

[0031] There is also described herein the use of Ciz1 nucleotide or polypeptide sequence, or any fragment or variant thereof, as a target for the identification of agents which modulate DNA replication.

[0032] As used herein the term 'fragment' or 'variant' is used to refer to any nucleic or amino acid sequence which is derived from the full length nucleotide or amino acid sequence of Ciz1 or derived from a splice variant thereof. In one embodiment the fragment is of sufficient length and/or of sufficient homology to full length Ciz1 to retain the DNA replication activity of Ciz1. In an alternative embodiment inactive Ciz1 fragments are used. The term 'fragment' or 'variant' also relates to the Ciz1 RNA transcripts described herein and protein isoforms (or parts thereof).

[0033] As used herein the term 'modulate' is used to refer to either increasing or decreasing DNA replication, above and below the levels which would normally be observed in the absence of the specific agent (i.e., any alterations in DNA replication activity which are either directly or indirectly linked to the use of the agent). The term 'modulate' also includes reference to a change of spacial or temporal organisation of DNA replication.

[0034] There is also described herein a screening method for the identification of agents which modulate DNA replication

wherein the screening method comprises the use of Ciz1 nucleotide or polypeptide sequence or fragments or variants thereof.

[0035] The screening method may comprise detecting or measuring the effect of an agent on a nucleic acid molecule selected from the groups consisting of:

- a) a nucleic acid molecule comprising a nucleic acid sequence represented in any of Figures 14, 15, or 21;
- b) a nucleic acid molecule which hybridises to the nucleic acid sequence in (a) and which has Ciz1 activity or activity of a variant thereof;
- c) a nucleic acid molecule which has a nucleic acid sequence which is degenerate because of the genetic code to the sequences in a) and b) and a candidate agent to be tested;
- d) a nucleic acid molecule derived from the genomic sequence at the Ciz1 locus or a nucleic acid molecule that hybridises to the genomic sequence.

[0036] The nucleic acid molecule may be modified by deletion, substitution or addition of at least one nucleic acid residue of the nucleic acid sequence.

[0037] Alternatively the screening method comprises the steps of:

- (i) forming a preparation comprising a polypeptide molecule, or an active fragment thereof, encoded by a nucleic acid molecule selected from the group consisting of:

- a) a nucleic acid molecule comprising a nucleic acid sequence represented in Figs 14, 15 or 21;
- b) a nucleic acid molecule which hybridises to the nucleic acid sequence in (a) and which has Ciz1 activity or activity of a variant thereof;
- c) a nucleic acid molecule which has a nucleic acid sequence which is degenerate because of the genetic code to the sequences in a) and b) and a candidate agent to be tested;
- d) a nucleic acid molecule derived from the genomic sequence at the Ciz1 locus or a nucleic acid molecule that hybridises to the genomic sequence; and

- (ii) detecting or measuring the effect of the agent on the activity of said polypeptide.

[0038] Assays for the detection of DNA replication are known in the art. Activity residing in Ciz1, or derived peptide fragments, and the effect of potential therapeutic agents on that activity would be assayed *in vitro* or *in vivo*.

[0039] *In vitro* assays for Ciz1 protein activity would comprise synchronised isolated G1 phase nuclei and either S phase extract or G1 phase extract supplemented with cyclin-dependent kinases. Inclusion of Ciz1 or derived peptide fragments stimulates initiation of DNA replication in these circumstances and can be monitored visually (by scoring nuclei that have incorporated fluorescent nucleotides during *in vitro* reactions) or by measuring incorporation of radioactive nucleotides. The assay for therapeutic reagents that interfere with Ciz1 protein function would involve looking for inhibition of DNA replication in these assays. The effect of agents on Ciz1 nuclear localisation, chromatin binding, stability, modification and protein-protein interactions could also be monitored in these assays.

[0040] *In vivo* assays will include creation of cell and mouse models that over-express or under-express Ciz1, or derived fragments, resulting in altered cell proliferation. The preparation of transgenic animals is generally known in the art and within the ambit of the skilled person. The assay for therapeutic reagents would involve analysis of cell-cycle time, initiation of DNA replication and cancer incidence in the presence and absence of drugs that either impinge on Ciz1 protein activity, or interfere with Ciz1 production by targeting Ciz1 and its variants at the RNA level.

Hybridisation conditions may be stringent.

[0041] Stringent hybridisation/washing conditions are well known in the art. For example, nucleic acid hybrids that are stable after washing in 0.1xSSC, 0.1% SDS at 60°C. It is well known in the art that optimal hybridisation conditions can be calculated if the sequence of the nucleic acid is known. Typically, hybridisation conditions uses 4 - 6 x SSPE (20x SSPE contains 175.3g NaCl, 88.2g NaH₂PO₄ H₂O and 7.4g EDTA dissolved to 1 litre and the pH adjusted to 7.4); 5-10x Denhardt's solution (50x Denhardt's solution contains 5g Ficoll (Type 400, Pharmacia), 5g polyvinylpyrrolidone abd 5g bovine serum albumen; 100µg-1.0mg/ml sonicated salmon/herring DNA; 0.1-1.0% sodium dodecyl sulphate; optionally 40-60% deionised formamide. Hybridisation temperature will vary depending on the GC content of the nucleic acid target sequence but will typically be between 42°- 65° C.

[0042] Said polypeptide may be modified by deletion, substitution or addition of at least one amino acid residue of the polypeptide sequence.

[0043] A modified or variant, i.e. a fragment polypeptide and reference polypeptide, may differ in amino acid sequence

by one or more substitutions, additions, deletions, truncations which may be present in any combination. Among preferred variants are those that vary from a reference polypeptide by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid by another amino acid of like characteristics. The following non-limiting list of amino acids are considered conservative replacements (similar): a) alanine, serine, and threonine; b) glutamic acid and aspartic acid; c) asparagine and glutamine d) arginine and lysine; e) isoleucine, leucine, methionine and valine and f) phenylalanine, tyrosine and tryptophan. Preferred are variants which retain the same biological function and activity as the reference polypeptide from which it varies. Alternatively, variants include those with an altered biological function, for example variants which act as antagonists, so called "dominant negative" variants.

[0044] Alternatively or in addition, non-conservative substitutions may give the desired biological activity see Cain SA, Williams DM, Harris V, Monk PN. Selection of novel ligands from a whole-molecule randomly mutated C5a library. Protein Eng. 2001 Mar, 14(3):189-93.

[0045] A functionally equivalent polypeptide sequence as described herein is a variant wherein one or more amino acid residues are substituted with conserved or non-conserved amino acid residues, or one in which one or more amino acid residues includes a substituent group. Conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxi residues Ser and Thr, exchange of the acidic residues Asp and Glu; substitution between amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among aromatic residues Phe and Tyr.

[0046] There is described herein nucleotide or polypeptide sequences having at least 50% identity with the nucleotide or polypeptides sequences as hereindisclosed, or fragments and functionally equivalent polypeptides thereof. In one embodiment, the nucleotide or polypeptide sequences have at least 75% to 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, still more preferably at least 97% identity, and most preferably at least 99% identity with the nucleotide and amino acid sequences illustrated herein.

[0047] In a preferred method of the invention said nucleic acid molecule comprises the nucleic acid sequence encoding the amino acid sequence Ciz1 described in Figures 20A and 20B. In a further preferred method of the invention said nucleic acid molecule consists of the nucleic acid sequence which encodes the amino acid sequence Ciz1 described in Figures 20A and 20B.

[0048] In a further preferred method of the invention said polypeptide molecule comprises the amino acid sequence Ciz1 described in Figures 20A and 20B. In a further preferred method of the invention said polypeptide molecule consists of the amino acid sequence Ciz1 described in Figures 20A and 20B.

[0049] Said polypeptide may be expressed by a cell, preferably a mammalian cell, or animal and said screening method is a cell-based screening method.

[0050] Said cell may naturally expresses the Ciz 1 polypeptide. Alternatively said cell is transfected with a nucleic acid molecule encoding a Ciz 1 polypeptide (or a variant molecule thereof, found, for example in cancer cell lineages).

[0051] There is described herein an agent obtainable by the method described herein.

[0052] Said agent may be an antagonist of Ciz1 mediated DNA replication. Alternatively said agent may be an agonist of Ciz1 mediated DNA replication.

[0053] In a further preferred method described herein said agent is selected from the group consisting of: polypeptide; peptide; aptamer; chemical; antibody; nucleic acid; or polypeptide or nucleotide probe.

[0054] Preferably the agent comprises a sequence that is complimentary or of sufficient homology to give specific binding to the target and can be used to detect the level of nucleic acid or protein for diagnostic purposes.

[0055] The agent identified by the method described herein may be a therapeutic agent and can be used for the treatment of disease.

[0056] In one embodiment of the invention the agent is an antibody molecule and binds to any of the sequences represented by figures 16, 17 or 20.

[0057] Preferably said antibody is a monoclonal antibody.

[0058] There is described herein an agent which is an anti-sense nucleic acid molecule which binds to and thereby blocks or inactivates the mRNA encoded by any of the nucleic acid sequences in (i) above.

[0059] In an alternative embodiment, said agent is an RNAi molecule and comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. Preferably the RNAi molecule is derived from the exonic sequence of the Ciz1 gene or from another over-lapping gene.

[0060] Unspliced mRNA may be targetted with RNAi to inhibit production of the spliced variant or the spliced variant mRNA may be ablated without affecting the non-variant mRNA

[0061] Said peptide may be a modified peptide.

[0062] It will be apparent to one skilled in the art that modified amino acids include, by way of example and not by way of limitation, 4-hydroxyproline, 5-hydroxylysine, N⁶-acetyllysine, N⁶-methyllysine, N⁶,N⁶-dimethyllysine, N⁶,N⁶,N⁶-trimethyllysine, cyclohexylalanine, D-amino acids, omithine. Other modifications include amino acids with a C₂, C₃ or C₄ alkyl R group optionally substituted by 1, 2 or 3 substituents selected from halo (eg F, Br, I), hydroxy or C₁-C₄ alkoxy.

[0063] Alternatively said peptide is modified by acetylation and/or amidation.

[0064] The polypeptides or peptides may be modified by cyclisation. Cyclisation is known in the art, (see Scott et al Chem Biol (2001), 8:801-815; Gellerman et al J. Peptide Res (2001), 57: 277-291; Dutta et al J. Peptide Res (2000), 8: 398-412; Ngoka and Gross J Amer Soc Mass Spec (1999), 10:360-363).

[0065] There is also described herein a vector as a delivery means for, for example, an antisense or an RNAi molecule which inhibits Ciz1 or variants thereof and thereby allows the targeting of cells expressing the protein to be targeted.

[0066] A viral vector may be used as delivery means.

[0067] Preferably the vectors including the expression cassette is adapted for eukaryotic gene expression. Typically said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell/tissue specific expression. These promoter sequences may be cell/tissue specific, inducible or constitutive.

[0068] Promoter elements typically also include so called TATA box and RNA polymerase initiation selection sequences which function to select a site of transcription initiation. These sequences also bind polypeptides which function, *inter alia*, to facilitate transcription initiation selection by RNA polymerase.

[0069] Adaptations also include the provision of selectable markers and autonomous replication sequences which both facilitate the maintenance of said vector in either the eukaryotic cell or prokaryotic host. Vectors which are maintained autonomously are referred to as episomal vectors. Further adaptations which facilitate the expression of vector encoded genes include the provision of transcription termination sequences.

[0070] These adaptations are well known in the art. There is a significant amount of published literature with respect to expression vector construction and recombinant DNA techniques in general. Please see, Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory, Cold Spring Harbour, NY and references therein; Marston, F (1987) DNA Cloning Techniques: A Practical Approach Vol III IRL Press, Oxford UK; DNA Cloning: F M Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc.(1994).

[0071] According to the present invention there is provided a diagnostic method for the identification of proliferative disorders comprising detecting the presence or expression of the Ciz1 gene, Ciz1 splice variants and mutations in the genomic or protein sequence thereof.

[0072] The diagnostic method of the invention may provide for a quantitative measure of Ciz1 RNA or protein variants in a sample.

[0073] There is also described herein the use of an agent which modulates Ciz1 DNA or protein, or variants thereof, as a pharmaceutical.

[0074] Said pharmaceutical may comprise an agent described herein in combination or association with a pharmaceutically acceptable carrier, excipient or diluent.

[0075] Preferably said pharmaceutical is for oral or topical administration or for administration by injection. In alternative embodiment the pharmaceutical is administered as an aerosol.

[0076] There is also described herein the use of an agent described herein for the manufacture of a medicament for use in the treatment of proliferative disease. Preferably said proliferative disease is cancer.

[0077] Preferably said cancer is a paediatric cancer and is selected from the group consisting of; retinoblastoma, neuroblastoma, Burkitt lymphoma, medulloblastoma, Ewings Sarcoma family tumours (ESFTs).

[0078] In an alternative embodiment the cancer is a carcinoma, adenocarcinoma, lymphoma or leukemia.

[0079] In an alternate embodiment the disease is liver, lung or skin cancer or metastasis.

[0080] There is also described herein a method to treat a proliferative disease comprising administering to an animal, preferably a human, an agent obtainable by the method described herein.

[0081] There is also described herein the use of an agent described herein for the manufacture of a medicament to slow cell division or growth.

[0082] Described herein is the use of the Ciz1 amino acid sequence and protein structure in rational drug design and the use of Ciz1 nucleotide and amino acid sequences thereof or variants thereof for screening chemical libraries for agents that specifically bind to Ciz1.

[0083] Also described is a kit comprising a diagnostic, prognostic or therapeutic agent identified by the method described herein.

[0084] In an alternative embodiment an array based sequencing chip is used for the detection of altered Ciz1.

Detailed Description

[0085] An embodiment of the invention will now be described by example only and with reference to the following figures:

Fig. 1 Illustrates the effect of cyclin A-cdk2 on late G1 nuclei. A) Anti-Cdc6 antibody V1 detects mouse Cdc6 and a second antigen in western blots of 3T3 whole cell extract, which migrates with approximate Mr of 100kDa (based on the mobility of the Mcm3 protein this was previously estimated at nearer 85kDa so the antigen was named p85 - we have kept the same name here for clarity). P85 is present in both the soluble fraction and insoluble nuclear

fraction (prepared under *in vitro* replication conditions). B) Initiation of DNA synthesis in 'replication competent' late G1 phase nuclei by G1 phase extract supplemented with recombinant cyclin A-cdk2. Control bar shows the proportion of nuclei already in S phase (unshaded), and those that initiated replication in extract from S phase cells (shaded). C) After 15 minutes under cell-free replication conditions nuclei were washed and the chromatin fraction was re-isolated and separated by SDS-Page and blotted for Mcm2 and Mcm3. D) The same nuclei blotted with antibody V1. p85 antigen is more abundant in nuclei exposed to initiation-inducing concentrations of cyclin A-cdk2. Antibody V1 was used to clone the gene for p85 from a mouse embryo expression library which was identified as Ciz1.

Fig. 2 Alignment of mouse Ciz1 variants. The predicted full-length Ciz1 amino-acid sequence ('Full') is identical to a mouse mammary tumour cDNA clone (BC018483), while embryonic Ciz1 ('ECiz1', AJ575057), and a melanoma-derived clone (AK089986) lack two discrete internal sequences. In addition, the first available methionine in ECiz1 is in the middle of exon 3 (Met84), which excludes a polyglutamine rich region from the N-terminus. Melanoma derived AK089986 may be incomplete as it ends 77 codons before the C-terminus of all other mouse and human clones. Stars indicate amino-acids changed by site-directed mutagenesis in the constructs shown in D. Amino-acids that correspond to codons targeted by siRNAs are underlined. B) Mouse Ciz1 is encoded by at least 17 exons. Coding exons are shown in grey, alternatively spliced regions are black, untranslated regions are white. Two alternative exon 1 sequences are included in some Ciz1 transcripts (not shown) but an alternative translational start site upstream of the two depicted here has not yet been found. C) Sequence features and putative domains in ECiz1. Predicted nuclear localisation sequence (NLS), putative cyclin-dependent kinase phosphorylation sites, C2H2 type zinc-fingers and a C terminal domain with homology to the nuclear matrix protein matrin 3 (Nakayasu and Berezney, 1991) are shown. The positions of sequences absent from ECiz1 are indicated by triangles. D) ECiz1 and derived truncations and point mutants used in cell-free DNA replication experiments. Numbers in parentheses relate to amino-acid positions in the full-length form of mouse Ciz1, shown in A. Stars indicate putative phosphorylation sites ablated by site-directed mutagenesis.

Fig. 3 Shows the effect of Ciz1 protein and derived fragments in cell-free DNA replication experiments and illustrates that ECiz1 promotes initiation of mammalian DNA replication A) Recombinant ECiz1 stimulates initiation of DNA replication in 'replication competent' late G1 phase nuclei, during incubation in S phase extract. Histogram shows the average number of nuclei that incorporated biotinylated nucleotides *in vitro* (black), in the presence or absence of ectopic ECiz1, with standard deviations calculated from four independent experiments. The 17% of nuclei that were already in S phase when the nuclear preparation was made are shown in white. Images show nuclei replicating *in vitro*, with or without 1 nM ECiz1. Total nuclei are counterstained with propidium iodide (red). B) The response to recombinant ECiz1 is concentration dependent with a sharp optimum in the nM range. In this experiment, and all those shown in B-1, results are expressed as % initiation rather than % replication. This is calculated from the number of nuclei that initiate *in vitro* and the number of nuclei that are 'competent' to initiate *in vitro* (see methods). C) Threonines 191/2 are involved in regulating Ciz1 DNA replication activity as ECiz1 cdk site mutant T(191/2)A escapes suppression at high concentrations. D) Cdk site mutant T(293)A stimulates initiation with a similar profile to ECiz1 but at lower concentrations. E) Truncated ECiz1 (Nterm 442) lacks C-terminal sequences, but stimulates *in vitro* initiation to a similar extent as ECiz1. F) Cterm 274 retains no DNA replication activity in this assay. G, H, I) Further deletion analysis in the N-terminal two thirds of the ECiz1 protein show that a short region 3' of exon 8 is required for Ciz1 function when assayed *in vitro*.

Fig. 4 Characterisation of anti-Ciz1 polyclonal antibodies and identification of 125kDa Ciz1-related bands A) Coomassie stained SDS-polyacrylamide gel showing purified recombinant ECiz1 fragment Nterm442, and western blots of recombinant Nterm442 using anti-Cdc6 antibody V1, and anti-Ciz1 antibodies 1793 and 1794. B) Western blot of 3T3 whole cell extract. Of the two bands detected by anti-Ciz1 antibody 1793 one has the same mobility as p85-Ciz1 (100kDa) recognized by antibody V1 and the other has an apparent Mr of 125kDa. Anti-Ciz1 antibody 1794 recognizes only the 125kDa form of Ciz1 (and a second antigen of around 80 kDa). C) Immuno-precipitation from 3T3 nuclear extract, using antibody V1 or anti-Ciz1 1793. Both antibodies precipitate p85, which is recognized by the reciprocal antibody in western blots. P125 is precipitated by antibody 1793, and to a lesser extent by antibody V1 and these are recognized by 1793 in western blots. Mcm3 is shown as a control.

Fig. 5 Immunofluorescence analysis of endogenous Ciz1. Ciz1 resides in sub-nuclear foci that overlap with sites of DNA replication A) Endogenous Ciz1 (red) in 3T3 cells fixed before (untreated) or after (detergent treated) exposure to TritonX100, detected with anti-Ciz1 antibody 1793. Nuclei are counterstained with Hoechst 33258 (blue). Cdc6 (green), detected with a Cdc6-specific monoclonal antibody is shown for comparison. B) Inclusion of recombinant Ciz1 blocks reactivity of antibody 1793 with detergent treated nuclei. C) Detergent-resistant Ciz1 (red) is present in all nuclei in cycling populations, while detergent resistant PCNA (green) persists only in S phase nuclei. D) High magnification confocal sections of detergent resistant Ciz1 and PCNA, and merged image showing co-localising foci (yellow). E) Line plots of red and green fluorescence across the merged image in D, at the positions indicated (i and ii). F) Cross-correlation plot (Rubbi and Milner, 2000; van Steensel et al., 1996) for green foci compared to red over the whole merged image in D, and (inset) for the marked section after thresholding fluorescence at the

levels shown in Eii. The red line in the inset to F shows loss of correlation when the Ciz1 image is rotated 90° with respect to PCNA. Bar is 10 μ M.

Fig. 6 RNA interference. Ciz1 depletion inhibits S phase A) siRNAs that target Ciz1 transcripts at four sites (see Fig. 2A) were individually applied to cycling 3T3 cells as a single 3nM dose and cell number was monitored at the indicated times. Images of cell populations at 16 and 40 hours after transfection with siRNA 8 (red outline) or mock treated cells (blue outline) are shown. B) Ciz1 protein detected with anti-Ciz1 1793 (green) 48 hours after exposure to Ciz1 siRNAs (4 and 8), or control GAPDH siRNA. C) Ciz1, GAPDH and α -actin transcript levels in cells exposed to Ciz1 siRNAs (4 and 8), or control GAPDH siRNA for 24 hours. Numbers in parentheses reflect band intensity in arbitrary units, and the overall reduction in Ciz1 and GAPDH transcripts (normalised against α -actin) is expressed as a percentage. D) The proportion of cells that incorporated BrdU into DNA (green) is significantly decreased in Ciz1 depleted cells, 48 hours after treatment with Ciz1 siRNA. Histogram shows average results from four independent experiments. E) The number of nuclei with detergent resistant Mcm3 (green) increases in populations treated with Ciz1 siRNA. F) The proportion of nuclei with detergent resistant PCNA (green) also increases under these conditions. All nuclei are counterstained and shown in pseudo-colour (red).

Fig. 7 RT-PCR analysis of Ciz1 exons 3/4 splice variant expression in mouse primordial germ cells and embryonic stem cells. Exons 3 and/or 4 are alternatively spliced in these cell types, but not in neonatal heart. These data are consistent with the hypothesis that full-length Ciz1 is the pre-dominant form in neonatal somatic tissue, and that variants occur with more frequency earlier in development, and in germ line tissues.

Fig. 8 Transient transfection of mouse 3T3 cells. A. GFP-tagged Ciz1 constructs were transfected into NIH3T3 cells or B. microinjected into the male pro-nucleus of fertilized mouse eggs at the one cell stage. By 24 hours Ciz1 and ECiz1 became localized to the nucleus forming a subnuclear spotty pattern, while GFP alone was present in both the nucleus and the cytoplasm. C. High magnification images of live 3T3 cell nuclei 24 hours after transfection showing the subnuclear organisation of EGFP tagged Ciz1 and ECiz1 and derived fragments with the C-terminal fragment (equivalent to Cterm274) removed. In the absence of C-terminal domains GFP-ECiz1 is diffusely localised in the nucleus 24 hours after transfection, while GFP-Ciz1 aggregates to form one or two large blobs within the nucleus. D. The Cterminal 274 domain alone is cytoplasmic until after cells have passed through mitosis (most likely due to lack of nuclear localisation sequences and passive entry to the nucleus), but once inside binds to nuclear structures and condenses with chromosomes. E. Representative images of GFP-Ciz1 (green), BrdU (red) and total nuclei (blue) in a population labelled with BrdU for the first 12 hours after transfection are shown. Histograms show the proportion of transfected (green) cells that incorporated BrdU compared to the number of untransfected (grey) cells for three separate labelling windows. During 0-22 hours after transfection rapidly cycling cells registered a consistent increase in the BrdU labelled fraction when transfected with either Ciz1 or ECiz1. Similar results were obtained with dense cultures in which most cells had exited the cell cycle and entered quiescence. However, when rapidly cycling cells were exposed to BrdU for a short (20 minute) pulse 22 hours after transfection the number of cells engaged in DNA synthesis was reduced in the Ciz1 and ECiz1 transfected populations, compared to untransfected controls and cells transfected with GFP alone. This indicates that by 22 hours DNA synthesis had ceased in Ciz1 expressing cells.

Fig. 9 Altered proliferation potential and cell morphology in transfected populations. Cell clusters arising in transfected 3T3 cell populations. A. Cells were transfected with the N-terminal two thirds of Ciz1 or ECiz1 (N-term442) tagged with GFP, and maintained under selection with 50 μ g/ml G418. After three weeks under selection, cell aggregates were visible with GFP positive cells within.

Fig. 10 Human Ciz1 splice variants in paediatric cancers. There are seven human Ciz1 cDNAs in public databases, but only one is derived from normal adult tissue (B cells) and it contains all predicted exons. The other six are derived from embryonic cells or paediatric cancers. Five of these are alternatively spliced with variability in exons 2, 3, 6, and 8 (like mouse ECiz1), and also in exon 4 (like mouse ES cells, primordial germ cells and testis). The sixth (AF159025) lacks the first methionine and contains single-nucleotide polymorphisms that give rise to amino-acid substitutions. All differences from the predicted sequence (AB030835) are marked.

Fig. 11 EST sequence analysis. On each map a schematic representation of the Ciz1 protein is included for reference, showing the positions of alternatively spliced exons (black), putative chromatin interaction domains (grey) and predicted zinc fingers (black vertical lines). All EST sequences are accompanied by their Genbank accession number with the library from which they were derived indicated in parentheses. Sequences absent from Ciz1 ESTs due to alternative splicing are shown in yellow, frame-shifts in red and putative deletions in grey. Single nucleotide polymorphisms that give rise to amino-acid substitutions are indicated by black dots and some of these occur in a consensus cdk phosphorylation site which we have shown to be important for the regulation of Ciz1 activity (blue dots). Position of the inserted sequence in the carcinoma cell line MGC102 is indicated by a triangle.

A) Translated ESTs from paediatric cancers and adult neural cancers.

B) Translated ESTs from various non-cancer cells and tissues

- C) Translated ESTs from leukemias, lymphomas, and from normal haematopoietic and lymphocytic cells
- D) Translated ESTs from carcinomas
- E) Translated ESTs from a range of other cancers
- F) Summary of alternatively spliced regions in human Ciz1 showing conditionally included sequences.

Fig. 12 Ciz1 splice variant expression in Ewings sarcoma family tumour cells lines (ESFT) and neuroblastoma cell lines. A. Whole RNA samples from six independent ESFT cell lines, two neuroblastomas and a control cell line (HEK293 cells) was subject to RT-PCR analysis using 4 different primer sets. ESFT cell lines are 1) A673, 2) RDES, 3) SKES1, 4) SKNMC, 5) TC3, 6) TTC466. Neuroblastoma cell lines are 1) IMR32, 2) SKNSH.

B. Analysis of Ciz1 Exons 3/4/5 PCR products in ESFTs and neuroblastoma. The products of primers h3 and h4 (spanning potentially variable exons 4 and 6) were analysed in more detail. PCR fragments were purified from agarose gels by standard procedures, subcloned and sequenced to identify the source of fragment size variations. Between one and eleven individual clones for each of the seven cell lines were sequenced and the results are summarised in tabular form. Ciz1 from ESFT cell lines lacks exon 4 in 31% of transcripts overall, and for some ESFT lines this is nearer 50%. DSSSQ is more commonly absent in the two neuroblastoma cell lines tested here.

Fig. 13 Ciz1 isoforms in normal human fibroblasts (Wi38) and metastatic prostate cancer cell lines (PC3 and LNCAP).

A. Both prostate cancer cell lines contain an excess of the largest p125 Ciz1 protein variant in the nuclear fraction, compared to the non-cancer cell line. B. Models for the production of p85 (100) from p125 variants by protein processing during initiation of DNA replication.

Fig. 14 illustrates the full length mouse mRNA sequence.

Fig. 15 illustrates the full length human mRNA sequence.

Fig. 16 illustrates the full length mouse protein sequence.

Fig. 17 illustrates the full length human protein sequence.

Fig. 18 illustrates human alternatively spliced protein sequences. Sequences shown are absent in the spliced protein sequences.

Fig. 19 illustrates human alternatively spliced mRNA sequences. Sequences shown are absent in the spliced protein sequences.

Fig. 20A and B illustrate unique junction sequences created in human Ciz1 proteins by missing exons. Junction sequences represent prime sites of target for therapeutic agents identified by the method of the invention.

Fig 21A to H illustrate junction sequences created in human Ciz1 mRNA.

[0086] Identification of Ciz1 We have exploited a polyclonal antibody (antibody V1) that was raised against recombinant human Cdc6 (Coverley et al., 2000; Stoeber et al., 1998; Williams et al., 1998) to identify and study an unknown antigen whose behaviour correlates with initiation of DNA replication in vitro. The antigen has an apparent Mr of 100kDa (called p85) and is readily detectable in extracts from 3T3 cells (Fig. 1A).

[0087] DNA synthesis can be activated in cell-free replication experiments using 'replication competent' late G1 phase nuclei, G1 extracts, and recombinant cyclin A-cdk2. Under these conditions nuclei will incorporate labelled nucleotides into nascent DNA, in a manner strictly dependent on the concentration of active protein kinase (Fig. 1B). Above and below the optimum concentration no initiation of DNA replication takes place. However, other events occur which inversely correlate with initiation (Coverley et al., 2002). Here we use activation of DNA synthesis (Fig. 1B), and Mcm2 phosphorylation (which results in increased mobility, Fig. 1C), to calibrate the effects of recombinant cyclin A-cdk2 in cell-free replication experiments, and correlate the behaviour of p85 with activation of DNA synthesis.

[0088] In G1 nuclei that are re-isolated from reactions containing initiation-inducing concentrations of cyclin A-cdk2, p85 antigen is more prevalent compared to nuclei exposed to lower or higher concentrations of kinase (Fig. 1D). This suggests that p85 is regulated at some level by cyclin A-cdk2, in a manner that is co-incident with activation of DNA synthesis. No other antigens correlate so closely with this stage in the cell-free initiation process, therefore we used antibody V1 to clone the gene for mouse p85. When applied to a cDNA expression library derived from 11-day mouse embryos antibody V1 picked out two clones that survived multiple rounds of screening (see methods). One encoded mouse Cdc6, while the other encoded 716 amino acids of the murine homologue of human Ciz1 (Mitsui et al., 1999). Full-length human and mouse Ciz1 have approximately 70% overall homology at the amino-acid level, with greatest (>80%) homology in the N and C terminal regions. Ciz1 is conserved among vertebrates as homologues exist in rat and fugu, but no proteins with a high degree of homology or similar domain structure could be identified in lower eukaryotes, raising the possibility that Ciz1 evolved to perform a specialised role in vertebrate development.

[0089] A previous publication on human Ciz1 (Mitsui et al 1999) demonstrated interaction with the cell-cycle protein p21-CIP1, leading to investigation of a proposed role as a transcription factor, not a DNA replication factor. A second paper (Warder and Keherly 2003) published after the priority date of this patent application suggests a role for Ciz1 in tumorigenesis, but does not demonstrate a role in DNA replication or recognise the importance of Ciz1 splice variant expression.

[0090] Multiple Ciz1 isoforms The predicted mouse Ciz1 open reading frame and a cDNA derived from a mouse mammary tumour library (BC018483) contain three regions that are not present in our embryonic clone (AJ575057), hereafter referred to as ECiz1 (Fig. 2A). The three variable regions in ECiz1 appear to be the result of alternative splicing of exons 2/3, 6 and 8 (Fig. 2B). Mouse melanoma clone AK089986 lacks two of the same three regions as ECiz1 (Fig. 2A), while the third encodes an N-terminal polyglutamine stretch that is also absent from human medulloblastoma derived clones. A fourth sequence block derived from exons 3/4 is absent from Ciz1 transcripts derived from mouse ES cells, and from exon 4 in mouse primordial germ cells (fig. 7). Human Ciz1 is also alternatively spliced at the RNA level to yield transcripts that exclude combinations of the same four sequence blocks as mouse Ciz1 (see below). In fact, all known variations in mouse Ciz1 cDNAs have close human parallels, some of which are identical at the amino-acid level. This suggests that the different Ciz1 isoforms have functional significance. A fifth variable regions (not yet observed in the mouse) is alternatively spliced in human Ciz1 transcripts derived mainly from carcinomas.

[0091] The data suggest that shorter forms of Ciz1 (lacking the alternatively spliced exons) are most prevalent early in development and in cell lineages that give rise to the germ line. In the analysis shown in fig. 7, only Ciz1 from fully developed neonatal heart shows no alternative splicing, while all embryonic cell types contain alternatively spliced forms. Furthermore, the only complete Ciz1 cDNAs in public databases (human or mouse) are derived from non-embryonic cell types, and the only ones derived from embryonic sources are alternatively spliced. Therefore, Ciz1 splice variant expression appears to occur preferentially in cell types that are not yet fully differentiated.

[0092] Notably, Ciz1 cDNAs from paediatric cancers are also alternatively spliced (see below). This lead us to the hypothesis that failure to express the appropriate Ciz1 isoform at the right point in development leads to inappropriately regulated Ciz1 activity. This could contribute to unscheduled proliferation and cellular transformation.

[0093] ECiz1 stimulates DNA replication in vitro Upon exposure to cytosolic extract from S phase cells, late G1 phase nuclei initiate DNA replication and begin synthesizing nascent DNA (Krude et al., 1997). We used this cell-free assay to test the effect of ECiz1, and derived recombinant fragments, on DNA synthesis (Fig. 3). Full-length ECiz1 protein consistently increased the number of nuclei that replicated in vitro, from 30% (+/-0.9%) to 46% (+/- 5.5%), which suggests that Ciz1 is limiting for initiation in S phase extracts (Fig. 3A). Only two other classes of protein (cyclin-dependent kinases, Coverley et al., 2002; Krude et al., 1997; Laman et al., 2001, and the Cdc6 protein, Coverley et al., 2002; Stoeber et al., 1998) have been previously found to stimulate cell-free initiation. Thus, ECiz1 is the first protein to have this property that was not already known to be involved in the replication process. The positive effect of recombinant ECiz1 on cell-free initiation argues that endogenous Ciz1 plays a positive role in DNA replication in mammalian cells.

[0094] Stimulation of cell-free initiation is concentration-dependent with peak activity in S phase extract at around 1nM ECiz1 (Fig. 3B). This echoes previous cell-free analyses with other recombinant proteins (Coverley et al., 2002; Krude et al., 1997), where stimulation of initiation typically peaks and then falls back to the un-stimulated level at high concentrations. For ECiz1, the reason for the drop in activity at high concentrations is not yet clear. However, mutagenesis studies (see below) suggest that the restraining mechanism is likely to be active and specific rather than due to a general imbalance in the composition of higher order protein complexes.

[0095] Down regulation of ECiz1 involves threonines 191/192 Ciz1 is likely to be a phosphoprotein in vivo since it contains numerous putative phosphorylation sites, and it displays altered mobility when 3T3 cell extracts are treated with lambda phosphatase (not shown). Murine Ciz1 contains two RXL cyclin binding motifs and five putative cdk-phosphorylation sites, which are present in all known variants. Four of these are located in the N-terminal fragment of ECiz1 that contains in vitro replication activity (see below), and one is adjacent to the site at which exon 6 is alternatively spliced to exclude a short DSSSQ (SEQ ID NO: 1) sequence motif (Fig. 2A, C). As this motif is 100% identical and alternatively spliced in both mouse and man we reasoned that conditional inclusion might serve to regulate Ciz1 activity, identifying this region of the protein as potentially important. We therefore chose to focus on the cdk site that is four residues upstream and which is also conserved in mouse and man, by combining a genetic approach with cell-free replication assays. Starting with ECiz1, two threonines at 191 and 192 were changed to two alanines, generating ECiz1T(191/2)A (Fig. 2D). When tested in vitro for DNA replication activity, ECiz1T(191/2)A stimulated initiation in late G1 nuclei to a similar extent as ECiz1 (Fig. 3C). However unlike ECiz1, stimulation of initiation was maintained over a broad range of concentrations that extended over at least three orders of magnitude. Therefore, a mechanism to restrict the activity of excess ECiz1 exists and operates in a cell-free environment. In a separate construct, the threonine at position 293 was also changed to alanine generating ECiz1T(293)A (Fig. 2D), but this alteration had little effect on ECiz1 activity assayed in vitro (Fig. 3D).

[0096] These results demonstrate that down-regulation of ECiz1 activity involves threonine 191/2, and is probably caused by cyclin-dependent kinase mediated phosphorylation at this site. This links Ciz1 activity to the cdk-dependent pathways that control all major cell-cycle events, including initiation of DNA replication.

[0097] Most pre-replication complex proteins and many replication fork proteins are phosphorylated in vivo, often by cyclin-dependent kinases (Bell and Dutta, 2002; Fujita, 1999). Our data suggests that nuclear accumulation of p85-Ciz1 antigen is regulated (directly or indirectly) by cyclin A-cdk2, and it shows that a specific consensus cdk phosphorylation site at threonine 191/192 is involved in controlling Ciz1 activity. When this site is made unphosphorylatable Ciz1 activity

is maintained over a broader range of concentrations in cell-free assays. Therefore, Ciz1 activity is normally down regulated by modification at this site. The functions of the other conserved cdk phosphorylation sites, and the effect of conditional inclusion of an RXL cyclin-binding motif in the alternatively spliced N-terminal portion of Ciz1, remain to be determined. Thus, the simple negative relationship between Ciz1 activity and cdk-dependent phosphorylation that has

[0098] In vitro replication activity resides in the N-terminus Ciz1 possesses several C-terminal features that may anchor the protein within the nucleus. The matrin 3 domain suggests interaction with the nuclear matrix and the three zinc-fingers imply interaction with nucleic acids. Indeed, recent evidence suggests that human Ciz1 binds DNA in a weakly sequence specific manner (Warder and Keherley, 2003). To determine whether C-terminal domains are important for ECiz1 replication activity we divided the protein into two fragments (Fig. 2D). Nterm442 (which contains the NLS, two conserved cdk sites, one zinc finger and all known sites where variable splicing has been observed) stimulates initiation to a similar extent and at the same concentration as ECiz1 (Fig. 3E). In contrast, the C-terminal portion (Cterm274) contains no residual replication activity (Fig. 3F). Therefore, the matrin 3 domain, one of the cyclin-dependent kinase phosphorylation sites and two of the zinc-fingers are not required for the DNA replication activity of ECiz1, when assayed in vitro. It should be noted however that this analysis measures ECiz1 activity in *trans* under conditions where the consequences of mis-localisation are unlikely to be detected. Therefore, it remains possible that the matrin 3 domain and zinc fingers act in vivo to direct Ciz1 activity to specific sites in the nucleus and thus limit the scope of Ciz1 activity.

[0099] Endogenous Ciz1 Antibody V1 recognises Cdc6 as well as p85-Ciz1 (Fig. 1A), so it is not suitable for immunofluorescence experiments aimed at visualizing the sub-cellular localization of endogenous Ciz1. We therefore generated two new rabbit polyclonal anti-sera against recombinant ECiz1 fragment Nterm442, designated anti-Ciz1 1793 and 1794. As expected, purified Nterm442 is recognised by anti-Ciz1 antibodies 1793 and 1794 in western blots, but it is also recognised by antibody V1 (Fig. 4A), supporting the conclusion that p85(p100) is indeed Ciz1.

[0100] When applied to protein extracts derived from growing 3T3 cells anti-Ciz1 1793 recognised two antigens, with Mr of 125 and 100 kDa (Fig. 4B), whose relative proportions vary from preparation to preparation. The 100 kDa band co-migrates with the cyclin-A responsive antigen that is recognized by antibody V1 (Fig. 1 and 4B), which suggests that both antibodies recognise the same protein in vivo. We confirmed that the p100-Ciz1 bands recognised by antibody V1 and 1793 are the same protein by immuno-precipitation (Fig. 4C). Antibody V1 precipitated a 100 kDa band that was recognised in western blots by 1793, and vice versa. Furthermore, in the same experiment 1793, and to a lesser extent antibody V1, precipitated a 125 kDa antigen, that was recognised in western blots by 1793. Taken together our observations show that the 100 kDa band is indeed Ciz1 (previously known as p85), and they suggest that Ciz1 protein exists in at least two forms in cycling cells.

[0101] In addition to the immuno-precipitation evidence described above, several other observations lead to the conclusion that p125 is also a form of Ciz1. First, both of our anti-Ciz1 antibodies (1793 and 1794) have this band in common. Both antibodies produce the same pattern of nuclear staining in immuno-fluorescence experiments, and this is disrupted in cells treated with Ciz1 siRNA (see below). Second, the relative proportions of p100 and p125 vary from preparation to preparation, and could therefore be the result of proteolytic cleavage. Thirdly, our results are strikingly similar to those of Mitsui et al (1999) whose anti-human Ciz1 monoclonal antibody detected two antigens with apparent Mr of 120 and 95 kDa in HEK293 cells. They proposed that the 120 kDa form of human Ciz1 protein is processed to produce the 95kDa form and our results are consistent with this proposal.

[0102] The 125kDa band recognized by antibody 1793 in mouse and human cells resolves into three Ciz1-related bands during high-resolution electrophoresis of material derived from non-transformed human cells (Wi38-see later), and mouse cells (NIH3T3-not shown). This may be the result of post-translational modification of the Ciz1 protein or of alternative splicing of the Ciz1 transcript.

[0103] Sub-cellular distribution of Ciz1 Anti-Ciz1 1793 was used to visualise the sub-cellular distribution of Ciz1 protein (p85 and p125) in 3T3 cells (Fig. 5A), and in HeLa cells (not shown). In both cell types 1793 reacted with a nuclear-specific antigen, and this was blocked by inclusion of recombinant Nterm442 fragment (Fig. 5B). Unlike Cdc6, which is shown for comparison (Fig. 5A), Ciz1 is clearly detectable in all 3T3 cells in this cycling population. Therefore Ciz1 is present in the nucleus throughout interphase, although minor variations in quantity, or isoform would not be detected by this method. After detergent treatment overall nuclear Ciz1 staining was reduced in all nuclei, which suggests that Ciz1 is present in the nucleus as both a soluble fraction and also bound to insoluble nuclear structures.

[0104] When soluble protein is washed away, the insoluble, immobilised antigen resolves into a punctate sub-nuclear speckled pattern at high magnification (Fig. 5C, D). Ciz1 speckles show a similar size range and distribution as replication 'foci' or 'factories', the sites at which DNA synthesis takes place in S phase. To ask whether Ciz1 is coincident with sites of replication factories, we compared the position of Ciz1 speckles to the position of PCNA, a component of replication complexes in S phase cells (Fig. 5C). In confocal section, PCNA foci are less abundant than Ciz1 foci, but they are almost all co-incident with Ciz1 (Fig. 5D, E, F). This is particularly striking for foci in the medium size range. In merged

images, overlap between the positions of PCNA and Ciz1 foci results in yellow spots, while the remaining Ciz1 foci that are not co-incident with PCNA are red. Green (PCNA alone) foci are virtually absent, which suggests that Ciz1 is present at all sites where DNA replication factories have formed.

[0105] Ciz1 is also present at sites that don't contain PCNA (Fig. 5D), and unlike PCNA, Ciz1 foci persist throughout interphase (Fig. 5A). One interpretation of these observations is that Ciz1 marks the positions in the nucleus at which PCNA-containing replication factories are able to form in S phase, but that not all of these sites are used at the same time. It remains to be determined whether different Ciz1 foci become active sites of DNA replication at different times in S phase, or whether other nuclear activities also occur at sites where Ciz1 is bound. Indeed, at this stage it also remains possible that the 100 kDa form and the 125 kDa variants of Ciz1 have different activities, and that they reside at nuclear sites with different functions.

[0106] Ciz1 is essential for cell proliferation So far we have shown that the behaviour of p85 (p100)-Ciz1 correlates with initiation of DNA replication in cell-free assays, that recombinant Ciz1 stimulates the frequency of initiation, and that Ciz1 resides at the same nuclear sites as the DNA replication machinery. However, these data do not show that Ciz1 has an *essential* function in proliferating cells. In order to test this we used RNA interference (RNAi) to selectively reduce Ciz1 transcript levels in NIH3T3 cells. Four target sequences within Ciz1 were chosen (see Fig. 2A) and short interfering (si) RNA molecules were produced in vitro. When applied to cells, all four Ciz1 siRNA's restricted growth (Fig. 6A) and caused a visible reduction in the level of Ciz1 protein after 48 hours (Fig. 6B). The effect of Ciz1 depletion on proliferation becomes apparent between 23 and 40 hours post-transfection, which suggests that the first cell cycle without Ciz1 RNA is relatively unaffected. By 40 hours, controls and Ciz1 siRNA treated cells diverged significantly with no further proliferation in the Ciz1 depleted population. To verify the specificity of Ciz1 depletion, transcript levels were monitored at 24 hours, before proliferation is significantly inhibited (Fig. 6C). At this point Ciz1 transcripts were reduced to 42% of the level in control cells treated with GAPDH siRNA. These experiments show that Ciz1 is required for cell proliferation and are consistent with a primary function in DNA replication.

[0107] To test this further, cells were pulse-labelled with BrdU 48 hours after siRNA treatment to determine the fraction of cells engaged in DNA synthesis (Fig. 6D). When Ciz1 levels were reduced the BrdU labelled fraction was also reduced, suggesting that DNA synthesis is inhibited under these conditions. Furthermore, cells in the Ciz1 depleted population that did incorporate BrdU (approximately 15% of the population) were less intensely labelled. Therefore, in some Ciz1 siRNA treated cells S phase is slowed down rather than inhibited completely, possibly due to incomplete depletion.

[0108] Inhibition of DNA synthesis by Ciz1 siRNAs could be a secondary consequence of a general disruption of nuclear function. Therefore, we looked in more detail at a range of other replication proteins whose levels are regulated in a cell cycle dependant manner, to ask whether depleted cells arrest randomly, or accumulate at a particular point.

[0109] During initiation of eukaryotic DNA replication Mcm complex proteins assemble at replication origins in late G1, in a Cdc6-dependent manner. Sometime later, DNA polymerases and their accessory factors (including PCNA) become bound to chromatin and origins are activated. This is associated with nuclear export and proteolysis of the majority of Cdc6 and, as DNA synthesis proceeds, gradual displacement of the Mcm complex from chromatin (Bell and Dutta, 2002). In order to identify the point of action of Ciz1 we used immuno-fluorescence to monitor Mcm3 and PCNA. In Ciz1 depleted cells (Fig. 6E, F) both proteins were detectable within the nucleus bound to detergent resistant nuclear structures. Therefore, these factors are unlikely to bind directly to Ciz1, or to be dependent upon Ciz1 for their assembly. In fact, in four independent experiments the average number of cells with detergent-resistant chromatin-bound Mcm3 actually *increased* from 31% (+/-6%) to 51% (+/-5%) (Fig. 6E). Increased Mcm3 indicates that the Ciz1 dependent step occurs after pre-replication complex assembly (but before completion of S phase). In the same cell populations the PCNA positive fraction also increased, from 32% (+/-5%) to 49% (+/-6%) (Fig. 6F), narrowing the point of Ciz1 action to after PCNA assembly. Thus, Ciz1 most likely acts to facilitate DNA replication during a late stage in the initiation process, while failure to act inhibits progression through S phase, leaving Mcm3 and PCNA in place.

[0110] Taken together, our cell-free and cell-based investigations paint a consistent picture about the primary function of Ciz1. They suggest that Ciz1 is a novel component of DNA replication factories, and they show that Ciz1 plays a positive role in the mammalian cell-cycle, acting to promote initiation of DNA replication.

[0111] Three of our lines of investigation suggest that Ciz1 is required during a late stage in the initiation process after pre-replication complex formation. First, p85 (p100)-Ciz1 antigen accumulates in nuclei exposed to cyclin A-cdk2 concentrations that activate DNA synthesis, implying that Ciz1 functions during this step rather than during earlier replication complex assembly steps (Coverley et al., 2002). Second, functional studies with late G1 nuclei show that recombinant ECiz1 increases the number of nuclei that incorporate labeled nucleotides in vitro. Therefore, Ciz1 must be active in a step that converts nuclei that are poised to begin DNA synthesis into ones that are actively synthesizing DNA. Third, RNA interference studies point to a Ciz1-dependent step after Mcm complex formation and after PCNA has become assembled onto DNA, but before these proteins are displaced. These distinct lines of investigation lead to strikingly similar conclusions about the point of action of Ciz1 placing it in the later stages of initiation.

[0112] Anti-Ciz1 siRNA as a therapeutic strategy Our analysis shows that Ciz1 is essential for cell proliferation, and that targeting Ciz1 is a viable strategy to restrain proliferation. The alternatively spliced forms of Ciz1 that we observe

in various cancers (see below) means that Ciz1 could be targeted in a selective way to restrain proliferation in a subset of cells within a population.

[0113] By way of example, this could be done by targeting siRNA's to the junction sequence created in Ciz1 transcripts when the C-terminal sequence GTTGAGGAGGAACTCTGCAAGCAG (SEQ ID NO:2) is missing, in small cell lung carcinoma cells, or by using Ciz1 protein lacking the corresponding VEEELCKQ (SEQ ID NO: 3) sequence to select specific chemical inhibitors.

[0114] Accordingly the present invention also provides for the use of junction sequences created in Ciz1 transcripts and proteins when alternatively spliced sequences are not present, as a diagnostic marker, prognostic indicator or therapeutic target.

[0115] Embryonic form Ciz1 is localized to the nucleus RT-PCR analysis across potentially variable exons suggest that 3T3 cells predominantly express full-length Ciz1, so our immuno-localization work on endogenous Ciz1 (Fig. 5) does not necessarily reflect the behavior of ECiz1, which lacks several sequence blocks and possibly therefore information that is used to localize the protein. To directly compare the localization of ECiz1 and full-length Ciz1, enhanced GFP tagged constructs were transfected into 3T3 cells (fig. 8A), and microinjected into mouse pro-nuclei (fig. 8B). In all cases tagged Ciz1 and ECiz1 were exclusively nuclear, while a control construct expressing GFP alone was present in the nucleus and the cytoplasm. GFP-Ciz1 and GFP-ECiz1 were both visible in live cells as sub-nuclear foci, similar to replication foci seen in fixed cells by immuno-fluorescence. Thus, the three sequence blocks that are absent from ECiz1 do not appear to contribute to the nuclear localization of Ciz1.

[0116] Over the three day period following transfection no cell division was observed in the GFP-Ciz1 and GFP-ECiz1 transfected cells. These data suggest that overexpression of functional Ciz1 has an inhibitory effect on the cell cycle (in cells that have their regulatory pathways intact).

[0117] Coalescence When GFP-tagged constructs in which the C-terminal one third of Ciz1 had been removed were transfected into 3T3 cells, differences between ECiz1 and full length Ciz1 were observed (fig. 8C). By 48 hours FL Ciz1 N-term(442 equivalent) had coalesced into large intra-nuclear blobs which only became apparent in the ECiz1 N-term442 transfected population by day 3 or later. Before this time ECiz1 N-term442 was localised as a nuclear specific but diffuse pattern. Thus ability to coalesce is quantifiably different between Ciz1 and ECiz1, and is therefore affected by one of the three alternatively spliced exons (2/3, 6 or 8).

[0118] Like cells transfected with full length Ciz1 and ECiz1, cells transfected with constructs in which the C terminal one third was removed were not seen to multiply during the three day monitoring period.

[0119] C-terminal domains anchor Ciz1 to nuclear structures As described above, the difference between Ciz1 and ECiz1 N-term is masked when C-terminal domains are also present (fig. 8A). Furthermore the C-terminal fragment alone directs GFP tag to chromatin, forming an irregular pattern that is not as spotty (focal) as Ciz1 or ECiz1, but which remains attached to chromosomes during mitosis (fig. 8D). This suggests that C-terminal domains are involved in immobilizing Ciz1 on a structural framework in the nucleus. Notably, cells transiently transfected with C-terminal fragment continued to divide resulting in gradual dilution of green fluorescence.

[0120] Ectopic Ciz1 promotes premature entry to S phase We looked at events occurring during the first day after transfection. The S phase fraction in transfected cells (green) was compared to the S phase fraction in untransfected cells, by labelling with BrdU at various intervals. During long labelling windows including 0-22 hours (fig. 8E), 0-12 hours and 0-7 hours (not shown), consistently more of the Ciz1 and ECiz1 transfected cells were engaged in DNA synthesis, compared to untransfected cells. This suggests that Ciz1 and ECiz1 have a positive effect on the G1-S transition, promoting unscheduled entry to S phase. Similar results were obtained with 3T3 cell populations that were densely plated before transfection. This was done in order to minimise the fraction in the untransfected population that was engaged in S phase as part of the normal cell cycle. Under these conditions the difference between the transfected and untransfected population was maximised, clearly demonstrating the effect of ectopic Ciz1 on initiation of DNA replication.

[0121] Conversely, when cells were labelled with BrdU during a short pulse administered at 22 hours (fig. 8E), or at 10 hours or 12 hours post-transfection (not shown), the labelled fraction was consistently *reduced* in the Ciz1 and ECiz1 transfected populations. This suggests that the S phase that is induced by ectopic Ciz1 or ECiz1 is abnormal, with slow or aborted DNA synthesis that is not sufficient to label cells during short windows of exposure to BrdU.

[0122] Therefore, ectopic Ciz1 and ECiz1 have two effects on S phase in cultured cells. They promote DNA replication, but this results in slow or aborted DNA synthesis.

[0123] Clones with altered proliferation potential We also monitored transfected populations of 3T3 cells over a three week time period. In cells transfected with the GFP-Nterm442 or the non-alternatively spliced equivalent and maintained under selection with G418, large foci containing hundreds of cells were observed (fig. 9A). These clusters contained large numbers of GFP expressing cells, demonstrating that over-expression of the N-terminal portion of ECiz1 (in which replication activity resides) is not lethal, and suggesting that over-expression leads to altered proliferation phenotype, compared to untransfected cells, including loss of contact inhibition and failure to form a monolayer. This Ciz1-dependent altered behaviour could contribute to tumour formation. A similar truncated version of mouse Ciz1, lacking putative chromatin interaction domains was previously isolated from a mouse melanoma (fig. 2).

Human Ciz1 and cancer

[0124] Ciz1 cDNAs in public databases As mentioned above human Ciz1 is alternatively spliced at the RNA level to yield transcripts that lack three of the same exons as mouse embryonic Ciz1. Seven human Ciz1 cDNAs have been recorded in public databases (fig. 10), submitted by Mitsui et al (1999), Warder and Keherly (2003) and large-scale genome analysis projects (NIH-MGC project, NEDO human cDNA sequencing project). Only one is derived from normal adult tissue, and this contains all predicted exons (AB030835). The rest are derived from embryonic cells (AK027287), or notably from four different types of paediatric cancer (medulloblastoma, AF159025, AF0234161, retinoblastoma, AK023978, neuroblastoma, BC004119 and burkitt lymphoma, BC021163). The embryonic form and the cancer derived forms lack sequence blocks from the same three regions as our embryonic mouse clone, and from a fourth region which corresponds to exon 4. Therefore, the limited data suggests that alternatively spliced forms are more prevalent early in development. This correlation has not previously been noted in the scientific literature. The presence of alternatively spliced Ciz1 in paediatric cancers raises the possibility that Ciz1 mis-splicing might be linked to inappropriate cell proliferation.

[0125] For example, one of the variable exons encodes a short conserved DSSSQ sequence motif that is absent in mouse ECiz1 and in a human medulloblastoma. This is directly adjacent to the consensus cdk phosphorylation site that we have shown to be involved in regulation of ECiz1 function. Conditional inclusion of the DSSSQ sequence might make Ciz1 the subject of regulation by the ATM/ATR family of protein kinases, which phosphorylate proteins at SQ sequences, thereby restraining Ciz1 initiation function in response to DNA damage.

[0126] Analysis of expressed sequence tags. The presence of alternatively spliced Ciz1 in paediatric cancers prompted a detailed analysis of Ciz1 ESTs. There are 567 expressed sequence tags (ESTs) included in NCBI unigene cluster Hs.23476 (human Ciz1). These are derived from a wide range of normal and diseased tissues and cell lines. Sequences have been translated and mapped against the predicted full-length amino-acid sequence of human Ciz1. Sequence alterations that give rise to amino-acid substitutions, deletions, frame-shifts and premature termination of translation have been recorded.

[0127] Alternatively spliced Ciz1 variants were also seen in this EST data set and are recorded here. The four sequence blocks that we previously reported to be alternatively spliced in human and mouse Ciz1 (Fig. 2) were observed in the EST sequences, as well as a previously undetected variant that lacks the exon 14 derived sequence VEEELCKQ. All of these recurrently variant sequence blocks are bounded by appropriate splice sites. A sixth variable sequence block was identified in one carcinoma derived library, caused by inclusion of.

GCCACCCACACCACGAAGAGATGTGTTTGCCACGTTCCAGTGCAGGGGTGGAG
CACAGCCCGGCTTGTTACAGATAT (SEQ ID NO: 4).

[0128] ESTs are grouped according to the cell type from which they were derived with the primary divisions occurring between neoplastic cells of adult, childhood or embryonic origin. ESTs from normal tissue of embryonic or adult origin are included for comparison. EST-derived Ciz1 protein maps are shown in fig. 11A-E and the alternatively spliced exons summarized in fig. 11F.

[0129] Three sequence blocks in the N-terminal end of human Ciz1 are absent in transcripts from medulloblastomas and neuroblastoma (fig. 11A), and occasionally absent from Ciz1 transcripts from other cancers. We also found similar alternative splicing in a third paediatric cancer, Ewings sarcoma (see below). Paediatric cancer-associated alternatively spliced sequences are from exons 2/3 (at least two versions), exon 4 and exon 6.

[0130] Exon 8 variants in which one or more copies of a Q-rich degenerate repeat are absent have been noted in transcripts derived from normal cells (of embryonic or adult neural origin) and from various cancers. Alternative splicing in this region could produce Ciz1 with inappropriate activity, therefore exon 8 variant expression, or occurrence of point mutations which influence splicing in this region, might be useful as diagnostic or prognostic markers in cancer. The alternatively spliced degenerate repeats in exon 8 are detailed below and summarised in fig. 11F.

[0131] In the C-terminal half of the human Ciz1 protein two sequence blocks are variably spliced. One of these is missing from transcripts derived from three out of five lung carcinoma and lung carcinoid libraries, and from three other carcinoma libraries (but very rarely from transcripts from other cell types).

[0132] The second variant sequence block is due to inappropriate inclusion of extra sequence in transcripts from the epidermoid carcinoma library (MGC102).

[0133] These sequences and the junction sequences formed in Ciz1 proteins, and Ciz1 transcripts when these segments are excluded or included, are potential targets for selective inhibition of cell proliferation in a wide range of different cancers. The remaining non-variant sequences are potential targets for non-selective inhibition of cell proliferation.

[0134] In addition to splicing variations, other non-typical Ciz1 transcripts were found to preferentially occur in some cancers. In Rhabdomyosarcomas Ciz1 is prematurely terminated leading to a predicted protein that lacks C-terminal

nuclear binding domains. This could lead to inappropriate DNA replication and might therefore be a therapeutic target or marker in this type of cancer.

[0135] Several transcripts contain point mutations that lead to amino-acid substitutions in putative cyclin-dependent kinase (cdk) phosphorylation sites. In the cervical carcinoma library MGC12, this occurs twice. We have shown that two cdk phosphorylation sites are involved in restraining Ciz1 activity (fig. 3C and D), implicating these mutations in the deregulation of proliferation in cancer cells. One of these is the same as the carcinoma-derived mutant mentioned above (fig. 11E). Cancer-derived transcripts with point mutations in Ciz1 could also be targeted by RNA interference, or have value as diagnostic or prognostic indicators.

Investigation of Ciz1 variant expression in paediatric cancers

[0136] Ciz1 variant expression was investigated in 6 Ewings Sarcoma family tumour cell lines (ESFTs) and two neuroblastoma cell lines, using RTPCR with primer sets that span three regions of known Ciz1 variability (fig. 12A). This analysis showed that the pattern of Ciz1 variant expression is different in ESFT cells compared to neuroblastoma cells compared to non-transformed cells, but apparently very similar within sets of cell lines from the same tumour. Therefore, Ciz1 variant expression could have prognostic or diagnostic potential for these cancers. Minor variations within a set of lines from the same tumour type could have prognostic value.

[0137] By subcloning and sequencing amplified transcripts we found that all six ESFT lines tested express an exon 4 minus form of Ciz1. As Ciz1 is essential for cell proliferation (see below), this offers a possible route for selective restraint of ESFT cells. Transcripts from the two neuroblastoma cell lines tested rarely lack exon 4 but frequently lack sequences the DSSSQ motif encoded by exon 6 (fig. 12B).

[0138] This experimental analysis confirms that paediatric cancers express forms of Ciz1 with variable inclusion of exons 4, 6 and probably exons 2/3.

[0139] Two versions of the sequence encompassing exon 8 and one form of the sequence encompassing the VEEELCKQ-coding sequence were detected in ESFTs, neuroblastomas and control suggesting that these regions do not contribute to deregulation of Ciz1 in these paediatric cancers.

[0140] In all cases, Ciz1 RT-PCR products were most abundant in reactions carried out with RNA samples from cancer cell lines, compared to controls (Wi38, HEK293, NIH3T3 cells, and primary human osteoblasts). This is consistent with increased expression of Ciz1 variants in tumours.

Analysis of Ciz1 protein expression in prostate cancer cell lines

[0141] Normal, non-transformed human lung fibroblasts (and mouse NIH3T3 cells) express two major forms of Ciz1 that are detected by anti-Ciz1 polyclonal antibody 1793 in western blots (fig. 13A). The larger (approximately 125kDa) band resolves into three distinct bands that are present in equal proportions in Wi38 cells, but grossly uneven proportions in prostate cancer cell lines PC3 and LNCAP (and ESFT cell lines -not shown). We postulate that these protein isoforms are generated by expression of variably spliced exons. Both tumour cell lines also contain more Ciz1 antigen than Wi38 cells, consistent with over-expression of Ciz1 in these cancer cell lines.

[0142] Taken together our results (experimental and bioinformatics analysis of genome data) support the conclusion that Ciz1 is mis-regulated in a wide range of human cancers. We have shown that the Ciz1 protein plays a positive role in the DNA replication process, therefore mutant Ciz1 could contribute to cellular transformation, rather than be a consequence of it. If deregulation of Ciz1 is a common step in this process it represents a very attractive target for development of therapeutic agents.

[0143] We have also associated particular changes with specific cancers, making it a real possibility that Ciz1 could be useful as a diagnostic or prognostic marker.

[0144] These include :-

- Alternative splicing in the N-terminal part of the protein (that contains replication activity in vitro) in paediatric cancers.
- Point mutations in cyclin-dependent kinase phosphorylation sites known to be involved in restraining Ciz1 replication activity.
- Non-typical expression and nuclear binding properties of Ciz1-p125 forms in prostate carcinoma cell lines, possibly due to mis-regulated splicing of the degenerate repeats in exon 8, or other exons.
- Conditional exclusion of a discrete motif (VEEELCKQ) in the C-terminal end of Ciz1 (probably involved in localization of Ciz1 protein within the nucleus) in small cell carcinoma of the lung and other carcinomas.
- Increased levels of Ciz1 protein and RNA (detected by Western blot and by RT-PCR) in all cancer derived cells lines tested so far, compared to Wi38 normal embryonic lung fibroblast, human osteoblast RNA and mouse NIH3T3 fibroblasts.

[0145] The sequences shown in figures 14 to 21 are of use for the development of therapeutic, diagnostic, or prognostic reagents.

Materials and Methods

[0146] Cloning. A lambda triplEx 5'-stretch, full length enriched cDNA expression library derived from 11 Day old mouse embryos (Clontech ML5015t) was used to infect *E. coli* X11 blue according to the recommended protocol (Clontech). Plaques were lifted onto 0.45 micron nitrocellulose filters pre-soaked in 10mM IPTG (Sigma). Affinity purified antibody V1 was applied to approximately 3×10^6 plaques at 1/1000 dilution in PBS, 10% non-fat milk powder, 0.4% Tween20, after blocking for 30 minutes in the absence of antibody. After two hours filters were washed three times with the same buffer and reactive plaques were visualized with anti-rabbit secondary antibody conjugated to horse-radish peroxidase (Sigma), and enhanced chemi-luminescence (ECL, Amersham) according to standard procedures. 43 independent plaques were picked but only two strains of phage survived a further three rounds of screening. These were converted to pTriplEx by transforming into BM25.8 and sequenced. One codes for mouse Cdc6 (clone P) and the other (clone L) for an unknown mouse protein that is homologous to human Ciz1. We refer to this as embryonic Ciz1 (ECiz1) and it was submitted to EMBL under the accession number AJ575057.

[0147] Bacterial expression pGEX based bacterial expression constructs (Amersham) were used to produce ECiz1 proteins for in vitro analysis. pGEX-ECiz1 was generated by inserting a 2.3kb SmaI-XbaI (blunt ended) fragment from clone L into the SmaI site of pGEX-6P-3. pGEX-Nterm442 was generated by inserting the 1.35kb XmaI-XhoI fragment into XmaI-XhoI digested pGEX-6P-3, and pGEX-Cterm274 by inserting the 0.95kb XhoI fragment into XhoI digested pGEX-6P-3. pGEX-T(191/2)A was generated from pGEX-ECiz1 by site directed mutagenesis (Stratagene Quikchange) using primers AACCCCTCTTCCGCCGCCCAATCGCAAGA (SEQ ID NO: 5) and TCTTGCGATTGGGGGCGGCGGAAGAGGGGGTT (SEQ ID NO: 6). pGEX-T(293)A was generated from pGEX-ECiz1 using primers AAGCAGACACAGGCCCGGATCGGCTGCCT (SEQ ID NO: 7) and AGGCAGCCGATCCGGGGCCTGTGTCTGCTT (SEQ ID NO: 8). Integrity and reading frame of all clones were sequence verified.

[0148] Recombinant Ciz1, Ciz1 fragments and point mutants were produced in BL21-pLysS (Stratagene) as glutathione S-transferase-tagged protein. This was purified from sonicated and cleared bacterial lysates by binding to glutathione sepharose 4B (Amersham). Recombinant protein was eluted by cleavage from the GST tag using precision protease (as recommended by the manufacturer, Amersham), into buffer (50mM Tris-HCl pH 7.0, 150mM NaCl, 1mM DTT). This yielded protein preparations between 0.2 and 2.0 mg/ml. For replication assays serial dilutions were made in 100mM Hepes pH 7.8, 1mM DTT, 50% glycerol so that not more than 1ml of protein solution was added to 10ml replication assays, yielding the concentrations shown. Consistent with previous observations (Mitsui et al., 1999; Warder and Keherly, 2003) recombinant Ciz1, and derived fragment N-term442 migrated through SDS-PAGE with anomalously high molecular weight. Cyclin A-cdk2 was produced in bacteria as previously described (Coverley et al., 2002).

[0149] Anti-Ciz1 antibodies Rabbit polyclonal antibody V1 (Coverley et al., 2000; Stoeber et al., 1998; Williams et al., 1998) was raised against an internal fragment of bacterially expressed human Cdc6 corresponding to amino-acids 145-360, and affinity purified by standard procedures (Harlow and Lane, 1988). This antibody reacts strongly with endogenous p100-Ciz1 and also with ECiz1 Nterm442 fragment. Alignment of Nterm442 with Cdc6 amino-acids 145-360 suggest that the shared epitope could be at 294-298 or 304-312 in mouse Ciz1. Recombinant Nterm442 was used to generate two Ciz1-specific polyclonal anti-sera designated 1793 and 1794 (Abcam). 1793 has been used routinely in the experiments described here. Its specificity was verified by reciprocal immuno-precipitation and western blot analysis with antibody V, by inclusion of Nterm 442 (25µg/ml in antibody buffer, 10mg/ml BSA, 0.02% SDS, 0.1% Triton X100 in PBS), which blocked reactivity with endogenous epitopes, and by siRNA-mediated depletion of Ciz1 that specifically reduced 1793 nuclear staining.

[0150] Immunoprecipitation Asynchronously growing 3T3 cells were washed in PBS, rinsed in extraction buffer (20mM Hepes pH7.8, 5mM potassium acetate, 0.5mM magnesium chloride) supplemented with EDTA-free protease inhibitor cocktail (Roche) and scrape harvested as for replication extracts. Cells were lysed with 0.1 % Triton X 100 and the detergent resistant pellet fraction extracted with 0.3M NaCl in extraction buffer. 5µl of 1793 or 2µl of antibody V were used per 100µl of extract and incubated for 1 hour at 4°C. Antigen-antibody complexes were extracted with 100µl of protein G-sepharose (Sigma) and beads were washed five times with 50mM Tris pH 7.8, 1 mM EDTA, 0.1% NP40, 150mM NaCl. Complexes were boiled in loading buffer (100mM DTT, 2% SDS, 60mM Tris pH6.8, 0.001% bromophenol blue) and resolved by 6.5% SDS-polyacrylamide gel electrophoresis.

[0151] Immuno-fluorescence Cells were grown on coverslips and fixed in 4% paraformaldehyde, with or without brief pre-exposure to 0.05% Triton X100 in PBS. Endogenous Ciz1 was detected with 1793 serum diluted 1/2000 in antibody buffer following standard procedures. Mcm3 was detected with monoclonal antibody sc9850 (1/1000), Cdc6 with monoclonal sc9964 (1/100) and PCNA with monoclonal antibody PC10 (1/100, all Santa Cruz Biotechnology). Co-localisation analysis of dual stained fluorescent confocal images was carried out as described (Rubbi and Milner, 2000; van Steensel et al., 1996).

[0152] Cell synchrony Mouse 3T3 cells were synchronized by release from quiescence as previously described (Coverley et al., 2002). Nuclei prepared from cells harvested 17 hours after release (referred to as 'late-G1') were used in all cell-free replication experiments described here. This yielded populations containing S phase nuclei, replication competent late G1 nuclei and unresponsive early G1/G0 nuclei, in varying proportions. Recipient, mid-G1 3T3 extracts were prepared at 15 hours (these typically contain approximately 5% S phase cells). The series of cell-free replication experiments described here required large amounts of standardized extract, therefore HeLa cells were used because they are easily synchronized in bulk. S phase HeLa extracts were prepared from cells released for two hours from two sequential thymidine-induced S phase blocks, as described (Krude et al., 1997).

[0153] Cell-free DNA replication DNA replication assays were performed as described (Coverley et al., 2002; Krude et al., 1997). Briefly, 10 μ l of mid G1 or S phase extract (supplemented with energy regenerating system, nucleotides and biotinylated dUTP), and 5×10^4 late G1 phase nuclei were incubated for 60 mins at 37°C. Reactions were supplemented with baculovirus lysate containing cyclin A-cdk2 (Fig.1B and C), where 0.1 μ l of lysate has the same specific activity as 1nM purified kinase (Coverley et al., 2002). All recombinant proteins were serially diluted in 100mM Hepes pH 7.8, 1mM DTT, 50% glycerol, so that not more than 1 μ l was added to 10 μ l replication assays, generating the concentrations indicated. Reactions were stopped with 50 μ l of 0.5% Triton X100 and fixed by the addition of 50 μ l of 8% paraformaldehyde, for 5 minutes. After transfer to coverslips nuclei were stained with streptavidin-FITC (Amersham) and counterstained with Toto-3-iodide (Molecular Probes). The proportion of labelled nuclei was quantified by inspection at 1000X magnification, and all nuclei with fluorescent foci or intense uniform labelling were scored positive. Images of *in vitro* replicating nuclei were generated by confocal microscopy at 600X magnifications, of samples counterstained with propidium iodide. For analysis of nuclear proteins, nuclei were re-isolated after 15 minutes exposure to initiating conditions, by diluting reactions two fold with cold PBS and gentle centrifugation.

[0154] Data analysis and presentation Prior to use in initiation assays each preparation of synchronized G1 phase nuclei is tested so that the proportion of nuclei that are already in S phase is established ('%S'). To do this nuclei are incubated in an extract that is incapable of inducing initiation of DNA synthesis (from mid-G1 phase cells harvested 15 hours after release from quiescence), but that will efficiently support elongation DNA synthesis from origins that were initiated *in vivo*. The elongating fraction of nuclei incorporates labeled nucleotides efficiently during *in vitro* initiation assays but is uninformative. Routinely this fraction is pre-established and subtracted from the raw data. Synchronized populations in which 20% or less are in S phase are used for initiation assays.

[0155] When 3T3 cells are released from quiescence by the protocol used here no more than 70% of the total population enters S phase (Coverley et al., 2002). However, the highest observed replication frequency *in vitro* is nearer 50%; usually obtained by incubation with ECiz1. For the G1 population of 3T3 nuclei used here 17% were in S phase (%S) and the maximum number that replicated in any assay *in vitro* was 51% (% replication). Therefore, 34% of this population is *competent* to initiate replication *in vitro* (%C). Thus, for each data point in Figs. 3B-F, % initiation = (% replication - %S)/%C x 100.

[0156] RNA interference Endogenous Ciz1 was targeted in proliferating NIH3T3 cells using *in vitro* transcribed siRNAs (Ambion Silencer kit), directed against four regions of mouse Ciz1. Oligonucleotide sequences that were used to generate siRNAs are AAGCACAGTCACAGGAGCAGACCTGT (SEQ ID NO: 9) CTC and AATCTGCTCCTGTGACTGTGCCCTGTCTC (SEQ ID NO: 10) for siRNA 4, AATCTGTACAC AAGTTCTACGACCTGTCTC (SEQ ID NO: 11) and AATCGTAGAAGTTGTGACAGACCTGTCTC (SEQ ID NO: 12) for siRNA 8, AATCGCAAGG ATTCTTCTTCTCCTGTCTC (SEQ ID NO: 13) and AAAGAAGAAGAA TCCTTGCGACCTGTCTC (SEQ ID NO: 14) for siRNA 9, and AATCTGCAGCAGTCTTTCCCCCTGTCTC (SEQ ID NO: 15) and AAGGGAAAGAACTGCTGCAGACCTGTCTC (SEQ ID NO: 16) for siRNA 11. Target sequences that are distributed throughout the Ciz1 transcript were chosen based on low secondary structure predictions and on location within exons that are consistently expressed in all known forms of Ciz1 (sequences 4, 8, 11), with the exception of one (siRNA 9) that is known to be alternatively spliced. Negative controls were untreated, mock treated (transfection reagents but no siRNA) and cells treated with GAPDH siRNA (Ambion). Cy3 labelled siRNAs (Ambion) were used to estimate transfection efficiency, which was found to be greater than 95%. RNA interference experiments were performed in 24 well format starting with 2×10^4 cells per well in 500 μ l of medium (DMEM with glutamax supplemented with 4% FCS). siRNA's were added 12 hours after plating using oligofectamine reagent for delivery (Invitrogen). Unless stated otherwise, siRNAs were used in pairs (at 2nM total concentration in medium), as two doses with the second dose delivered in fresh medium 24 hours after the first. Results were assessed at 48 hours after first exposure, by counting cell number, S phase labelling, and immuno-staining. Northern blots were performed on RNAs isolated from cells treated for 24 hours with a single dose of siRNA, in reactions that were scaled up 5 fold. RNA was prepared using Trizol Reagent (Invitrogen) and samples were electrophoresed through 1% agarose, transferred onto Hybond N+ nylon membrane (Amersham), and sequentially hybridised at 50°C with cDNA probes using NorthernMax kit reagents (Ambion), following manufacturers instructions. The membrane was stripped between each hybridisation using 0.5% SDS solution at 90°C, allowed to cool slowly to room temperature. Probes were [³²P]-dCTP labelled using Random Primers DNA labelling system (Gibco BRL), and used in the following order: i. A 1.35kb Xma1-Xho1 fragment derived from ECiz1. ii. Human α -actin cDNA (Clontech) and iii. Mouse GAPDH cDNA (RNWAY laboratories). The

membrane was washed twice in 2X SSC 0.2% SDS for 30-60 mins each, followed by one wash in 0.2X SSC 0.2% SDS for 30 mins, at 55-65°C, depending on probe used. Hybridisation signals were quantified using an Amersham Biosciences Typhoon 9410 variable mode imager, and Image Quant TL software (v2002). Band intensities are expressed in arbitrary units (in parentheses), and results for Ciz1 and GAPDH were normalised against those for α -actin, and expressed as a %.

[0157] S phase labelling The fraction of nuclei undergoing DNA synthesis in vivo was monitored by supplementing culture medium with 20 μ M bromodeoxyuridine (BrdU, Sigma) for 20 minutes. Incorporated BrdU was visualized after acid treatment with FITC-conjugated anti-BrdU monoclonal antibody (Alexis Biochemicals) according to manufacturers instructions. Nuclei were counterstained with Hoescht 33258 and scored under high (1000X) magnification.

Green fluorescent protein tagged Ciz1

[0158] Full-length mouse Ciz1 cDNA was obtained from UK HGMP Resource Centre (MGC clone 27988) and the sequence fully verified. A 2.8kb SmaI-XbaI (blunt ended) full length Ciz1 fragment from this clone, and a 2.3kb SmaI-XbaI (blunt ended) ECiz1 fragment from pTriplEx-clone L were ligated in frame with enhanced green fluorescent protein (EGFP) into the SmaI site of pEGFP-C3 (Clontech). pEGFP-C3 with no insert was used as a control. Constructs were transfected into NIH3T3 cells using *TransIT*-293 (Mirus), following manufacturers instructions or microinjected into the male pro-nucleus of fertilized mouse eggs at the one cell stage. Growing 3T3 cells transfected with full length EGFP-Ciz1, or EGFP-ECiz1 were analysed by live cell fluorescent microscopy up to three days after transfection. DNA synthesis was monitored during the first 24 hours after transfection, by including the nucleotide analogue BrdU in cell culture medium for various time periods as indicated in figure legends. As described above any cells undergoing DNA synthesis while exposed to BrdU stain with anti- BrdU monoclonal antibody generating red nuclei.

[0159] Ciz1 transfected cells were also maintained under selection with 50 μ g/ml G418, in standard culture medium (DMEM Glutamax plus 10% fetal calf serum) for up to a month, yielding cell populations with altered morphology.

EST sequence analysis

[0160] Individual expressed sequence tags (ESTs) mapping to NCBI unigene cluster Hs.23476 (human Ciz1) were translated using GeneJockey and the predicted amino-acid sequence compared to the predicted sequence for full length Ciz1, with the aim of identifying recurrent changes in cancer cells. In order to exclude errors that reflect poor quality DNA sequence such as that which occurs at the end of long sequencing runs, only those changes positioned more than 8 amino-acids from the end of uninterrupted sequence are included in this analysis. Frame-shifts that are restored by a second alteration later in the read, and frame-shifts that are followed by a stop codon are only included if followed by uninterrupted sequence. Thus the majority of sequencing errors are excluded from this analysis. However, it is expected that many of the point mutations that remain (including frame-shifts and stops) reflect errors introduced during sequencing. Therefore, this analysis is aimed at uncovering trends, with weight being given to point mutations only if they appear more than once.

[0161] Of 567 sequences, that map to Ciz1 unigene cluster we have analysed most (all paediatric cancers, prostate and lung carcinomas, leukemias and lymphomas and a wide range of non-diseased tissues). Some were not mapped because they are extremely short reads or yielded very short amino-acid sequences upon translation, and for a small number we detected no homology to the Ciz1 coding sequence. A small number of ESTs were excluded from the analysis because of multiple frameshifts that produced stretches of homology in all three frames, with no indication of the reading frame used in vivo. These were all from cancer derived material, usually adenocarcinomas.

[0162] RT-PCR analysis of Ciz1 isoform expression RNA was isolated using trizol reagent following recommended procedures, DNase treated and reverse transcribed using random hexamers and superscript II, then amplified with Ciz1 specific primers: -

h/m5 CAGTCCCCACACAGGCC (SEQ ID NO: 17),
h/m2 GGCTTCCTCAGACCCCTCTG (SEQ ID NO: 18).
H/m3 ACACAGACCTCTCCAGAGCACTTAG (SEQ ID NO: 19)
H/m4 ATGGTGACCTTCAGGGAGC (SEQ ID NO: 20)
H4 TCCTTGCGCA TGTCTCTGG GCAGG (SEQ ID NO: 21)
H3 TCCCTCCTCA ACGGCTCCAT GCTGC (SEQ ID NO: 22)
H6 CG TGGGGGCGAC TTGAGCGTTG AGG (SEQ ID NO: 23)
H1 GATGCCAGGGGT ATGGGGCGCC GGG (SEQ ID NO: 24)
H2 TCCGAGCCCT TCCACTCCTC TCTGG (SEQ ID NO: 25)

Analysis of Ciz1 protein isoforms in cancer cell lines

[0163] Cells were grown in DMEM with 10% FCS until sub-confluent, rinsed in cold hepes buffered saline supplemented with EDTA free protease inhibitor cocktail (Roche) then scrape harvested and supplemented with 0.1% Triton X100. Detergent-insoluble material (including nuclei) was pelleted by gentle centrifugation to yield supernatant (SN) and pellet fractions (P). These were boiled in reducing SDS-PAGE sample buffer and proteins resolved by electrophoresis through 8% SDS-PAGE. After transfer to nitrocellulose, Ciz1 isoforms were detected with anti-Ciz1 antibody 1793). All methods used in this analysis are well documented elsewhere.

References**[0164]**

- Bell, S. P. and Dutta, A. (2002). DNA replication in eukaryotic cells. *Annu Rev Biochem* 71, 333-74.
- Cook, P. R. (1999). The organization of replication and transcription. *Science* 284, 1790-5.
- Corpet, F. (1998). Multiple sequence alignment with hierarchical clustering. *Nucl. Acids Res.* 16, 10881-10890.
- Coverley, D., Laman, H. and Laskey, R. A. (2002). Distinct roles for cyclins E and A during DNA replication complex assembly and activation. *Nat Cell Biol* 4, 523-8.
- Coverley, D., Pelizon, C., Trewick, S. and Laskey, R. A. (2000). Chromatin bound Cdc6 persists in S and G2 phases in human cells, while soluble Cdc6 is destroyed in a cyclin A-cdk2 dependent process. *J. Cell Sci.* 113, 1929-1938.
- Fujita, M. (1999). Cell cycle regulation of DNA replication initiation proteins in mammalian cells. *Front Biosci* 4, D816-23.
- Hanahan, D. and Weinberg, R. A. (2000). The Hallmarks of Cancer. *Cell* 100, 57-70. Harlow, E. and Lane, D. (1988). *Antibodies : A laboratory manual*. New York: Cold Spring Harbour Laboratory Press.
- Jones, D. L., Alani, R. M. and Munger, K. (1997). The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. *Genes Dev.* 11, 2101-2111.
- Krude, T. (2000). Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state. *J. Biol. Chem.* 275, 13699-13707.
- Krude, T., Jackman, M., Pines, J. and Laskey, R. A. (1997). Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. *Cell* 88, 109-119.
- Laman, H., Coverley, D., Krude, T. K., Laskey, R. A. and Jones, N. (2001). Viral cyclin/cdk6 complexes initiate nuclear DNA replication. *Mol. Cell. Biol.* 2, 624-635.
- Mercatante, D. R. and Kole, R. (2002). Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. *Biochim Biophys Acta* 1587, 126-32.
- Mitsui, K., Matsumoto, A., Ohtsuka, S., Ohtsubo, M. and Yoshimura, A. (1999). Cloning and characterization of a novel p21cip1/waf1-interacting zinc finger protein, Ciz1. *Biochem. Biophys. Res. Com.* 264, 457-464.
- Nakayasu, H. and Berezney, R. (1991). Nuclear matrins: identification of the major nuclear matrix proteins. *Proc Natl Acad Sci U S A* 88, 10312-6.
- Ohnuma, S., Philpott, A. and Harris, W. A. (2001). Cell cycle and cell fate in the nervous system. *Curr Opin Neurobiol* 11, 66-73.
- Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W. and Elledge, S. J. (1995). p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. *Science* 267, 1024-7.
- Rubbi, C. P. and Milner, J. (2000). Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. *Oncogene* 19, 85-96.
- Sherr, C. J. and Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev.* 13, 1501-1512.
- Stoeber, K., Mills, A. D., Kubota, Y., Krude, T., Romanowski, P., Marheineke, K., Laskey, R. A. and Williams, G. H. (1998). Cdc6 protein causes premature entry into S phase in a mammalian cell-free system. *EMBO J.* 17, 7219-7229.
- van Steensel, B., van Binnendijk, E. P., Hornsby, C. D., van der Voort, H. T., Krozowski, Z. S., de Kloet, E. R. and van Driel, R. (1996). Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. *J Cell Sci* 109 (Pt 4), 787-92.
- Warder, D. E. and Keherly, M. J. (2003). Ciz1, Cip1 interacting zinc finger protein 1 binds the consensus DNA sequence ARYSR(0-2)YYAC. *J Biomed Sci* 10, 406-17.
- Williams, G. H., Romanowski, P., Morris, L., Madine, M., Mills, A. D., Stoeber, K., Marr, J., Laskey, R. A. and Coleman, N. (1998). Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. *Proc. Natl. Acad. Sci. USA* 95, 14932-14937.

ZeZula, J., Casaccia-Bonnelil, P., Ezhevsky, S. A., Osterhout, D. J., Levine, J. M., Dowdy, S. F., Chao, M. V. and Koff, A. (2001). p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep 2, 27-34.

Claims

1. An *in vitro* diagnostic method for the identification of a proliferative disorder, the method comprising detecting the presence or expression of a Ciz1 splice variant, wherein the method provides for a quantitative measure of a Ciz1 protein variant in a sample from a subject, and the protein variant is a human alternatively spliced protein sequence in which the sequence:

(a) QQLQQLQQQLQQQLQQQLLQLQQLLQQSPP, or
MFSQQQQQLQQQQQLQQQLQQQLQQQLQQQLLQLQQLLQQSPPQA is absent;
(b) GLDQFAMPPATYDTAGLTMTPTATL is absent;
(c) DSSSQ is absent;
(d) PQVQPAHSQPPRQVQLQLQKQVQTQTY;

PQVQPAHSQGPRQVOLQQEAEPLKQVQPQVQPAHSQPPRQVQLQLQKQ
VQTQTY,

or

QVQSQTQPRIPSTDQTQVQPKLQKQAQTQTSPEHLVLQKQVQVQVQLQQEAEPPKQVQ
PQVQPAHSQGPRQVQLQQEAEPLKQVQPQVQPAHSQPPRQVQLQLQKQVQTQT

Y is absent; or
(e) VEEELCKQ is absent.

2. An *in vitro* diagnostic method for the identification of a proliferative disorder, the method comprising detecting the presence or expression of a Ciz1 splice variant, wherein the method provides for a quantitative measure of a Ciz1 RNA variant in a sample from a subject, and wherein the Ciz1 RNA variant is a human alternatively spliced RNA sequence in which the sequence:

(a)

(a) TGGGGGCTGCGGGGCCGGGCCCATCCGTGGGGGCGACTTGAGCGTTGAGG
GCGCGCGGGGAGGCGAGCCACCATGTTACGCCAGCAGCAGCAGCAGCTCCAGCA
ACAGCAGCAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTG
CAGCAGCAGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACAGG
CC, or

or

CAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTGCAGCAGC
AGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACA is absent;

is absent;

(b)

GGA CTGG ACCAG TTTG CAATGCC ACCAGCC ACGTATG ACACTGCC GGT

5

CTC ACCAT GCCC ACAGCA ACACTG

10

is absent;

(c) AGGATTCTTCTTCTC is absent;

(d)

15

(d) CCACAGGTGCAGCCCCAGGCACATTCACAGCCCCCAAGGCAGGTGC
AGCTGCAGCTGCAGAAGCAGGTCCAGACACAGACATATCC, or

or

20

CCACAGGTACAGCCACAGGCACATTCACAGGGCCCAAGGCAGGTGCAGCT
GCAGCAGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCCCAGGC
ACATTCACAGCCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCCAGACA
CAGACATAT, or

25

or

30

CAGGTGCAGTCACAGACTCAGCCGCGGATACCATCCACAGACACCCAGGT
GCAGCCAAAGCTGCAGAAGCAGGCGCAAACACAGACCTCTCCAGAGCACTTAGTG
CTGCAACAGAAGCAGGTGCAGCCACAGCTGCAGCAGGAGGCAGAGCCACAGAAG
CAGGTGCAGCCACAGGTACAGCCACAGGCACATTCACAGGGCCCAAGGCAGGTG
CAGCTGCAGCAGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCC
CAGGCACATTCACAGCCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCC
AGACACAGACATAT is absent; or

35

40

is absent; or

45

(e) GTTGAGGAGGA ACTCTGCAAGCAG is absent.

3. The method of claim 1 or claim 2, wherein the proliferative disorder is cancer.

50

4. The method of claim 3, wherein the cancer is a pediatric cancer selected from the group consisting of retinoblastoma, neuroblastoma, Burkett lymphoma, medulloblastoma, and Ewings sarcoma family tumors.

5. The method of claim 3, wherein the cancer is carcinoma, adenocarcinoma, lymphoma or leukemia.

55

6. The method of claim 3, wherein the cancer is liver, lung, or skin cancer.

7. The method of claim 1 or claim 2, wherein the diagnostic method comprises one or more of the following steps:

(a) contacting the sample with an agent that specifically binds a polypeptide with Ciz1 activity and measuring

the binding of the agent to the polypeptide in the sample;

(b) using reverse-transcribed PCR or real-time PCR to monitor Ciz1 isoform expression and to measure expression levels;

(c) measuring the presence of nucleic acid or amino acid mutations based on altered conformational properties of the molecule.

8. The method of claim 7, wherein the agent that specifically binds a polypeptide with Ciz1 activity is an anti-Ciz1 antibody.

9. The method of claim 8, wherein the antibody is a monoclonal antibody.

Patentansprüche

1. Diagnostisches *in-vitro*-Verfahren zum Identifizieren einer proliferativen Erkrankung, wobei das Verfahren das Nachweisen des Vorliegens oder der Expression einer Cizl-Spleißvariante umfasst, wobei das Verfahren eine quantitative Messung einer Cizl-Proteinvariante in einer Probe von einem Individuum bereitstellt und es sich bei der Proteinvariante um eine menschliche alternativ gespleißte Proteinsequenz handelt, in der die Sequenz

- (a) **QQLQQLQQQLQQQLQQQLLQLQQLLQQSPP** oder **MFSQQQQQLQQQQQLQLQQLQQQLQQQLQQQLLQLQQLLQQSPPQA** fehlt;
- (b) **3LDQFAMPPATYDTAGLTMPATL** fehlt;
- (c) **DSSSQ** fehlt;
- (d) **POVOPOAHSOPPROVOLOLOKOVOTOTV**,

PQVQPQAHSQGPQRQVOLQQEAEPLKQVQPQVQPQAHSQPPRQVQLQLQKQVQTQTY

oder

**QVQSQTQPRIPSTDTQVQPKLQKQAQTQTSPEHLVLQQKQVQPQLQQEAEPPQKQVQ
PQVQPQAHSQGPQRQVOLQQEAEPLKQVQPQVQPQAHSQPPRQVQLQLQKQVQTQT**

Y fehlt; oder

- (e) **VEEELCKQ** fehlt.

2. Diagnostisches *in-vitro*-Verfahren zum Identifizieren einer proliferativen Erkrankung, wobei das Verfahren das Nachweisen des Vorliegens oder der Expression einer Cizl-Spleißvariante umfasst, wobei das Verfahren eine quantitative Messung einer Cizl-RNA-Variante in einer Probe von einem Individuum bereitstellt und es sich bei der Cizl-RNA-Variante um eine menschliche alternativ gespleißte RNA-Sequenz handelt, in der die Sequenz

(a)

**TGGGGGCTGCGGGGCGGGGCCCATCCGTGGGGGCGACTTGAGCGTTGAGG
GCGCGCGGGGAGGCGAGCCACCATGTTGAGCCAGCAGCAGCAGCAGCTCCAGCA
ACAGCAGCAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTG
CAGCAGCAGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACAGG
CC**

oder

CAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTGCAGCAGC
AGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACA

5

fehlt
(b)

10

GGACTGGACCAGTTTGCAATGCCACCAGCCACGTATGACACTGCCGGT
CTCACCAT GCCACAGCAACTG

15

fehlt
(c) AGGATTCTTCTTCTC fehlt
(d)

20

CCACAGGTGCAGCCCCAGGCACATTCACAGCCCCCAAGGCAGGTGC
AGCTGCAGCTGCAGAAGCAGGTCCAGACACAGACATATCC

oder

25

CCACAGGTACAGCCACAGGCACATTCACAGGGCCCAAGGCAGGTGCAGCT
GCAGCAGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCCCAGGC
ACATTCACAGCCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCCAGACA
CAGACATAT

30

oder

35

CAGGTGCAGTCACAGACTCAGCCGCGGATACCATCCACAGACACCCAGGT
GCAGCCAAAGCTGCAGAAGCAGGCGCAAACACAGACCTCTCCAGAGCACTTAGTG
CTGCAACAGAAGCAGGTGCAGCCACAGCTGCAGCAGGAGGCAGAGCCACAGAAG
CAGGTGCAGCCACAGGTACAGCCACAGGCACATTCACAGGGCCCAAGGCAGGTG
CAGCTGCAGCAGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCC
CAGGCACATTCACAGCCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCC
AGACACAGACATAT

40

45

fehlt oder
(e) GTTGAGGAGGAACTCTGCAAGCAG fehlt.

3. Verfahren nach Anspruch 1 oder Anspruch 2, wobei es sich bei der proliferativen Erkrankung um Krebs handelt.
4. Verfahren nach Anspruch 3, wobei es sich bei dem Krebs um einen Krebs des Kindesalters, ausgewählt aus der Gruppe bestehend aus Retinoblastom, Neuroblastom, Burkett-Lymphom, Medulloblastom und der Ewing-Sarkom-Tumorfamilie handelt.
5. Verfahren nach Anspruch 3, wobei es sich bei dem Krebs um Karzinom, Adenokarzinom, Lymphom oder Leukämie handelt.
6. Verfahren nach Anspruch 3, wobei es sich bei dem Krebs um Leber-, Lungen- oder Hautkrebs handelt.

7. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das diagnostische Verfahren einen oder mehrere der folgenden Schritte umfasst:

- (a) Inkontaktbringen der Probe mit einem Agens, das spezifisch ein Polypeptid mit Cizl-Aktivität bindet, und Messen der Bindung des Agens an das Polypeptid in der Probe;
 (b) Einsatz der revers transkribierten PCR oder Echtzeit-PCR zum Verfolgen der Cizl-Isoform-Expression und zum Messen der Expressionsniveaus;
 (c) Messen des Vorhandenseins von Nukleinsäure- oder Aminosäuremutationen auf Basis von veränderten Konformationseigenschaften des Moleküls.

8. Verfahren nach Anspruch 7, wobei es sich bei dem Agens, das spezifisch ein Polypeptid mit Cizl-Aktivität bindet, um einen anti-Ciz1-Antikörper handelt.

9. Verfahren nach Anspruch 8, wobei es sich bei dem Antikörper um einen monoklonalen Antikörper handelt.

Revendications

1. Procédé de diagnostic *in vitro* pour l'identification d'un trouble prolifératif, le procédé comprenant la détection de la présence ou l'expression d'un variant d'épissage de Ciz1, le procédé permettant une mesure quantitative d'un variant de protéine Ciz1 dans un échantillon d'un sujet, et le variant de protéine étant une séquence de protéine de variant d'épissage humaine dans laquelle la séquence :

- (a) **QQLQQLQQQOLOQQQLQQQQLLQLQQLLQQSPP** ou **MFSQQQQQLQQQQQLQQQLQQQQLLQLQQLLQQSPPQA** est absente ;
 (b) **GLDQFAMPPATYDTAGLTMPATL** est absente ;
 (c) **DSSSQ** est absente ;
 (d) **PQVQPPAHSQPPRQVQLQLQKQVQTQTY**;

PQVQPPAHSQGPQRQVOLQQEAEPLKQVQPPQVQPPAHSQPPRQVQLQLQKQVQTQTY,

ou

**QVQSQTQPRIPSTDQVQPKLQKQAQTQTSPEHLVLQQKQVQPPQLQQEAEPPQKQVQ
 PQVQPPAHSQGPQRQVQLQQEAEPLKQVQPPQVQPPAHSQPPRQVQLQLQKQVQTQT**

Y est absente ; ou

- (e) **VEEELCKQ** est absente.

2. Procédé de diagnostic *in vitro* pour l'identification d'un trouble prolifératif, le procédé comprenant la détection de la présence ou l'expression d'un variant d'épissage de Cizl, le procédé permettant une mesure quantitative d'un variant d'ARN de Cizl dans un échantillon d'un sujet, et le variant d'ARN Ciz1 étant une séquence d'ARN de variant d'épissage humaine dans laquelle la séquence :

- (a)

TGGGGGCTGCGGGGCCGGGCCCATCCGTGGGGGCGACTTGAGCGTTGAGG
GCGCGCGGGGAGGCGAGCCACCATGTTTCAGCCAGCAGCAGCAGCAGCTCCAGCA
5 ACAGCAGCAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTG
CAGCAGCAGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACAGG
CC,

ou

CAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTGCAGCAGC
15 AGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACA

est absente ;
(b)

GGACTGGACCAGTTTGCAATGCCACCAGCCACGTATGACACTGCCGGT
CTCACCAT GCCACAGCAAACTG

est absente ;
(c) AGGATTCTTCTTCTC est absente ;
(d)

CCACAGGTGCAGCCCCAGGCACATTCACAGCCCCCAAGGCAGGTGC
30 AGCTGCAGCTGCAGAAGCAGGTCCAGACACAGACATATCC,

ou

CCACAGGTACAGCCACAGGCACATTCACAGGGCCCCAAGGCAGGTGCAGCT
GCAGCAGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCCCAGGC
ACATTCACAGCCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCCAGACA
40 CAGACATAT,

ou

CAGGTGCAGTCACAGACTCAGCCGCGGATACCATCCACAGACACCCAGGT
GCAGCCAAAGCTGCAGAAGCAGGCGCAAACACAGACCTCTCCAGAGCACTTAGTG
CTGCAACAGAAGCAGGTGCAGCCACAGCTGCAGCAGGAGGCAGAGCCACAGAAG
50 CAGGTGCAGCCACAGGTACAGCCACAGGCACATTCACAGGGCCCCAAGGCAGGTG
CAGCTGCAGCAGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCC
CAGGCACATTCACAGCCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCC
55 AGACACAGACATAT

est absente , iy
(e) GTTGAGGAGGAACTCTGCAAGCAG est absente.

EP 2 316 966 B1

3. Procédé de la revendication 1 ou la revendication 2, dans lequel le trouble prolifératif est un cancer.
4. Procédé de la revendication 3, dans lequel le cancer est un cancer pédiatrique choisi dans le groupe constitué de tumeurs de la famille des rétinoblastome, neuroblastome, lymphome de Burkett, médulloblastome et sarcome d'Ewing.
5. Procédé de la revendication 3, dans lequel le cancer est un carcinome, un adénocarcinome, un lymphome ou une leucémie.
6. Procédé de la revendication 3, dans lequel le cancer est un cancer du foie, du poumon ou de la peau.
7. Procédé de la revendication 1 ou la revendication 2, **caractérisé en ce que** le procédé de diagnostic comprend une ou plusieurs des étapes suivantes :
 - (a) mise en contact de l'échantillon avec un agent qui se lie spécifiquement à un polypeptide ayant une activité Cizl et mesure de la liaison de l'agent au polypeptide dans l'échantillon ;
 - (b) utilisation de la PCR par transcription inverse ou la PCR en temps réel pour surveiller l'expression d'isoforme de Cizl et mesurer les taux d'expression ;
 - (c) mesurer la présence de mutations d'acide nucléique ou d'acide aminé sur la base de propriétés conformationnelles modifiées de la molécule.
8. Procédé de la revendication 7, dans lequel l'agent qui se lie spécifiquement à un polypeptide ayant une activité Cizl est un anticorps anti-Ciz1.
9. Procédé de la revendication 8, dans lequel l'anticorps est un anticorps monoclonal.

Figure 1A-D





Figure 2A
Mouse Ciz1 isoforms

Figure 2B




Figure 2C and D




Figure 3A to I




Figure 4A-C





Figure 5A-D






Figure 5E-F

Figure 6A and B




Figure 6C to F




Figure 7




Figure 8A to D




Figure 8E




Figure 9A




Figure 10 continued





Figure 11a



47




Figure 11c




Figure 11d




Figure 11e




Figure 11F




Figure 12A




Figure 12B

	1	2	3	4	5	6	N1	N2	293
'DSSSQ'	0	0	0	0	2	0	1	2	0
'exon4'	1*	0	1*	3	0	3	1	0	0
'FL'	4	1	5	2	2	3	8	3	4
other	0	0	0	1	0	0	1	0	0

Summary of PCR products

Examples of PCR products

Ewings 6

ESFTs

DSSSQ 2/26

Exon4 8/26

Neuroblastomas

DSSSQ 3/16

Exon4 1/16

Summary of PCR products

Examples of PCR products

Neuroblastoma 2

HEK293

Figure 13A




Figure 13B





Figure 14

CATGTTCAAC CCGCAACTCC AGCAGCAGCA ACAGTTGCAG CAGCAGCAGC
 AACAGTTGCA GCAGCAGCTC CAGCAGCAGC AGTCCAGCA GCAGCAACAG
 CAGATACTGC AGCTCCAACA GCTGCTGCAA CAGTCCCCAC CACAGGCCTC
 CTTGTCCATT CCTGTCAGCC GGGGCCTCCC CCAGCAGTCA TCCCCGCAAC
 AGCTTCTGAG TCTCCAGGGC CTCCACTCGA CCTCCCTGCT CAATGGCCCC
 ATGCTGCAAA GAGCTTTGCT CCTACAGCAG TTGCAAGGAC TGGACCAGTT
 TGCAATGCCA CCAGCCACGT ATGACGGTGC CAGCCTCACC ATGCCTACGG
 CAACACTGGG TAACCTCCGT GCTTTCAATG TGACAGCCCC AAGCCTAGCA
 GCTCCCAGCC TTACACCACC CCAGATGGTC ACCCCAAATC TGCAGCAGTT
 CTTTCCCCAG GCTACTCGAC AGTCTCTGCT GGGGCCTCCT CTTGTTGGGG
 TCCCAATAAA CCCTTCTCAG CTCAACCACT CAGGGAGGAA CACCCAGAAA
 CAGGCCAGAA CCCCCTCTTC CACCACCCCC AATCGCAAGG ATTCTTCTTC
 TCAGACGGTG CCTCTGGAAG ACAGGGAAGA CCCCACAGAG GGGTCTGAGO
 AAGCCACGGA GCTCCAGATG GACACATGTG AAGACCAAGA TTCACTAGTC
 GGTCCAGATA GCATGCTGAG TGAGCCCCAA GTGCCTGAGC CTGAGCCCTT
 TGAGACATTG GAACCACCAG CCAAGAGGTG CAGGAGCTCA GAGGAGTCCA
 CCGAGAAAGG CCCTACAGGG CAGCCACAAG CAAGGGTCCA GCCTCAGACC
 CAGATGACAG CACCAAAGCA GACACAGACC CCGGATCGGC TGCCTGAGCC
 ACCAGAAGTC CAAATGCTGC CGCGTATCCA GCCACAGGCA CTGCAGATCC
 AGACCCAGCC AAAGCTGCTG AGGCAGGCAC AGACACAGAC CTCTCCAGAG
 CACTTAGCGC CCCAGCAGGA TCAGGTAGAG CCACAGGTAC CATCACAGCC
 CCCATGGCAG TTGCAGCCAC GGGAGACAGA CCCACCGAAC CAAGCTCAGG
 CACAGACCCA GCCTCAGCCC CTCTGGCAGG CGCAGTCACA GAAGCAGGCC
 CAGACACAGG CACATCCACA GGTACCCACC CAAGCACAGT CACAGGAGCA
 GACATCAGAG AAGACCCAGG ACCAGCCTCA GACCTGGCCA CAGGGGTCTAG
 TACCCCCACC AGAACAAGCG TCAGGTCCAG CCTGTGCCAC GGAACCACAG
 CTATCCTCTC ACGCTGCAGA AGCTGGGAGT GACCCAGACA AGGCCTTGCC
 AGAACCAGTA AGTGCCAGAG GCAGTGAAGACAGGAGCCGG GAGGCGTCCG
 CTGGTGGCCT GGATTTGGGA GAATGTGAAA AGAGAGCGGG AGAGATGCTG
 GGGATGTGGG GGGCTGGGAG CTCCCTGAAG GTCACCATCC TGCAGAGTAG
 CAACAGCCGG GCCTTTAACA CCACACCCCT CACATCTGGA CCTCGCCCTG
 GGGACTCTAC CTCTGCCACC CTTGCCATTG CCAGCACACC CTCCAAGCAA
 AGCCTCCAGT TCTTCTGCTA CATCTGCAAG GCCAGCAGCA GCAGCCAGCA
 GGAGTTCCAG GATCACATGT CAGAGGCTCA GCACCAACAG CGGCTTGGGG
 AAATACAACA CTCGAGCCAG ACCTGCCTGC TGTCCCTGCT GCCCATGCCT
 CGGGACATCC TGGAGAAAGA AGCGGAAGAT CCTCCGCCCA AACGCTGGTG
 CAACACCTGC CAGGTGTACT ACGTGGGAGA CTTGATCCAG CACCGTAGGA
 CACAGGAGCA CAAGGTGGCC AAACAATCCC TGAGGCCCTT CTGCACCATA
 TGCAACCGTT ACTTCAAGAC CCCTCGAAAG TTTGTGGAGC ACGTGAAGTC
 CCAGGGACAC AAGGACAAGG CCAAGAGCT GAAGACACTTGAAAAGGAGA
 CAGGCAGCCC AGATGAGGAC CACTTCATCA CTGTGGACGC CGTCGGTTGC
 TTTGAGAGTG GTCAAGAAGA GGACGAGGAT GACGACGAGGAAGAAGAAGA
 AGAAGGAGAG ATTGAGGCTG AGGAGGAATT CTGCAAGCAG GTGAAGCCGA
 GAGAAACATC CTCAGAGCAA GGGAAAGGGCT CTGAGACGTA CAACCCCAAC
 ACAGCCTATG GTGAGGATTT CCTGGTGCCA GTGATGGGCT ATGTCTGTCA
 AATCTGTAC AAGTTCTACG ACAGCAACTC AGAATTGCGG CTTTCTCACT
 GCAAGTCCCT GGCCCACTTT GAGAACCTGC AGAAATACAA AGCCAAGAAC
 CCAAGCCCTC CTCCTACCCG GCCTGTGAGC CGCAAGTGTG CCATCAACGC
 CCGCAACGCC CTGACTGCAC TGTTACCTC TAGCCACCAG CCCAGCCCCC
 AGGACACAGT GAAAATGCCC AGCAAGGTGA AGCCTGGATC CCCCAGACTC
 CCTCCTCCCC TTCGGCGCTC AACACGCCCTC AAAACCTGAT AGAGGGAGCT
 CTGGCCACTC AGCCTGACTA AGGCTCAGTC TGCTAATGCT TCCTAGGTAT
 CTGTGTAGAA ATGTTCAAGT GGTTGGTGT TTTACTCAA ATCCAATAAA
 GAGTCAGTAG TTTGGCAAAA AAAAAAAAAA AAAAAA

Figure 15

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GCGCACTTGA GCGTTGAGGG
 CGCGCGGGGA GCGGAGCCAC CATGTTTCAGC CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG CTCACGACAG
 AGCAATTGCA GCAGCAGCAG TTA CTGCAGC TCCAGCAGCT GCTCCAGCAG
 TCCCCACCAC AGGCCCGGTT GCCCATGGCT GTCAGCCGGG GGCTCCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCCTCCTCAA CGGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGACTGG ACCAGTTTGC AATGCCACCA GCCACGTATG AACTGCCGG
 TCTCACCATG CCCACAGCAA CACTGGGTAA CCTCCGAGGC TATGGCATGG
 CATCCCCAGG CCTCGCAGCC CCCAGCCTCA CACCCCAACA ACTGGCCACT
 CCAAATTTGC AACAGTTCTT TCCCCAGGCC ACTCGCCAGT CCTTGCTGGG
 ACCTCCTCTT GTTGGGGTCC CCATGAACCC TTCCCAAGTC AACCTTTCAG
 GACGGAACCC CCAGAAACAG GCCCGGACCT CCTCCTCTAC CACCCCAAT
 CGAAAGGATT CTTCTTCTCA GACAATGCCT GTGGAAGACA AGTCAGACCC
 CCCAGAGGGG TCTGAGGAAG CCGCAGAGCC CCGGATGGAC ACACCAGAA
 ACCAAGATTT ACCGCCCTGC CCAGAGGACA TCGCCAAGGA AAAACGCACT
 CCAGCACCTG AGCCTGAGCC TTGTGAGGCG TCCGAGCTGC CAGCAAAGAG
 ATTGAGGAGC TCAGAAAGAG CCACAGAGAA GGAACCTCCA GGGCAGTTAC
 AGGTGAAGGC CCAGCCGAG GCGCGGATGA CAGTACCGAA ACAGACACAG
 ACACCAGACC TGCTGCCTGA GGCCCTGGAA GCCCAAGTGC TGCCACGATT
 CCAGCCACGG GTCCTGCAGG TCCAGGCCCA GGTGCAGTCA CAGACTCAGC
 CGCGGATACC ATCCACAGAC ACCCAGGTGC AGCCAAAGCT GCAGAAGCAG
 GCGCAAAACAC AGACCTCTCC AGAGCACTTA GTGCTGCAAC AGAAGCAGGT
 GCAGCCACAG CTGCAGCAGG AGGCAGAGCC ACAGAAGCAGGTGCAGCCAC
 AGGTACAGCC ACAGGCACAT TCACAGGGCC CAAGGCAGGT GCAGCTGCAG
 CAGGAGGCAG AGCCGCTGAA GCAGGTGCAG CCACAGGTGC AGCCCCAGGC
 ACATTACAG CCCCCAAGGC AGGTGCAGCT GCAOCTGCAG AAGCAGGTCC
 AGACACAGAC ATATCCACAG GTCCACACAC AGGCACAGCC AAGCGTCCAG
 CCACAGGAGC ATCTCCAGC GCAGGTGTCA GTACAGCCAC CAGAGCAGAC
 CCATGAGCAG CCTCACACCC AGCCGAGGT GTCGTTGCTG GCTCCAGAGC
 AAACACCAGT TGTGGTTTCAT GTCTGCGGGC TGGAGATGCC ACCTGATGCA
 GTAGAAAGCTG GTGGAGGCAT GGAAAAGACC TTGCCAGAGC CTGTGGGCAC
 CCAAGTCAGC ATGGAAGAGA TTCAGAAATGA GTCGGCCTGT GGCCTAGATG
 TGGGAGAATG TGA AAAACAGA GCGAGAGAGA TGCCAGGGTATGGGGCGCC
 GGGGGCTCCC TGAAGGTCAC CATTCTGCAG AGCAGTGACA GCGGGGCTTT
 TAGCACTGTA CCCCTGACAC CTGTCCCCCG CCCCAGTGAC TCCGTCTCCT
 CCACCCTGC GGCTACCAGC ACTCCCTCTA AGCAGGCCCT CAGTTTCTC
 TGCTACATCT GCAAGGCCAG CTGCTCCAGC CAGCAGGAGT TCCAGGACCA
 CATGTCCGAG CCTCAGCACC AGCAGCGGCT AGGGGAGATC CAGCACATGA
 GCCAAGCCTG CCTCTGTCC CTGCTGCCCC TGCCCCGGGA CGTCTGGAG
 ACAGAGGATG AGGAGCCTCC ACCAAGGCGC TGGTGCAACA CTGCCAGCT
 CTACTACATG GGGGACCTGA TCCAACACCG CAGGACACAG GACCACAAGA
 TTGCCAAACA ATCCTTGCGA CCCTTCTGCA CCGTTTGCAA CCGCTACTTC
 AAAACCCCTC GCAAGTTTGT GGAGCACGTG AAGTCCCAGG GGCATAAGGA
 CAAAGCCAAG GAGCTGAAGT CGCTTGAGAA AGAAATTGCT GGCCAAGATG
 AGGACCACTT CATTACAGTG GACGCTGTGG GTTGCTTCGA GGGTGATGAA
 GAAGAGGAAG AGGATGATGA GGATGAAGAAGAGATCAGAGTTGAGGAGGA
 ACTCTGCAAG CAGGTGAGGT CCAGAGATAT ATCCAGAGAG GAGTGGAAGG
 GCTCGGAGAC CTACAGCCCC AATACTGCAT ATGGTGTGGA CTTCTGGTG
 CCCGTGATGG GCTATATCTG CCGCATCTGC CACAAGTTCT ATCAGACAA
 CTCAGGGGCA CAGCTCTCCC ACTGCAAGTC CCTGGGCCAC TTTGAGAACC
 TGCAGAAATA CAAGGCGGCC AAGAACCCCA GCCCCACCAC CCGACCTGTG
 AGCCGCGGCT GCGCAATCAA CGCCCGGAAC GCTTTGACAG CCCTGTTTCA
 CTCCAGCGGC CGCCACCCCT CCCAGCCCAA CACCCAGGAC AAAACACCCA
 GCAAGGTGAC GGCTCGACCC TCCCAGCCCC CACTACCTCG GCGCTCAACC
 CGCCTCAAAA CCTGATAGAG GGACCTCCCT GTCCCTGGCC TGCTGGGTG
 CAGATCTGCT AATGCTTTTT AGGAGTCTGC CTGGAACTT TGACATGGTT
 CATGTTTTTA CTCAAAATCC AATAAAACAA GGTAGTTTGG CTGTGCAAAA
 AAAAAAAAAA AAAAAAAAAA AA

Figure 16

MFNPQLQQQQ QLQQQQQLQ QQLQQQLQQ QQQQLQLQQ LLQQSPQAS
 LSIPVSRGLP QQSSPQQLS LQGLHSTSL NGPMLQRALL LQQLQGLDQF
 AMPPATYDGA SLTMTATLG NLRAFNVTP SLAAPSLTP QMVTPLNQQF
 FPQATRQSLL GPPVGVPIV PSQLNHSGRN TQKQARTPS TTPNRKDS
 QTVPLEDRED PTEGSEATE LQMDTCEDQD SLVGPDSMLS EPQVPEPEPF
 ETLEPPAKRC RSSEESTEG PTQQPQARVQ PQQTMTAPKQ TQTPDRLPEP
 PEVQMLPRIQ PQALQIQTOP KLLRQAQTQT SPEHLAPQD QVEPQVPSQP
 PWQLQPRETD PPNQAQATQ PQPLWQAQSQ KQAQTQAHQ VPTQAQSQEQ
 TSEKTQDQFQ TWPQGSVPPP EQASGPACAT EPQLSSHAAE AGSDPKALP
 EPVSAQSSSED RSREASAGGL DLGECEKRAE EMLGMWAGS SLKVITLQSS
 NSRAFNTTPL TSGPRPGDST SATPAIASTP SKQSLQFFCY ICKASSSQQ
 EFQDHMSEAQ HQQRLGEIQH SSQTCLLSLL PMPRDILEKE AEDPPKRW
 NTCQVYYVGD LIQHRRTQEH KVAQSLRPF CTICNRYFKT PRKFVEHVKS
 QGHKDKAQEL KTLKETGSP DEDHFTVDA VGCESGQEE DEDDDEEE
 EGEIEAEEEF CKQVKPRETS SEQGKGSETY NPNTAYGEDF LVPVMGYVCQ
 ICHKFYDSNS ELRLSHCKSL AHFENLQKYK AKNPSPPTTR PVSRRKCAINA
 RNALTALFTS SHQSPSPQDTV KMPSKVKPGS PGLPPPLRRS TRLKT

Figure 17

MF SQQQQQLQQQ QQLQLQQQ QLQQQLQQQ QLLQLQLQQSPQ APLPM AVSRGLPPQQ PQQPLLNLQG TNSASLLNGS M
 LQRALLQLQ GL DQFAMP PATYDTAGLT MPTATLGNLR GYGMA SPGLA APSLTPQLATPN LQOFFPQ ATRQSLLGPP PVGVPM
 NPSQ FNLSGRNPQK QARTSSTTPNRK DSSSQTM PVEDKSDPPE GSEEA AEPRM DTPEDQDLPP CPEDIAKEKRTPA PEPEPCE ASEL
 PAKRLR SSEEPTKEP PGQLQVKAQP QARMTVPKQTQTP DLLPEAL EAQVLPFRQP RVLQVQAQVQ SQTQPRIPST DTQVQPKLQK
 QAQTQTSPEH LVLQKQVQP QLQQAEPQK QVQPVQVQQAHSQGPQRQ VQLQQAEPKQV QPQVQQAHS QPPRQVQLQL QKQV
 QTQTP QVHT QAQPSVQPEHPPAQV SVQPPEQTHE QPHTQPQVSL LAPEQTPVVV HVC GLEMPDPAVEAGGMEK TLPEPVGTQ
 V SMEEIQNEA CGLDVGECEN RAREMPGVWGAGGSLKVITL QSSDSRAFST VPLTPVPRPS DSVSSTPAAT STPSKQALQFFCYICKA
 SCS SQQEFQDHMS EPQHQQRLGE IQHMSQACLL SLLPVPRDVLETEDEEPPR RWCNTCQLYY MGDLIQHRRT QDHKIAKQSL RPF
 CTVCNRYFKTPRKFEVH VKSQGHKDKA KELKSLEKEI AGQDEDHFT VDAVGCFEGDEEEDEDEE EIEVEEEELC KQVRSRDISR E
 EWKGSETYS PNTAYGVDFLVPMGYICRI CHKFYHSNSG AQLSHCKSLG HFENLQKYKA AKNPSPTTRPVSRRCAINAR NALTALFTS
 S GRPPSQPNTQ DKTPSKVTAR PSQPPLPRRSTRLKT

Figure 18

From exons 2/3 (at least two versions)
MFSQQQQQL QQQQQQLQL QQQLQQQL QQQQLQLQL LLQSPQA

QQLQL QQQLQQQL QQQQLQLQL LLQSP

Exon 4
GLDQFAMPPATYDTAGLTMTATL

From exon 6
DSSSQ

From exon 8 (at least three versions)
PQVQPAHSQPPRQVQLQLKQVQTQTY

PQVQPAHSQPRQVQLQQAEPKQVQVQPAHSQPPRQVQLQLKQVQTQTY

QVQSQTQPRIPSTDQVQPKLQKQAQTQ
TSPEHLVLQKQVQVQLQQAEPKQVQ
PQVQPAHSQPRQVQLQQAEPKQVQ
PQVQPAHSQPPRQVQLQLKQVQTQ TY

From exon 14
VEEELCKQ

The following sequence is inserted in one carcinoma derived library (MGC102) between the third and fourth zinc finger, altering the spacing between them.
PPTPRRDVFAHVPVQGWSTARLVTDM

Figure 19

From exons 2/3 (at least two versions)

TGGGGGCTGC GGGGCGGGCC CATCCGTGGG GCGGACTTGA GCGTTAGGGGCGGGGGA GCGGAGCCAC
CATGTTACAGC CAGCAGCAGC AGCAGCTCCAGCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG
CTCCAGCAGCAGCAATTGCA GCAGCAGCAG TTA CTGCAGC TCCAGCAGCT GCTCCAGCAGTCCCCACCCAC
AGGCC

CAGCAG CTCCAGCAGT TACAGCAGCA GCAGCTCCAG CAGCAGCAATTGCAGCAGCA GCAGTTACTG CAGC
TCCAGC AGCTGCTCCA GCAGTCCCCACCACA

Exon 4

GGACTGGAC CAGTTTGCAA TGCCACCAGC CACGTATGAC ACTGCCGGTCTCACCATGCC CACAGCAACA CTG
From exon 6

AGGATTCTTCTTCTC

From exon 8 (at least three versions)

CCACAGGTGC AGCCCCAGGC ACATTACAG CCCCCAAGGC AGGTGCAGCTGCAGCTGCAG AAGCAGGTCC
AGACACAGAC ATATCC

CCACAGGTAC AGCCACAGGC ACATTACAG GGGCCCAAGGC AGGTGCAGCTGCAGCAGGAG GCAGAGCCGC
TGAAGCAGGT GCAGCCACAG GTGCAGCCCCAGGCACATT CACAGCCCCCA AGGCAGGTGC AGCTGCAGCT
GCAGAAGCAGGTCCAGACAC AGACATAT

CAGGTGCAGT CACAGACTCA GCGCGGATA CCATCCACAG ACACCCAGGTGCAGCCAAAG CTGCAGAAGC
AGGCGCAAC ACAGACCTCT CCAGAGCAGCTTAGTGTGCA ACAGAAAGCAG GTGCAGCCAC AGCTGCAGCA
GGAGGCAGAGCCACAGAAGC AGGTGCAGCC ACAGGTACAG CCACAGGCAC ATTACAGGGCCCAAGGCAG
GTGCAGCTGC AGCAGGAGGC AGAGCCGCTG AAGCAGGTGCAGCCACAGGT GCAGCCCCCAG GCACATTAC
AGCCCCCAAG GCAGGTGCAGCTGCAGCTGC AGAAGCAGGT CCAGACACAG ACATAT

From exon 14

GTTGAGGAGGA ACTCTGCAAGCAG

The following sequence is inserted in to Ciz1 transcripts in one carcinoma library (from Ciz1 intron 12)

GCCACCCACACCACGAAGAGATGTGTTTGCCCCACGTTCCAGTGCAGGGGTGGAGCACAGCCCCGGCTTGTACAGATAT

Figure 20A

Part of exons 2/3 absent

Exon 4 absent

Part of exon 6 absent

Exon 8 minus variant 1

MF SQQQQQLQQ QQQQLQQQLQQQ QLLQLQQLLQQSPQ APLPM AVSRGLPPQ PQQLPLNLQ TNSASLLNGS MLQRALLLQQLQ GL DQFAMP PATYDTCAGLT MPT
 ATIANLNR GYGMAASGLA APSLTTPQLATPN LQQFFPQ ATTRSLGQP PAVGMVNPSP FNLSGRNPQK QARTSSSTTPNRK DSSSQTM PVEDKSDPPE GSEEAAPRM DTPEQDLPT CPE
 DIAKEKRTPA PEPECEA ASELPAKRLR SBEETPEKER PQQLQVKAQP PQVMPVKTQTP DLLPEAL EAQVLPRLQP RVLQVQAQVQ SQTPRLPST DTQVQPKLQKQAQTQTSPEH LVL
 QQQKQVP QLQEEAEQK QVQVQQAHSQGPQ VQLQEEAEPLKQV QVHT QAQSVQBEHPQAQV SVQPEQTHE QPHTQPVSL LAPEQTPIVV HVC GLEMPDPAVEAGGG
 MEK TLPEPVGTQV SMEEIQNEA CGLDVGECEA RAREMPGVWAGGSLKVTL QSSDSRAFT VPLTPVPRPS DSVSSTPA AT STPSKQALQFFCYICKASC SQQEQFDHMS EPQHQQR
 LGE IQHMSQACL SLLPVRDVLTEDEEPPR RWCNTCLQY MGDLIQHRRT QDHKIAKQSL RPFECTVGNRYFKPRFVEH VKSQGHKDKA KELKSLEKEI AQODEDHFT VDAVGC
 FEGDEEEDDEDE EEIEVEEEL KQVRSRTPR EEWKGSSETYS PNTAYGVDFLPVMVGYICRI CHKFYHNSG AOLSHCKSLG HEENLQKYKA AKNPSPTTRPVSRRCAINAR NALTAL
 FTSS GRPSPSDQD DKTPSKVTAR SQSPPLPRRSTRLKT

MF 5000QQQL000 Q00LQ0L000 Q1QQ0QL000 Q1LLQ0LLQ0SPQ AP1PM AV5RGLPPQ Q00PLLNLQ TN5AS1LNG5 MLQ0RALLQ0LQGNLR GYGMASPG1A APS
 .TPPOLAT1PN LQQPPTQ AT9SL1GPP PVGVMPNPSQ FNL5RGNPK QARTSS1TPNPK DSSSOTM PVEDKSDPPE G3EEAAEPRM DTPEDQDLP CPEDIAKEKRTPA PEPCEP
 AS5ELAKPLNR S3EEFTEPK PG0LQVKAQP QARM1VPKQ1TPT DLLPEAL EAQVLLPRPQ RVLQVQAQVQ SQTQPR1ST DTQVQKQQAQQTQTSPLH LV1QQKQVQP Q1QQ
 QAAEPK QVQVQVQAHSQGRQ V1QQQEAEP1KQV QVQVQQAHS QPQRQVQLQK QKQVQ1TPT QVHT QAQPSVQPEHPQAQV SVQPEQTHE QPH1QPVSL1 LAPEQT
 VVVVV HVC GLEMPDPAVEAGGMEK TL1PEPVGTQV S3EEIQNE5A CGLDVGEEN RAREMPGVWAGGSLKVTL QSSDSRAFFT V1LTPVPRS D3VSSTPAAT STFSQAALQF
 QCYICKASCS SQQE1QDMS EPQH0HQRLQE IQHMSQACLL S1LLPV1RDLDEDEEPPR RWCN1CQLY1 MGDL1QHRT QDH1K1AQSL RPCTVCNRYKTRPKRFVEH VKSQG
 K1DKDA KELKSLKE1AQDDEDH1T VDAVGCFFDEDEEDEDDE EE1EVEEELC KQVRSRDIR EEWKQ5ET55 PNTAYGVDFLVPVMGYICR1 CHK7FHSN5G AQL5HCKSLG
 IFEN1QKYKA AKNP5TPTRV5RRCAINAR NALTALFTSS GRP5QNP1TQ DKTP5KQV1TAR PSQ1P1R5TR1KLT

Figure 21A

Part of exons 2/3 absent

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GGGGACTTGA GCGTTGAGGG
 CGCGCGGGGA GGCAGGCCAC CATGTTTCAGC CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG GGGCCCGTT GCCCATGGCT GTCAGCCGGG GGCTCCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCTCCTCAA CGGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGACTGG ACCAGTTTGC AATGCCACCA GCCACGTATG ACACTGCCGG
 TCTCACCATG CCCACAGCAA CACTGGGTAA CCTCCGAGGC TATGGCATGG
 CATCCCCAAG CCTCGCAGCC CCCAGCCTCA CCCCCCACA ATGGGCACT
 CCAAATTTGC AACAGTTCTT TCCCCAGGCC ACTCGCCAGT CTTGCTGGG
 ACCTCCTCT GTTGGGGTCC CCATGAACCC TTCCCAAGTT AACCTTTTCA
 GACGGAACCC CCAGAAACAG GCCCGGACCT CCTCCTCTAC CACCCCCAAT
 CGAAAGGATT CTTCTTCTCA GACAATGCCT GTGGAAGACA AGTCAGACCC
 CCCAGAGGGG TCTGAGGAAG CCGCAGAGCC CCGGATGGAC ACACCAGAAG
 ACCAAGATTT ACCGCCCTGC CCAGAGGACA TCGCCAAGGA AAAACGCACT
 CCAGCACCTG AGCCTGAGCC TTGTGAGGCG TCCGAGCTGC CAGCAAAGAG
 ATTGAGGAGC TCAGAAGAGC CCACAGAGAA GGAACCTCCA GGGCAGTTAC
 AGGTGAAGGC CCAGCCGCAG GCCCGGATGA CAGTACCGAA ACAGACACAG
 ACACCAGACC TGCTGCCTGA GGCCCTGGAA GCCCAAGTGC TGCCACGATT
 CCAGCCACGG GTCCTGCAGG TCCAGGCCCA GGTGCAGTCA CAGACTCAGC
 CGCGGATACC ATCCACAGAC ACCCAGGTGC AGCCAAAGCT GCAGAAGCAG
 GCGCAAACAC AGACCTCTCC AGAGCACTTA GTGCTGCAAC AGAAGCAGGT
 GCAGCCACAG CTGCAGCAGG AGGCAGAGCC ACAGAAGCAG GTGCAGCCAC
 AGGTACAGCC ACAGGCACAT TCACAGGGCC CAAGGCAGGT GCAGTGCAG
 CAGGAGGCAG AGCCGCTGAA GCAGGTGCAG CCACAGGTGC AGCCCCAGGC
 ACATTCACAG CCCCCAAGGC AGGTGCAGCT GCAGCTGCAG AAGCAGGTCC
 AGACACAGAC ATATCCACAG GTCCACACAC AGGCACAGCC AAGCGTCCAG
 CCACAGGAGC ATCCTCCAGC GCAGGTGTCA GTACAGCCAC CAGAGCAGAC
 CCATGAGCAG CCTCACACCC AGCCGCAGGT GTCGTTGCTG GCTCCAGAGC
 AAACACCAGT TGTGGTTTAT GTCTGCGGGC TGGAGATGCC ACCTGATGCA
 GTAGAAGCTG GTGGAGGCAT GGAAAAGACC TTGCCAGAGC CTGTGGGCAC
 CCAAGTCAGC ATGGAAGAGA TTCAGAATGA GTCGGCCTGT GGCCTAGATG
 TGGGAGAATG TGAAAACAGA GCGAGAGAGA TGCCAGGGGT ATGGGGCGCC
 GGGGGCTCCC TGAAGGTCAC CATTCTGCAG AGCAGTGACA GCGGGGCTT
 TAGCACTGTA CCCCTGACAC CTGTCCCCCG CCCCAGTGAC TCCGTCTCCT
 CCACCCCTGC GGCTACCAGC ACTCCCTCTA AGCAGGCCCT CCAGTTCTTC
 TGCTACATCT GCAAAGCCAG CTGCTCCAGC CAGCAGGAGT TCCAGGACCA
 CATGTCCGAG CCTCAGCACC AGCAGCGGCT AGGGGAGATC CAGCACATGA
 GCCAAGCCTG CCTCCTGTCC CTGCTGCCCG TGCCCCGGGA CGTCTGGAG
 ACAGAGGATG AGGAGCCTCC ACCAAGGCGC TGGTGCAACA CCTGCCAGCT
 CTACTACATG GGGGACCTGA TCCAACACCG CAGGACACAG GACCACAAGA
 TTGCCAAACA ATCCTTGCGA CCCTTCTGCA CCGTTTGCAA CCGCTACTTC
 AAAACCCCTC GCAAGTTTGT GGAGCACGTG AAGTCCCAGG GGCATAAGGA
 CAAAGCCAAG GAGCTGAAGT CGCTTGAGAA AGAAATTGCT GGCCAAGATG
 AGGACCACTT CATTACAGTG GACGCTGTGG GTTGCTTCGA GGGTGATGAA
 GAAGAGGAAG AGGATGATGA GGATGAAGAA GAGATCGAGG TTGAGGAGGA
 ACTCTGCAAG CAGGTGAGGT CCAGAGATAT ATCCAGAGAG GAGTGGAAGG
 GCTCGGAGAC CTACAGCCCC AATACTGCAT ATGGTGTGGA CTTCCTGGTG
 CCCGTGATGG GCTATATCTG CCGCATCTGC CACAAGTTCT ATCACAGCAA
 CTCAGGGGCA CAGCTCTCCC ACTGCAAGTC CCTGGGCCAC TTTGAGAAC
 TGCAGAAATA CAAGGCGGCC AAGAACCCCA GCCCACCAC CCGACCTGTG
 AGCCGCCGGT GCGCAATCAA CGCCCGGAAC GCTTTGACAG CCCTGTTTAC
 CTCCAGCGGC CGCCACCCCT CCCAGCCCAA CCCCAGGAC AAAACACCCA
 GCAAGGTGAC GGCTCGACCC TCCCAGCCCC CACTACCTCG GCGCTCAACC
 CGCCTCAAAA CCTGATAGAG GGACCTCCCT GTCCCTGGCC TGCCTGGGTC
 CAGATCTGCT AATGCTTTTT AGGAGTCTGC CTGGAAACTT TGACATGGTT
 CATGTTTTTA CTCAAAATCC AATAAAACAA GGTAGTTTGG CTGTGCAAAA
 AAAAAAAAAA AAAAAAAAAA AA

Figure 21B

Exon 4 absent

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GCGCACTTGA GCGTTGAGGG
 CGCGCGGGGA GCGGAGCCAC CATGTTTCAGC CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG CTCCAGCAGC
 AGCAATTGCA GCAGCAGCAG TTA CTGCAGC TCCAGCAGCT GCTCCAGCAG
 TCCCCACCAC AGGCCCGTT GCCCATGGCT GTCAGCCGGG GGCTCCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCTCCTCAA CGGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGTAACC TCCGAGGCTA TGGCATGGCA TCCCCAGGCC TCGCAGCCCC
 CAGCCTCACA CCCCCACAAC TGGCCA CTCC AAATTTGCAA CAGTTCTTTC
 CCCAGGCCAC TCGCCAGTCC TTGCTGGGAC CTCCTCCTGT TGGGGTCCCC
 ATGAACCTT CCCAGTTCAA CTTTTCAGGA CGGAACCCCC AGAAACAGGC
 CCGGACCTCC TCCTCTACCA CCCCCAATCG AAAGGATTCT TCTTCTCAGA
 CAATGCCTGT GGAAGACAAG TCAGACCCCC CAGAGGGGTC TGAGGAAGCC
 GCAGAGCCCC GGATGGACAC ACCAGAAGAC CAAGATTTAC CGCCTGGCC
 AGAGGACATC GCAAGGAAA AACGCACTCC AGCACTTGAG CCTGAGCCTT
 GTGAGGCGTC CGAGTGCCA GCAAAGAGAT TGAGGAGCTC AGAAGAGCCC
 ACAGAGAAGG AACCTCCAGG GCAGTTACAG GTGAAGGCC AGCCGAGGGC
 CCGGATGACA GTACCGAAAC AGACACAGAC ACCAGACCTG CTGCTGAGG
 CCTGGAAGC CCAAGTGCTG CCACGATTCC AGCCACGGGT CCTGCAGGTC
 CAGGCCAAGG TGCAGTACA GACTCAGCCG CGGATACCAT CCACAGACAC
 CCAGGTGCAG CCAAAGCTGC AGAAGCAGGC GCAAACACAG ACCTCTCCAG
 AGCACTTAGT GCTGCAACAG AAGCAGGTGC AGCCACAGCT GCAGCAGGAG
 GCAGAGCCAC AGAAGCAGGT GCAGCCACAG GTACAGCCAC AGGCACATTC
 ACAGGGCCCA AGGCAGGTGC AGCTGCAGCA GGAGGCAGAG CCGTGGAAGC
 AGGTGCAGCC ACAGGTGCAG CCCCAGGCAC ATTACAGGCC CCAAAGGCAG
 GTGCAGCTGC AGCTGCAGAA GCAGGTCCAG ACACAGACAT ATCCACAGGT
 CCACACACAG GCACAGCCAA GCGTCCAGCC ACAGGAGCAT CCTCCAGGCC
 AGGTGTCACT ACAGCCACCA GAGCAGACCC ATGAGCAGCC TCACACCCAG
 CCGCAGGTGT CGTTGCTGGC TCCAGAGCAA ACACCACTTG TGGTTCATGT
 CTGCGGGCTG GAGATGCCAC CTGATGCAGT AGAAGCTGGT GGAGGCATGG
 AAAAGACCTT GCCAGAGCCT GTGGGCACCC AAGTCAGCAT GGAAGAGATT
 CAGAATGAGT CGGCCTGTGG CCTAGATGTG GGAGAATGTG AAAACAGAGC
 GAGAGAGATG CCAGGGGTAT GGGGCGCCGG GGGCTCCCTG AAGGTCACCA
 TTCTGCAGAG CAGTGACAGC CGGGCCTTTA GCACTGTACC CCTGACACCT
 GTCCCCCGCC CAGTGACTC CGTCTCTCC ACCCTGCGG CTACCAGCAC
 TCCCTCTAAG CAGGCCCTCC AGTTCTTCTG CTACATCTGC AAGGCCAGCT
 GCTCCAGCCA GCAGGAGTTC CAGGACCACA TGTCGGAGCC TCAGCACCAG
 CAGCGGCTAG GGGAGATCCA GCACATGAGC CAAGCCTGCC TCCTGTCCCT
 GCTGCCGTG CCCCAGGACG TCCTGGAGAC AGAGGATGAG GAGCCTCCAC
 CAAGGCGCTG GTGCAACACC TGCCAGCTCT ACTACATGGG GGACCTGATC
 CAACACCGCA GGACACAGGA CCACAAGATT GCCAAACAAT CCTTGCGACC
 CTTCTGCACC GTTTGCAACC GCTACTTCAA AACCCCTCGC AAGTTTGTGG
 AGCACGTGAA GTCCAGGGG CATAAGGACA AAGCCAAGGA GCTGAAGTCG
 CTTGAGAAAG AAATTGCTGG CCAAGATGAG GACCACTTCA TTACAGTGGA
 CGCTGTGGGT TGCTTCGAGG GTGATGAAGA AGAGGAAGAG GATGATGAGG
 ATGAAGAAGA GATCGAGGTT GAGGAGGAAC TCTGCAAGCA GGTGAGGTCC
 AGAGATATAT CCAGAGAGGA GTGGAAGGGC TCGGAGACCT ACAGCCCCAA
 TACTGCATAT GGTGTGACT TCCTGGTGCC CGTGATGGGC TATATCTGCC
 GCATCTGCCA CAAGTTCTAT CACAGCAACT CAGGGGCACA GCTCTCCAC
 TGCAAGTCCC TGGGCCACTT TGAGAACCTG CAGAAATACA AGGCGGCCAA
 GAACCCAGC CCCACACCC GACCTGTGAG CCGCCGGTGC GCAATCAACG
 CCGGAACGC TTTGACAGCC CTGTTCACT CCAGCGGCC CCCACCTCC
 CAGCCCAACA CCCAGGACAA AACACCCAGC AAGGTGACCG CTCGACCTC
 CCAGCCCCA CTACCTCGG CTTCAACCCG CCTCAAAACC TGATAGAGGG
 ACCTCCTGT CCTGGCCTG CCTGGGTCCA GATCTGCTAA TGCTTTTATG
 GAGTCTGCCT GGAACCTTTG ACATGGTTCA TGTTTTTACT CAAAATCCAA
 TAAAAAAGG TAGTTTGGCT GTGCAAAAAA AAAAAAAAAA AAAAAAAAAA

Figure 21C

Exon 6 minus transcript

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GGC GACTTGA GCGTTGAGGG
 CGCGCGGGGA GCGGAGCCAC CATGTTTCAGC CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG CTCCAGCAGC
 AGCAATTGCA GCAGCAGCAG TTA CTGCAGC TCCAGCAGCT GCTCCAGCAG
 TCCCCACCAC AGGCCCGGTT GCCCATGGCT GTCAGCCGGG GGCTCCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCTCCTCAA CGGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGACTGG ACCAGTTTGC AATGCCACCA GCCACGTATG AACTGCGCGG
 TCTCACCATG CCCACAGCAA CACTGGGTAA CCTCCGAGGC TATGGCATGG
 CATCCCCAGG CCTGCAGCC CCCAGCCTCA CACCCCCA ACTGGCCACT
 CCAAATTTGC AACAGTTCTT TCCCCAGGCC ACTCGCCAGT CCTTGCTGGG
 ACCTCCTCCT GTTGGGGTCC CCATGAACCC TTCCAGTTTC AACCTTTCAG
 GACGGAACCC CCAGAAACAG GCCCCGACCT CCTCCTCTAC CACCCCCAAT
 CGAAAGACAA TGCCTGTGGA AGACAAGTCA GACCCCCAG AGGGGCTGTA
 GGAAGCCGCA GAGCCCCGGA TGGACACACC AGAAGACCAA GATTTACCGC
 CCTGCCCAGA GGACATCGCC AAGGAAAAAC GCACTCCAGC ACCTGAGCCT
 GAGCCTTGTG AGGCGTCCGA GCTGCCAGCA AAGAGATTGA GGAGCTCAGA
 AGAGCCCCACA GAGAAGGAAC CTCCAGGGCA GTTACAGGTG AAGGCCCAGC
 CGCAGGCCCG GATGACAGTA CCGAAACAGA CACAGACACC AGAGCTGCTG
 CCTGAGGCC TGGAAAGCCCA AGTGCTGCCA CGATTCCAGC CACGGGTCTT
 GCAGGTCCAG GCCCAGGTGC AGTCACAGAC TCAGCCGCGG ATACCATCCA
 CAGACACCCA GGTGCAGCCA AAGCTGCAGA AGCAGGCGCA AACACAGACC
 TCTCCAGAGC ACTTAGTGCT GCAACAGAAG CAGGTGCAGC CACAGCTGCA
 GCAGGAGGCA GAGCCACAGA AGCAGGTGCA GCCACAGGTA CAGCCACAGG
 CACATTTCACA GGGCCCAAGG CAGGTGCAGC TGCAGCAGGA GGCAGAGCCG
 CTGAAGCAGG TGCAGCCACA GGTGCAGCCC CAGGCACATT CACAGCCCCC
 AAGGCAGGTG CAGCTGCAGC TGCAGAAGCA GGTCCAGACA CAGACATATC
 CACAGGTCCA CACACAGGCA CAGCCAAGCG TCCAGCCACA GGAGCATCCT
 CCAGCGCAGG TGTCAGTACA GCCACCAGAG CAGACCCATG AGCAGCCTCA
 CACCCAGCCC CAGGTGTCGT TGCTGGCTCC AGAGCAAACA CCAGTTGTGG
 TTCATGTCTG CGGGCTGGAG ATGCCACCTG ATGCAGTAGA AGCTGGTGGA
 GGCATGGAAA AGACCTTGCC AGAGCCTGTG GGCACCCAAG TCAGCATGGA
 AGAGATTCAG AATGAGTCGG CCTGTGGCCT AGATGTGGGA GAATGTGAAA
 ACAGAGCGAG AGAGATGCCA GGGGTATGGG GCGCCGGGGG CTCCCTGAAG
 GTCACATTG TGCAGAGCAG TGACAGCCGG GCCTTTAGCA CTGTACCCCT
 GACACCTGTC CCCCCCCCCA GTGACTCCGT CTCCTCCACC CCTGCGGCTA
 CCAGCACTCC CTCTAAGCAG GCCCTCCAGT TCTTCTGCTA CATCTGCAAG
 GCCAGCTGCT CCAGCCAGCA GGAGTTCCAG GACCACATGT CGGAGCCTCA
 GCACCAGCAG CGGCTAGGGG AGATCCAGCA CATGAGCCAA GCCTGCCTCC
 TGTCCTGCT GCCCGTGCCC CGGGACGTCC TGGAGACAGA GGATGAGGAG
 CCTCCACCAA GCGCTGGTG CAACACCTGC CAGCTCTACT ACATGGGGGA
 CCTGATCCAA CACCGCAGGA CACAGGACCA CAAGATTGCC AAACAATCCT
 TGCGACCCCT CTGCACCGTT TGCAACCGCT ACTTCAAAAC CCCTCGCAAG
 TTTGTGGAGC ACGTGAAGTC CCAGGGGCAT AAGGACAAAG CCAAGGAGCT
 GAAGTCGCTT GAGAAAGAAA TTGCTGGCCA AGATGAGGAC CACTTCATTA
 CAGTGGACGC TGTGGGTTGC TTCGAGGGTG ATGAAGAAGA GGAAGAGGAT
 GATGAGGATG AAGAAGAGAT CGAGGTTGAG GAGGAACTCT GCAAGCAGGT
 GAGGTCCAGA GATATATCCA GAGAGGAGTG GAAGGGCTCG GAGACCTACA
 GCCCCAATAC GATATATGGT GTGGA CTGCTGCTGCT GATGGGCTAT
 ATCTGCCGCA TCTGCCACAA GTTCTATCAC AGCAACTCAG GGCACAGCT
 CTCCCACTGC AAGTCCCTGG GCCACTTTGA GAACCTGCAG AAATACAAGG
 CGGCCAAGAA CCCCAGCCCC ACCACCCGAC CTGTGAGCCG CCGGTGCGCA
 ATCAACGCCC GGAACGCTTT GACAGCCCTG TTCACCTCCA GCGGCCGCC
 ACCCTCCCAG CCAACACCC AGGACAAAAC ACCCAGCAAG GTGACGGCTC
 GACCTCCCA GCCCCCACTA CCTCGGCGCT CAACCCGCT CAAAACCTGA
 TAGAGGGACC TCCTGTCCC TGGCCTGCCT GGGTCCAGAT CTGCTAATGC
 TTTTGGAG TGTCCCTGGA AACTTTGACA TGGTTCAATG TTTTACTCAA
 AATCAATAA AACAAGGTAG TTTGGCTGTG CAAAAAAAAA AAAAAAAAAA
 AAAAAA

Figure 21D

Exon 8 minus variant 1

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GGGCACTTGA GCGTTGAGGG
 CGCGCGGGGA GGGCAGCCAC CATGTTTCAGC CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG CTCCAGCAGC
 AGCAATTGCA GCAGCAGCAG TTAAGTCAGC TCCAGCAGCT GCTCCAGCAG
 TCCCCACCAC AGGCCCGGTT GCCCATGGCT GTCAGCCGGG GGTCCTCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCCTCCTCAA CGGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGACTGG ACCAGTTTGC AATGCCACCA GCCACGTATG AACTGCCGG
 TCTCACCATG CCCACAGCAA CACTGGGTAA CCTCCGAGGC TATGGCATGG
 CATCCCCAGG CCTCGCAGCC CCCAGCCTCA CACCCCCACA ACTGGCCACT
 CCAAATTTGC AACAGTTCTT TCCCCAGGCC ACTCGCCAGT CCTTGCTGGG
 ACCTCCTCCT GTTGGGGTCC CCATGAACCC TTCCAGTTT ACCTTTTCAG
 GACGGAACCC CCAGAAACAG GCCCGGACCT CCTCCTCTAC CACCCCAAT
 CGAAAGGATT CTTCTTCTCA GACAATGCCT GTGAAGACA AGTCAGACCC
 CCCAGAGGGG TCTGAGGAAG CCGCAGAGCC CCGGATGGAC ACACCAGAA
 ACCAAGATTT ACCGCCCTGC CCAGAGGACA TCGCCAAGGA AAAACGCACT
 CCAGCACCTG AGCCTGAGCC TTGTGAGGCG TCCGAGCTGC CAGCAAGAG
 ATTGAGGAGC TCAGAAGAGC CCACAGAGAA GGAACCTCCA GGCAGTTAC
 AGGTGAAGGC CCAGCCGAGC GCCCGGATGA CAGTACCGAA ACAGACACAG
 ACACCAGACC TGCTGCCTGA GGCCCTGGAA GCCCAAGTGC TGCCACGATT
 CCAGCCACGG GTCTGCAGG TCCAGGCCCA GGTGCAGTCA CAGACTCAGC
 CGCGGATACC ATCCACAGAC ACCCAGGTGC AGCCAAAGCT GCAGAAGCAG
 GCGCAACAC AGACCTCTCC AGAGCACTTA GTGCTGCAAC AGAAGCAGGT
 GCAGCCACAG GTGCAGCAGG AGGCAGAGCC ACAGAAGCAG GTGCAAGCCAG
 AGGTACAGCC ACAGGCACAT TCACAGGGCC CAAGGCAGGT GCAGCTCAG
 CAGGAGGAGC AGCCGCTGAA GCAGGTGCAG ACAG GTCCACACAC AGGCA
 CAGCC AAGCGTCCAG
 CCACAGGAGC ATCCTCCAGC GCAGGTGTCA GTACAGCCAC CAGAGCAGAC
 CCATGAGCAG CCTCACACCC AGCCGCAGGT GTCGTTGCTG GCTCCAGAGC
 AAACACCACT TGTGGTTTCAT GTCTGCGGGC TGGAGATGCC ACCTGATGCA
 GTAGAAGCTG GTGGAGGCAT GGAAAAGACC TTGCCAGAGC CTGTGGGCAC
 CCAAGTCAGC ATGGAAGAGA TTCAGATGA GTCGGCTGT GGCCTAGATG
 TGGGAGAATG TGAAAACAGA GCGAGAGAGA TGCCAGGGGT ATGGGGCGCC
 GGGGGCTCCC TGAAGGTAC CATTCTGCAG AGCAGTGAAC GCCGGCCTT
 TAGCACTGTA CCCCTGACAC CTGTCCCCCG CCCCAGTGAC TCCGTCTCCT
 CCACCCCTGC GGCTACCAAGC ACTCCCTCTA AGCAGGCCCT CCAAGTTCTT
 TGCTACATCT GCAAGGCCAG CTGCTCCAGC CAGCAGGAGT TCCAGGACCA
 CATGTGCGAG CCTCAGCACC AGCAGCGGCT AGGGGAGATC CAGCACATGA
 GCCAAGCCTG CCTCCTGTCC CTGCTGCCCG TGCCCCGGGA CGTCTGGAG
 ACAGAGGATG AGGAGCCTCC ACCAAGGCGC TGGTGCAACA CCTGCCAGCT
 CTACTACATG GGGGACCTGA TCCAACACCG CAGGACACAG GACCACAAGA
 TTGCCAAACA ATCCTTGCGA CCCTTCTGCA CCGTTTGCAA CCGCTACTTC
 AAAACCCCTC GCAAGTTTGT GGAGCACGTG AAGTCCCAGG GGCATAAGGA
 CAAAGCCAAG GAGCTGAAGT CGCTTGAGAA AGAAATTGCT GGCCAAGATG
 AGGACCACTT CATTACAGTG GACGCTGTGG GTTGCTTCGA GGTGATGAA
 GAAGAGGAAG AGGATGATGA GGATGAAGAA GAGATCGAGG TTGAGGAGGA
 ACTCTGCAAG CAGGTGAGGT CCAGAGATAT ATCCAGAGAG GAGTGGAAGG
 GCTCGGAGAC CTACAGCCCC AATACTGCAT ATGGTGTGGA CTTCCTGGTG
 CCCGTGATGG GCTATATCTG CCGCATCTGC CACAAGTTCT ATCAGACAA
 CTCAGGGGCA CAGCTCTCCC ACTGCAAGTC CCTGGGCCAC TTTGAGAACC
 TGCAGAAATA CAAGGCGGCC AAGAACCCCA GCCCACCAC CCGACCTGTG
 AGCCGCCGGT GCGCAATCAA CGCCCGGAAC GCTTTGACAG CCCTGTTTAC
 CTCCAGCGGC CGCCACCCT CCCAGCCCA CACCCAGGAC AAAACACCCA
 GCAAGGTGAC GGCTCGACCC TCCAGCCCC CACTACCTCG GCGCTCAACC
 CGCCTCAAAA CCTGATAGAG GGACCTCCCT GTCCCTGGCC TGCTGGGT
 CAGATCTGCT AATGCTTTTT AGGAGTCTGC CTGGAACCTT TGACATGGT
 CATGTTTTTA CTAAAATCC AATAAAACAA GGTAGTTTGG CTGTGCAAAA
 AAAAAAAAAA AAAAAAAAAA AA

Figure 21E

Exon 8 minus variant 2

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GCGCACTTGA GCGTTGAGGG
 CGCGCGGGGA GGCGAGCCAC CATGTTCAAGC CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG CTCCAGCAGC
 AGCAATTGCA GCAGCAGCAG TTAAGTCAAGC TCCAGCAGCT GCTCCAGCAG
 TCCCCACCAC AGGCCCCGTT GCCCATGGCT GTCAGCCGGG GGCTCCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCTCCTCAA CGGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGACTGG ACCAGTTTGC AATGCCACCA GCCACGTATG AACTGCCGG
 TCTACCATG CCCACAGCAA CACTGGGTAA CCTCCGAGGC TATGGCATGG
 CATCCCCAGG CCTCGCAGCC CCCAGCCTCA CACCCCCACA ACTGGCCACT
 CCAAATTTGC AACAGTTCTT TCCCCAGGCC ACTCGCCAGT CCTTGCTGGG
 ACCTCCTCTT GTTGGGGTCC CCATGAACCC TTCCAGTTT AACCTTTTCA
 GACGGAACCC CCAGAAACAG GCCCGGACCT CCTCCTCTAC CACCCCCAAT
 CGAAAGGATT CTTCTTCTCA GACAATGCCT GTGGAAGACA AGTCAGACCC
 CCCAGAGGGG TCTGAGGAAG CCGCAGAGCC CCGATGGAC ACACAGAAG
 ACCAAGATTT ACCGCCCTGC CCAGAGGACA TCGCAAGGA AAAACGCACT
 CCAGCACCTG AGCCTGAGCC TTGTGAGGCG TCCGAGCTGC CAGCAAGAG
 ATTGAGGAGC TCAGAAGAGC CCACAGAGAA GGAACCTCCA GGGCAGTTAC
 AGGTGAAGGC CCAGCCGAGC GCCCGATGA CAGTACCGAA ACAGACACAG
 ACACAGACC TGCTGCCTGA GGCCCTGGA GCGCAAGTGC TGCCACGATT
 CCAGCCACGG GTCTGCAGG TCCAGGCCCA GGTGCAGTCA CAGACTCAGC
 CGCGGATACC ATCCACAGAC ACCCAGGTGC AGCCAAAGCT GCAGAAGCAG
 GCGCAACAC AGACCTCTCC AGAGCACTTA GTGCTGCAAC AGAAGCAGGT
 GCAGCCACAG CTGCAGCAGG AGGCAGAGCC ACAGAAGCAG GTGCAGCCAC
 AGGTCCACAC ACAAGCAGC CCAAGCGTCC AGCCACAGGA GCATCTCCA
 GCGCAGGTGT CAGTACAGCC ACCAGAGCAG ACCCATGAGC AGCCTCACAC
 CCAGCCGAG GTGCTGTTGC TGGCTCCAGA GCAACACCA GTTGTGGTTC
 ATGTCTGCGG GCTGGAGATG CCACCTGATG CAGTAGAAGC TGGTGGAGGC
 ATGGAAAAGA CTTGCCAGA GCCTGTGGG ACCCAAGTCA GCATGGAAGA
 GATTGAGAT GAGTCGGCT GTGGCTAGA TGTGGGAGAA TGTGAAAACA
 GAGCGAGAGA GATGCCAGGG GTATGGGGCG CCGGGGGCTC CCTGAAGTTC
 ACCATTCTGC AGAGCAGTGA CAGCCGGGCC TTTAGCACTG TACCCCTGAC
 ACCTGTCCCC CGCCCCAGTG ACTCCGTCTC CTCCACCCCT GCGGCTACCA
 GCACTCCCTC TAAGCAGGCC CTCCAGTTCT TCTGCTACAT CTGCAAGGCC
 AGCTGCTCCA GCCAGCAGGA GTTCCAGGAC CACATGTCCG AGCCTCAGCA
 CCAGCAGCGG CTAGGGGAGA TCCAGCACAT GAGCCAAGCC TGCCTCCTGT
 CCTGCTGCC CGTGCCCGG GACGTCTGG AGACAGAGGA TGAGGAGCCT
 CCACCAAGGC GTGGTGCAA CACCTGCCAG CTCTACTACA TGGGGGACCT
 GATCCAACAC CGCAGGACAC AGGACCACAA GATTGCCAAA CAATCCTTGC
 GACCTTCTG CACCGTTTGC AACCGCTACT TCAAAACCCC TCGCAAGTTT
 GTGGAGCAGG TGAAGTCCA GGGGCATAAG GACAAAGCCA AGGAGCTGAA
 GTCGCTTGAG AAAGAAATTG CTGGCCAAGA TGAGGACCAC TTCATTACAG
 TGGACGCTGT GGTTGCTTC GAGGGTGATG AAGAAGAGGA AGAGGATGAT
 GAGGATGAAG AAGAGATCGA GGTGAGGAG GAACTCTGCA AGCAGGTGAG
 GTCCAGAGAT ATATCCAGAG AGGAGTGGA GGGCTCGGAG ACCTACAGCC
 CCAATACTGC ATATGGTGTG GACTTCTTGG TGCCCGTGAT GGGCTATATC
 TGCCGCATCT GCCACAAGTT CTATCACAGC AACTCAGGGG CACAGCTCTC
 CCACTGCAAG TCCCTGGGCC ACTTTGAGAA CCTGCAGAAA TACAAGGCGG
 CCAAGAACCC CAGCCCCACC ACCCGACCTG TGAGCCGCGG GTGCACAATC
 AACGCCCCGA ACGCTTTGAC AGCCCTGTTT ACCTCCAGCG GCCGCCCCACC
 CTCCCAGCCC AACACCCAGG ACAAACACC CAGCAAGGTG ACGGCTCGAC
 CCTCCAGCC CCACTACCT CGGCGCTCAA CCGCCTCAA AACCTGATAG
 AGGGACCTCC CTGTCCCTGG CCTGCCTGGG TCCAGATCTG CTAATGCTTT
 TTAGGAGTCT GCCTGGAAC TTTGACATGG TTCATGTTTT TACTCAAAAT
 CCAATAAAAC AAGGTAGTTT GGCTGTGCAA AAAAAAAAAA AAAAAAAAAA

Figure 21F

Exon 8 minus variant 3

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GCGCACTTGA GCGTTGAGGG
 CGCGCGGGGA GCGGAGCCAC CATGTTTCAGC CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG CTCCAGCAGC
 AGCAATTGCA GCAGCAGCAG TTAAGTGCAG TCCAGCAGCT GCTCCAGCAG
 TCCCCACCAC AGGCCCCGTT GCCCATGGCT GTCAGCCGGG GGCTCCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCTCCTCAA CGGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGACTGG ACCAGTTTGC AATGCCACCA GCCACGTATG AACTGCCGG
 TCTCACCATG CCCACAGCAA CACTGGGTAA CCTCCGAGGC TATGGCATGG
 CATCCCCAGG CCTCGCAGCC CCCAGCCTCA CACCCCCACA ACTGGCCAAT
 CCAAATTTGC AACAGTTCTT TCCCCAGGCC ACTCGCCAGT CTTTGCTGGG
 ACCTCCTCCT GTTGGGGTCC CCATGAACCC TTCCAGTTC AACCTTTCAG
 GACGGAACCC CCAGAAACAG GCGCGGACCT CCTCCTCTAC CACCCCCAAT
 CGAAAGGATT CTTCTTCTCA GACAATGCCT GTGGAAGACA AGTCAGACCC
 CCCAGAGGGG TCTGAGGAAG CCGCAGAGCC CCGGATGGAC ACACCAGAAG
 ACCAAGATTT ACCGCGCTGC CCAGAGGACA TCGCCAAGGA AAAACGCACT
 CCAGCACCTG AGCCTGAGCC TTGTGAGGCG TCCGAGCTGC CAGCAAAGAG
 ATTGAGGAGC TCAGAAGAGC CCACAGAGAA GGAACCTCCA GGGCAGTTAC
 AGGTGAAGGC CCAGCCGCGAG GCGCGGATGA CAGTACCGAA ACAGACACAG
 ACACCAGACC TGCTGCCTGA GGCCTGGAA GCCCAAGTGC TGCCACGATT
 CCAGCCACGG GTCCTGCAGG TCCAGGCCTC CACAGGTCCA CACACAGGCA
 CAGCCAAGCG TCCAGCCACA GGAGCATCCT CCAGCGCAGG TGTCAGTACA
 GCCACCAGAG CAGACCCATG AGCAGCCTCA CACCCAGCCG CAGGTGTCTG
 TGCTGGCTCC AGAGCAAACA CCAGTTGTGG TTCATGTCTG CCGGCTGGAG
 ATGCCACCTG ATGCAGTAGA AGCTGGTGA GGCATGAAA AGACCTTGCC
 AGAGCCTGTG GGCACCCAAG TCAGCATGGA AGAGATTGAG AATGAGTCGG
 CCTGTGGCCT AGATGTGGGA GAATGTGAAA ACAGAGCGAG AGAGATCCA
 GGGGTATGGG GCGCCGGGGG CTCCCTGAAG GTCACCATC TGCAAGACAG
 TGACAGCCGG GCCTTTAGCA CTGTACCCCT GACACCTGTC CCGCGCCCA
 GTGACTCGT TCCTCCACC CCGCGGCTA CCAGCACTCC CTCTAAGCA
 GCCCTCCAGT TCTCTGCTA CATCTGCAAG GCCAGCTGCT CCAGCCAGCA
 GGAGTTCCAG GACCACATGT CGGAGCCTCA GCACCAGCAG CGGCTAGGGG
 AGATCCAGCA CATGAGCCAA GCCTGCCTCC TGTCCCTGCT GCCGTGCC
 CGGGACGTCC TGGAGACAGA GGATGAGGAG CCTCCACCA GCGCGTGGT
 CAACACCTGC CAGCTCTACT ACATGGGGGA CCTGATCCAA CACCGCAGGA
 CACAGGACCA CAAGATTGCC AAACAATCCT TGCGACCTTT CTGCACCGTT
 TGCAACCGCT ACTTCAAAAC CCCTCGCAAG TTTGTGGAGC ACGTGAAGTC
 CCAGGGGCAT AAGGACAAAG CCAAGGAGCT GAAGTCGCTT GAGAAAGAAA
 TTGCTGGCCA AGATGAGGAC CACTTCATTA CAGTGOACGC TGTGGGTGC
 TTCGAGGGTG ATGAAGAAGA GGAAGAGGAT GATGAAGATG AAGAAGAGAT
 CGAGGTTGAG GAGGAACTCT GCAAGCAGGT GAGGTCCAGA GATATATCCA
 GAGAGGAGTG GAAGGGCTCG GAGACCTACA GCGCCAATAC TGATATGGT
 GTGGAATTCC TGGTGCCCGT GATGGGCTAT ATCTGCCGCA TCTGCCCAA
 GTTCTATCAC AGCAACTCAG GGGCACAGCT CTCCCACTGC AAGTCCCTGG
 GCCACTTTGA GAACCTGCAG AAATACAAG GCGCCAAGAA CCCCAGCCCC
 ACCACCCGAC CTGTGAGCCG CCGGTGCGCA ATCAACGCCC GGAACGCTTT
 GACAGCCCTG TTCACCTCCA GCGGCCGCC ACCCTCCAG CCAACACCC
 AGGACAAAAC ACCCAGCAAG GTGACGGCTC GACCTCCCA GCCCCACTA
 CCTCGGCGCT CAACCCGCCT CAAAACCTGA TAGAGGGACC TCCCTGTCCC
 TGGCCTGCCT GGGTCCAGAT CTGCTAATGC TTTTAGGAG TCTGCCTGGA
 AACTTTGACA TGGTTCATGT TTTTACTCAA AATCCAATAA AACAAGGTAG
 TTTGGCTGTG CAAAAAAAAA AAAAAAAAAA AAAAAA

Figure 21G

Exon 14 minus transcript

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GGCGACTTGA GCGTTGAGGG
 CGCGCGGGGA GGCGAGCCAC CATGTTTCAAG CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG CTCCAGCAGC
 AGCAATTGCA GCAGCAGCAG TTAAGTCAGC TCCAGCAGCT GCTCCAGCAG
 TCCCCACCAC AGGCCCGGTT GCCCATGGCT GTCAGCCGGG GGCTCCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCTCTCTAA CGGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGACTGG ACCAGTTTGC AATGCCACCA GCCACGTATG AACTGCCGG
 TCTCACCATG CCCACAGCAA CACTGGGTAA CCTCCGAGGC TATGGCATGG
 CATCCCCAGG CCTCGCAGCC CCCAGCCTCA CACCCCAACA ACTGGCACT
 CCAAATTTGC AACAGTTCTT TCCCCAGGCC ACTCGCCAGT CTTTGCTGGG
 ACCTCCTCCT GTTGGGGTCC CCATGAACCC TTCCAGTTT AACCTTTTCA
 GACGGAACCC CCAGAAACAG GCGCCGACCT CCTCTCTAC CACCCCAAT
 CGAAAGGATT CTTCTTCTCA GACAATGCCT GTGGAAGACA AGTCAGACCC
 CCCAGAGGGG TCTGAGGAAG CCGCAGAGCC CCGGATGGAC ACACCAAGAG
 ACCAAGATTT ACCGCGCTGC CCAGAGGACA TCQCCAAGGA AAAACGCACT
 CCAGCACCTG AGCCTGAGCC TTGTGAGGCG TCCGAGTGC CAGCAAAGAG
 ATTGAGGAGC TCAGAAGAGC CCACAGAGAA GGAACCTCCA GGGCAGTTAC
 AGGTGAAGGC CCAGCCGAGC GCGCGGATGA CAGTACCGAA ACAGACACAG
 ACACCAGACC TGCTGCCTGA GCGCCTGGAA GCCCAAGTGC TGCCACGATT
 CCAGCCACGG GTCCTGCAGG TCCAGGCCCA GGTGCAGTCA CAGACTCAGC
 CGCGGATACC ATCCACAGAC ACCCAGGTGC AGCCAAAGCT GCAGAAGCAG
 GCGCAAACAC AGACCTCTCC AGAGCACTTA GTGCTGCAAC AGAAGCAGGT
 GCAGCCACAG CTGCAGCAGG AGGCAGAGCC ACAGAAGCAG GTGCAGCCAC
 AGGTACAGCC ACAGGCACAT TCACAGGGCC CAAGGCAGGT GCAGCTGCAG
 CAGGAGGCAG AGCCGCTGAA GCAGGTGCAG CCACAGGTGC AGCCCAAGGC
 ACATTCACAG CCCCCAAGGC AGGTGCAGCT GCAGCTGCAG AAGCAGGTCC
 AGACACAGAC ATATCCACAG GTCCACACAC AGGCACAGCC AAGCGTCCAG
 CCACAGGAGC ATCCTCCAGC GCAGGTGTCA GTACAGCCAC CAGAGCAGAC
 CCATGAGCAG CCTCACACCC AGCCGCAGGT GTCGTTGCTG GCTCCAGAGC
 AAACACCAGT TGTGGTTTAT GTCTGCGGGC TGGAGATGCC ACCTGATGCA
 GTAGAAGCTG GTGGAGGCAT GGAAAAGACC TTGCCAGAGC CTGTGGGCAC
 CCAAGTCAGC ATGGAAGAGA TTCAGAATGA GTCGGCCTGT GGCCTAGATG
 TGGGAGAATG TGAAGACAGA GCGAGAGAGA TGCCAGGGGT ATGGGGCGCC
 GGGGGTCCC TGAAGGTAC CATTCTGCAG AGCAGTGACA CCGGGGCTT
 TAGCACTGTA CCCCTGACAC CTGTCCCCCG CCCCAGTGAC TCCGTCTCCT
 CCACCCCTGC GGCTACCAGC ACTCCCTCTA AGCAGGCCCT CCAGTTCTTC
 TGCTACATCT GCAAGGCCAG CTGCTCCAGC CAGCAGGAGT TCCAGACCA
 CATGTCCGAG CCTCAGCACC AGCAGCGGCT AGGGGAGATC CAGCACATGA
 GCCAAGCCTG CCTCTGTCC CTGCTGCCCG TGCCCCGGGA CGTCTGGAG
 ACAGAGGATG AGGAGCCTCC ACCAAGGGCG TGGTGCAACA CCTGCCAGCT
 CTAATACATG GGGGACCTGA TCCAACACCG CAGGACACAG GACCACAAGA
 TTGCCAAACA ATCCTTGCGA CCCTTCTGCA CCGTTTGCAA CCGCTACTTC
 AAAACCCCTC GCAAGTTTGT GGAGCACGTG AAGTCCCAGG GGCATAAGGA
 CAAAGCCAAG GAGCTGAAGT CGCTTGAGAA AGAAATTGCT GGCCAAGATG
 AGGACCACTT CATTACAGTG GACGCTGTGG GTTGCTTCGA GGGTGATGAA
 GAAGAGGAAG AGGATGATGA GGATGAAGAA GAGATCGAGG TGAGGTCCAG
 AGATATATCC AGAGAGGAGT GGAAGGGGCT GGAGACCTAC AGCCCAATA
 CTGCATATGG TGTGGACTTC CTGGTGCCCG TGATGGGCTA TATCTGCCCG
 ATCTGCCACA AGTTCTATCA CAGCAACTCA GGGGCACAGC TCTCCCACTG
 CAAGTCCCTG GGCCACTTTG AGAACCTGCA GAAATACAAG GCGGCCAAGA
 ACCCAGCCC CACCACCCGA CCTGTGAGCC GCGGTGCGC AATCAACGCC
 CGGAACGCTT TGACAGCCCT GTTACCTCC AGCGGCCGCC CACCTCCCA
 GCCCAACACC CAGGACAAAA CACCCAGCAA GGTGACGGCT CGACCTCC
 AGCCCCACT ACCTCGGCGC TCAACCCGCC TCAAAACCTG ATAGAGGGAC
 CTCCCTGTCC CTGGCCTGCC TGGGTCCAGA TCTGCTAATG CTTTGTAGGA
 GTCTGCCTGG AAACCTTGAC ATGGTTTATG TTTTACTCA AAATCCAATA
 AAACAAGGTA GTTTGGCTGT GCAAAAAAAA AAAAAAAAAA AAAAAAAAAA

Figure 21H

Also to be protected are transcripts which lack combinations of the variable exons. For example:-

Exon 14 and partial exon 6 minus variant

TGGGGGCTGC GGGGCCGGCC CATCCGTGGG GGCGACTTGA GCGTTGAGGG
 CGCGCGGGGA GGCGAGCCAC CATGTTTCAGC CAGCAGCAGC AGCAGCTCCA
 GCAACAGCAG CAGCAGCTCC AGCAGTTACA GCAGCAGCAG CTCCAGCAGC
 AGCAATTGCA GCAGCAGCAG TTA CTGCAGC TCCAGCAGCT GCTCCAGCAG
 TCCCCACCAC AGGCCCGGTT GCCCATGGCT GTCAGCCGGG GGCTCCCCC
 GCAGCAGCCA CAGCAGCCGC TTCTGAATCT CCAGGGCACC AACTCAGCCT
 CCTCTCTCA CCGCTCCATG CTGCAGAGAG CTTTGCTTTT ACAGCAGTTG
 CAAGGACTGG ACCAGTTTGC AATGCCACCA GCCACGTATG AACTGCCGG
 TCTCACCATG CCCACAGCAA CACTGGGTAA CCTCCGAGGC TATGGCATGG
 CATCCCCAGG CCTCGCAGCC CCCAGCCTCA CACCCCACTA ACTGGCCACT
 CCAAATTTGC AACAGTTCTT TCCCCAGGCC ACTCGCCAGT CCTTGCTGGG
 ACCTCTCTCT GTTGGGGTCC CCATGAACCC TTCCAGTTT AACCTTTTAC
 GACGGAACCC CCAGAAACAG GCGCGGACCT CCTCTCTAC CACCCCAAT
 CGAAAGACAA TGCTGTGGA AGACAAGTCA GACCCCCAG AGGGGTCTGA
 GGAAGCCGCA GAGCCCCGGA TGGACACACC AGAAGACCAA GATTACCCG
 CCTGCCCAGA GGACATCGCC AAGGAAAAAC GCACTCCAGC ACCTGAGCCT
 GAGCCTTGTG AGGCGTCCGA GCTGCCAGCA AAGAGATTGA GGAGCTCAGA
 AGAGCCCA GAGAAGGAAC CTCCAGGGCA GTTACAGGTG AAGGCCCAGC
 CGCAGGCCCG GATGACAGTA CCGAAACAGA CACAGACACC AGACCTGCTG
 CCTGAGGCC TGGAGGCCA AGTGCTGCCA CGATTCCAGC CACGGGTCCT
 GCAGGTCCAG GCCCAGGTGC AGTCACAGAC TCAGCCCGG ATACCATCCA
 CAGACACCA GGTGCAGCCA AAGCTGCAGA AGCAGCCGCA AACACAGACC
 TCTCCAGAGC ACTTAGTGCT GCAACAGAAG CAGGTGCAGC CACAGCTGCA
 GCAGGAGGCA GAGCCACAGA AGCAGGTGCA GCCACAGGTA CAGCCACAGG
 CACATTACA GGGCCCAAGG CAGGTGCAGC TGCAGCAGGA GGCAGAGCCG
 CTGAAGCAGG TGCAGCCACA GGTGCAGCCC CAGGCACATT CACAGCCGCC
 AAGGCAGGTG CAGCTGCAGC TGCAGAGCA GGTCCAGACA CAGACATATC
 CACAGGTCCA CACACAGGCA CAGCCAAGCG TCCAGCCACA GGAACATCCT
 CCAGCGCAGG TGTCAGTACA GCCACCAGAG CAGACCCATG AGCAGCCTCA
 CACCCAGCCG CAGGTGTCGT TGCTGGCTCC AGAGCAAACA CCAGTTGTGG
 TTCATGTCTG CGGCTGGAG ATGCCACCTG ATGCAGTAGA AGCTGGTGGA
 GGCATGGAAA AGACCTTGCC AGAGCCTGTG GGCACCCAAG TCAGCATGGA
 AGAGATTAG AATGAGTCGG CCTGTGGCCT AGATGTGGGA GAATGTGAAA
 ACAGAGCGAG AGAGATGCCA GGGGTATGGG GCGCCGGGGG CTCCTGAAAG
 GTCACCATTC TGCAGAGCAG TGACAGCCGG GCCTTTAGCA CTGTACCCCT
 GACACCTGTC CCCC GCCCA GTGACTCGT CTCCTCCACC CCTGGGCTA
 CCAGCACTCC CTCTAAGCAG GCCCTCCAGT TCTCTGCTA CATCTGCAAG
 GCCAGCTGCT CCAGCCAGCA GGAGTTCCAG GACCACATGT CGGAGCCTCA
 GCACCAGCAG CGGCTAGGGG AGATCCAGCA CATGAGCCAA GCCTGCCTCC
 TGTCCTGCT GCCCGTGGCC CGGACGTCC TGGAGACAGA GGATGAGGAG
 CCTCCACAA GGCCTGGTG CAACACCTGC CAGCTCTACT ACATGGGGGA
 CCTGATCCAA CACCGCAGGA CACAGGACCA CAAGATTGCC AAACAATCCT
 TGCGACCCCT CTGCACCGTT TGCAACCGCT ACTTCAAAAC CCCTCGCAAG
 TTTGTGGAGC ACGTGAAGTC CCAGGGGCAT AAGGACAAAG CCAAGGAGCT
 GAAGTCGCTT GAGAAAGAAA TTGCTGGCCA AGATGAGGAC CACTTCATTA
 CAGTGAACGC TGTGGGTTGC TTCGAGGGTG ATGAAGAAGA GGAAGAGGAT
 GATGAGGATG AAGAAGAGAT CGAGGTGAGG TCCAGAGATA TATCCAGAGA
 GGAGTGAAG GGCTCGGAGA CCTACAGCCC CAATACTGCA TATGGTGTGG
 ACTTCCTGGT GCCCGTGATG GGCTATATCT GCCGCATCTG CCACAAGTTC
 TATCACAGCA ACTCAGGGGC ACAGCTCTCC CACTGCAAGT CCCTGGGCCA
 CTTTGAGAAC CTGCAGAAAT ACAAGGCGGC CAAGAACCCC AGCCCCACCA
 CCCGACCTGT GAGCCGCGCG TGCGAATCA ACGCCCGGAA CGCTTTGACA
 GCCCTGTTC CCTCAGCGG CCGCCACCC TCCCAGCCCA ACACCCAGGA
 CAAAAACCCC AGCAAGGTGA CGGCTCGACC CTCACAGCCC CCACTACCTC
 GGCCTCAAC CCGCCTCAA ACCTGATAGA GGGACCTCCC TGTCCCTGGC
 CTGCCTGGGT CCAGATCTGC TAATGCTTTT TAGGAGTCTG CTGGAAACT
 TTGACATGGT TCATGTTTTT ACTCAAAATC CAATAAAACA AGGTAGTTTG
 GCTGTGCAAA AAAAAAAAAA AAAAAAAAAA AAA

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- Using Antibodies: A laboratory manual. Cold Spring Harbour Laboratory Press [0017]
- **CAIN SA ; WILLIAMS DM ; HARRIS V ; MONK PN.** Selection of novel ligands from a whole-molecule randomly mutated C5a library. *Protein Eng.*, March 2001, vol. 14 (3), 189-93 [0044]
- **SCOTT et al.** *Chem Biol*, 2001, vol. 8, 801-815 [0064]
- **GELLERMAN et al.** *J. Peptide Res*, 2001, vol. 57, 277-291 [0064]
- **DUTTA et al.** *J. Peptide Res*, 2000, vol. 8, 398-412 [0064]
- **NGOKA ; GROSS.** *J Amer Soc Mass Spec*, 1999, vol. 10, 360-363 [0064]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Laboratory, 1989 [0070]
- **MARSTON, F.** DNA Cloning Techniques: A Practical Approach. IRL Press, 1987, vol. III [0070]
- **F M AUSUBEL et al.** Current Protocols in Molecular Biology. John Wiley & Sons, Inc, 1994 [0070]
- **BELL, S. P. ; DUTTA, A.** DNA replication in eukaryotic cells. *Annu Rev Biochem*, 2002, vol. 71, 333-74 [0164]
- **COOK, P. R.** The organization of replication and transcription. *Science*, 1999, vol. 284, 1790-5 [0164]
- **CORPET, F.** Multiple sequence alignment with hierarchical clustering. *Nucl. Acids Res.*, 1998, vol. 16, 10881-10890 [0164]
- **COVERLEY, D. ; LAMAN, H. ; LASKEY, R. A.** Distinct roles for cyclins E and A during DNA replication complex assembly and activation. *Nat Cell Biol*, 2002, vol. 4, 523-8 [0164]
- **COVERLEY, D. ; PELIZON, C. ; TREWICK, S. ; LASKEY, R. A.** Chromatin bound Cdc6 persists in S and G2 phases in human cells, while soluble Cdc6 is destroyed in a cyclin A-cdk2 dependent process. *J. Cell Sci.*, 2000, vol. 113, 1929-1938 [0164]
- **FUJITA, M.** Cell cycle regulation of DNA replication initiation proteins in mammalian cells. *Front Biosci*, 1999, vol. 4, D816-23 [0164]
- **HANAHAN, D. ; WEINBERG, R. A.** *The Hallmarks of Cancer.* *Cell*, 2000, vol. 100, 57-70 [0164]
- **HARLOW, E. ; LANE, D.** Antibodies : A laboratory manual. Cold Spring Harbour Laboratory Press, 1988 [0164]
- **JONES, D. L. ; ALANI, R. M. ; MUNGER, K.** The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. *Genes Dev.*, 1997, vol. 11, 2101-2111 [0164]
- **KRUDE, T.** Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state. *J. Biol. Chem.*, 2000, vol. 275, 13699-13707 [0164]
- **KRUDE, T. ; JACKMAN, M. ; PINES, J. ; LASKEY, R. A.** Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. *Cell*, 1997, vol. 88, 109-119 [0164]
- **LAMAN, H. ; COVERLEY, D. ; KRUDE, T. K. ; LASKEY, R. A. ; JONES, N.** Viral cyclin/cdk6 complexes initiate nuclear DNA replication. *Mol. Cell. Biol.*, 2001, vol. 21, 624-635 [0164]
- **MERCATANTE, D. R. ; KOLE, R.** Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. *Biochim Biophys Acta*, 2002, vol. 1587, 126-32 [0164]
- **MITSUMI, K. ; MATSUMOTO, A. ; OHTSUKA, S. ; OHTSUBO, M. ; YOSHIMURA, A.** Cloning and characterization of a novel p21cip1/waf1-interacting zinc finger protein, Ciz1. *Biochem. Biophys. Res. Com.*, 1999, vol. 264, 457-464 [0164]
- **NAKAYASU, H. ; BEREZNEY, R.** Nuclear matrices: identification of the major nuclear matrix proteins. *Proc Natl Acad Sci U S A*, 1991, vol. 88, 10312-6 [0164]
- **OHNUMA, S. ; PHILPOTT, A. ; HARRIS, W. A.** Cell cycle and cell fate in the nervous system. *Curr Opin Neurobiol*, 2001, vol. 11, 66-73 [0164]
- **PARKER, S. B. ; EICHELE, G. ; ZHANG, P. ; RAWLS, A. ; SANDS, A. T. ; BRADLEY, A. ; OLSON, E. N. ; HARPER, J. W. ; ELLEDGE, S. J.** p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. *Science*, 1995, vol. 267, 1024-7 [0164]
- **RUBBI, C. P. ; MILNER, J.** Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. *Oncogene*, 2000, vol. 19, 85-96 [0164]
- **SHERR, C. J. ; ROBERTS, J. M.** CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev.*, 1999, vol. 13, 1501-1512 [0164]

- **STOEBER, K. ; MILLS, A. D. ; KUBOTA, Y. ; KRUDE, T. ; ROMANOWSKI, P. ; MARHEINEKE, K. ; LASKEY, R. A. ; WILLIAMS, G. H.** Cdc6 protein causes premature entry into S phase in a mammalian cell-free system. *EMBO J.*, 1998, vol. 17, 7219-7229 [0164]
- **VAN STEENSEL, B. ; VAN BINNENDIJK, E. P. ; HORNSBY, C. D. ; VAN DER VOORT, H. T. ; KROZOWSKI, Z. S. ; DE KLOET, E. R. ; VAN DRIEL, R.** Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. *J Cell Sci*, 1996, vol. 109, 787-92 [0164]
- **WARDER, D. E. ; KEHERLY, M. J.** Ciz1, Cip1 interacting zinc finger protein 1 binds the consensus DNA sequence ARYSR(0-2)YYAC. *J Biomed Sci*, 2003, vol. 10, 406-17 [0164]
- **WILLIAMS, G. H. ; ROMANOWSKI, P. ; MORRIS, L. ; MADINE, M. ; MILLS, A. D. ; STOEBER, K. ; MARR, J. ; LASKEY, R. A. ; COLEMAN, N.** Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 14932-14937 [0164]
- **ZEZULA, J. ; CASACCIA-BONNEFIL, P. ; EZHEVSKY, S. A. ; OSTERHOUT, D. J. ; LEVINE, J. M. ; DOWDY, S. F. ; CHAO, M. V. ; KOFF, A.** p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. *EMBO Rep*, 2001, vol. 2, 27-34 [0164]

CIZI REPLIKÁCIÓS PROTEIN

Szabadalmi igénypontok

1. *In vitro* diagnosztikai eljárás proliferatív betegség azonosítására, amely eljárás tartalmazza Ciz1 illesztési ("splice") variáns jelenlétének vagy expressziójának detektálását, ahol az eljárás kvantitatív lépést biztosít Ciz1-proteinvariáns kvantitatív mérésére személyből származó mintában, és a proteinvariáns humán, alternatívan illesztett proteinszekvencia, amelyből a következő szekvencia:

- (a) QQLQQLQQQLQQQLQQQLLQLQQLLQQSPP, vagy
MFSQQQQQLQQQLQQQLQQQLQQQLQQQLLQLQQLLQQSPPQA hiányzik;
- (b) GLDQFAMPPATYDTAGLTMPTATL hiányzik;
- (c) DSSSQ hiányzik;
- (d) PQVQPAHSQPPRQVQLQLQKQVQTQTY;
PQVQPAHSQGPQRQVQLQQAEPKQVQVQVQPAHSQPPRQVQLQLQKQVQTQTY
vagy
QVQSQTQPRIPSTDITQVQPKLQKQAQTQTSPEHLVLQKQVQVQLQQAEPKQVQ
PQVQPAHSQGPQRQVQLQQAEPKQVQVQVQVQPAHSQPPRQVQLQLQKQVQTQY
Y hiányzik; vagy
- (e) VEEELCKQ hiányzik.

2. *In vitro* diagnosztikai eljárás proliferatív betegség azonosítására, amely eljárás tartalmazza Ciz1 illesztési ("splice") variáns jelenlétének vagy expressziójának detektálását, ahol az eljárás kvantitatív lépést biztosít Ciz1-RNS-variáns kvantitatív mérésére személyből származó mintában, és ahol az RNS-variáns humán, alternatívan illesztett RNS-szekvencia, amelyből a következő szekvencia:

- (a)
TGGGGGCTGCGGGGCCGGGCCATCCGTGGGGGGCGACTTGAGCGTTGAGG
GCGCGCGGGGAGGCGAGCCACCATGTTCCAGCCAGCAGCAGCAGCAGCTCCAGCA
ACAGCAGCAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTG
CAGCAGCAGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACAGG
CC vagy
CAGCAGCTCCAGCAGTTACAGCAGCAGCAGCTCCAGCAGCAGCAATTGCAGCAGC
AGCAGTTACTGCAGCTCCAGCAGCTGCTCCAGCAGTCCCCACCACA hiányzik;
- (b)
GGACTGGACCAGTTTGCAATGCCACCAGCCACGTATGACACTGCCGGT
CTCACCAT GCCACAGCAAGACTG hiányzik;
- (c)
AGGATTCTTCTTCTC hiányzik;
- (d)
CCACAGGTGCAGCCCCAGGCACATTCACAGCCCCCAAGGCAGGTGC
AGCTGCAGCTGCAGAAGCAGGTCCAGACACAGACATATCC,

vagy

CCACAGGTACAGCCACAGGCACATTACAGGGCCCAAGGCAGGTGCAGCT
GCAGCAGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCCCAGGC
ACATTCACAGCCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCCAGACA
CAGACATAT,

vagy

CAGGTGCAGTCACAGACTCAGCCGCGGATACCATCCACAGACACCCAGGT
GCAGCCAAAGCTGCAGAAGCAGGCGCAACACAGACCTCTCCAGAGCACTTAGTG
CTGCAACAGAAGCAGGTGCAGCCACAGCTGCAGCAGGAGGCAGAGCCACAGAAG
CAGGTGCAGCCACAGGTACAGCCACAGGCACATTACAGGGCCCAAGGCAGGTG
CAGCTGCAGCAGGAGGCAGAGCCGCTGAAGCAGGTGCAGCCACAGGTGCAGCCC
CAGGCACATTCACAGCCCCCAAGGCAGGTGCAGCTGCAGCTGCAGAAGCAGGTCC
AGACACAGACATAT

hiányzik; vagy

(e)

GTTGAGGAGGAAGTCTGCAAGCAG hiányzik.

3. Az 1. vagy 2. igénypont szerinti eljárás, ahol a proliferatív betegség rák.

4. A 3. igénypont szerinti eljárás, ahol a rák a következők alkotta csoportból választott pediatrikus rák: retinoblasztóma, neuroblasztóma, Burkett-limfóma, medulloblasztóma, és Ewings-sarkóma családokba tartozó tumorek.

5. A 3. igénypont szerinti eljárás, ahol a rák karcinóma, adenokarcinóma, limfóma vagy leukémia.

6. A 3. igénypont szerinti eljárás, ahol a rák máj-, tüdő- vagy bőrrák.

7. Az 1. vagy 2. igénypont szerinti eljárás, ahol a diagnosztikai eljárás a következő lépésekből egyet vagy többet tartalmaz:

(a) a minta érintkeztetése olyan szerrel, amely specifikusan kötődik Ciz1-aktivitású polipeptidhez és a szer kötődésének mérése a polipeptidhez a mintában;

(b) reverz transzkripció PCR vagy valós idejű PCR alkalmazása Ciz1-izoforma expressziójának monitorozására és expressziós szintjeinek mérésére;

(c) nukleinsav- vagy aminosav-mutációk jelenlétének mérése a molekula megváltozott konformációs tulajdonságai alapján.

8. A 7. igénypont szerinti eljárás, ahol a szer, amely specifikusan kötődik Ciz1-aktivitású polipeptidhez, anti-Ciz1-antitest.

9. A 8. igénypont szerinti eljárás, ahol az antitest monoklonális antitest.